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Abstract 
Hypothesis/Objectives: It has always been assumed that good drug compliance 
improves treatment outcomes. However, critical appraisal of current literature revealed 
no evidence to support this association. There had also been no well-designed studies to 
examine the effects of medication compliance on clinically important endpoints such as 
morbidity and mortality. Hence, we hypothesize that non-compliance is associated with 
poor clinical outcomes and that strategy to improve compliance will improve outcomes. 
The objectives of this project are (1) To examine the pattern and reasons for medication 
non-compliance (2) Medication compliance affects patient outcome and (3) Telephone 
reminders by a pharmacist, as a compliance-enhancing strategy, improves medication 
compliance and mortality in a cohort of polypharmacy patients attending the medical 
clinics at the Prince of Wales Hospital (PWH). 
Methods: Patients were included if they attended any medical clinics at PWH and 
received >5 chronic drugs. A pharmacist interviewed eligible patients regarding their 
drug-taking habits. A patient was considered compliant with a particular drug if he/she 
remembered the regimen correctly and had taken 80-120% of that drug based on self-
report and pill count. The patient was considered compliant if he/she was compliant with 
all of his/her prescribed chronic drugs, and vice-versa. Patients considered non-
compliant at the first visit were reassessed at the second visit and were reclassified as 
compliant (C) and non-compliant (NC). Within the C and NC groups, patients were 
randomized into intervention (T+) or control (T-)，giving a total of 2x2 thus 4 treatment 
arms; namely CT+, CT-, NCT+ and NCT-. Patients in the intervention groups (CT+ or 
NCT+) received a telephone call from the pharmacist before every doctor visit for 2 
years. Each telephone call lasted for 10 minutes and served to remind patients of their 
next clinic appointment and reinforce drug compliance. Patients in the control groups 
(CT- or NCT-) did not receive any interventions. Mortality and hospitalization data were 
captured from the hospital database. 
Results: 1011 patients were assessed (age 71 士 10 years, male 49%, number of prescribed 
chronic drugs 5.9士 1.2). 502 (49.7%) patients were found to be non-compliant. The types 
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of non-compliance were modified frequency (27%), dose omission (24%), premature 
cessation (20%), modified dosage (17%), and adjustment of both frequency and dosage 
(12%). Insufficient knowledge (65%), forgetfulness (16%), problems with health beliefs 
(10%) and experience of side effects (9%) were the main reasons for non-compliance. 
Using the log-rank test, the relative risk of 2-year mortality was 1.63 for all non-
compliant patients compared to compliant patients (P=0.003). Among the 502 non-
compliant patients, 60 defaulted the second visit while 442 were reassessed and 
randomized into CT- (n=119), CT+ (n=117), NCT- (n=104) and NCT+ (n=102). By 
study design, all patients in NCT+ and NCT- were non-compliant at the second visit but 
at 2-year, significantly more patients turned compliant in the NCT+ than in the NCT-
groups (80.7% vs. 57.7%, P<0.001). In contrast, all patients in CT+ and CT- were 
compliant at the second visit. At the end of 2-year, significantly less patients in the CT+ 
than CT- groups turned non-compliant (7.3% vs. 18.3%, P=0.038). Upon Cox regression 
modeling, old age [RR (95% CI): 1.06 (1.024-1.088), P=0.0005], male [1.99 (1.118-
3.331), P=0.0089], more frequent hospitalization prior to the 2-year study period [1.16 
(1.074-1.258)，P=0.0002] and without pharmacist's intervention [1.66 (1.002-2.757), 
P=0.049] were independent predictors of mortality. 
Conclusions: Half of the polypharmacy patients were non-compliant with one or more 
of their prescribed medications for different reasons with different patterns. 
Interventions to combat non-compliance must be individualized based on the underlying 
causes. Non-compliance with medication was associated with an increased mortality and 
periodic telephone call by a pharmacist improved patient compliance and reduced 
mortality rate. These findings strongly support the importance of a continuous and 
regular reinforcement by pharmacist to improve drug compliance or sustain behavioral 
































更多的NCT+比NCT-變得有良好的服藥依從性 (80%比57 .7%，P<0 .001)�反 
之，所有CT+和CT-於再次訪問中已具有良好的服藥依從性。兩年後明顯地較少 
的CT+比CT-變回有不良的服藥依從性 (7 .3%比18 .3% ’ P=0 .038)�根據Cox-
regression modeling ’ 較年長病人 [相對危機（ 9 5 % CI): 1.06(1.024-1.088)， 
P=0.0005]，男性病人[1.99(1.118-3.331)，P=0.0089] ’首次_見病人的前兩年，病 
人有較頻密的入院次數[1.16(1.074-1.258)，P=0.()002]和缺乏藥劑師的電話跟進服 
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1.1 Hong Kong health care system 
Due to aging，increasing personal affluence and unhealthy lifestyles, chronic diseases 
such as diabetes, hypertension, cardiovascular and respiratory diseases have become 
highly prevalent in Hong Kong. 1 
Despite its rapid socio-economic development, Hong Kong has yet to develop a 
comprehensive health care policy. Without medical insurance or saving schemes, 
patients with chronic diseases tend to seek medical treatment from public hospitals 
where patients only need to pay a nominal fee of $42 (~US$5.4) to take all medications 
including consultation. This has led to the services at the public hospitals in Hong Kong 
being overwhelmed. The lack of a comprehensive primary health care system has 
compounded the problem because of the relative inability to discharge patients with 
chronic diseases effectively to the community for their continued care. Due to the lack of 
a long-term health care financing policy and effective interface between hospital and 
primary health care providers, patients with chronic diseases, especially those with 
multiple medical problems, are often followed up, at long intervals, at the hospital 
medical clinics. 
This is followed by a series of vicious cycles as illustrated in Figure 1, of long 
waiting lists, long follow up intervals, short consultation times, inadequate patient 
education, poor treatment compliance, considerable drug wastage, progression of disease 
with advanced presentation and increased hospital admission rates. The overall results 
are sub-optimal patient care, increased health care costs as well as poor quality of life 
and reduced life expectancy. 
2 
Figure 1: Vicious cycles of Hong Kong healthcare system 
Large patient pool in the community with chronic disease (5-10%) 
i \ 
Under provision of quality care by generalists 
一 了 一 ； / T 
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Oversized hospital medical clinics / 
1 1 / 
•:• Short consultation times / 
•:• Long follow up intervals / 
Incomplete assessments 
•:• Brief patient education 
•:• Poor treatment compliance 
• Considerable drug wastage Increased health costs 
•:• Compromised quality of care 
y 
> Poor quality of life 
> Increased morbidity 
Failure to discharge stable patient > Increased mortality 
1.2 Medication compliance and treatment responses 
In light of the chronic and silent nature of many of these diseases, especially during 
remissions, patients often have little incentives to take prescribed medications on a 
regular basis. The latter are often prescribed with an aim to reduce long-term 
complications and prevent hospital admissions. However, the most well established 
treatment regimens are worthless if a patient chooses not to follow the instructions. 2-4 
Similarly, it is futile for physicians to prescribe, for drug companies to develop new 
» 
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drugs, for pharmacists to dispense and counsel, or for taxpayers to pay for drug therapy 
if it is not consumed properly. 
Though over the last fifty years, there have been thousands of published 
literatures on compliance studies; non-compliance is still a widespread phenomenon in 
many health care disciplines and considered one of the most serious challenges facing 
health care workers. 
In recent years, pharmaceutical industries have made tremendous advances in 
developing drugs for chronic medical illnesses that have been proven to be very 
efficacious when given in a closely supervised environment of the clinical trials. Most 
randomized trials of these new medications are tested in highly selected patients who are 
monitored very intensively, with results compared with placebo. Many of these drugs 
are potentially life saving and cost effective by reducing the rates of hospitalization, 
morbidity and mortality if prescribed and taken appropriately. 8-13 in the "real world" of 
primary care, patients are much more heterogeneous — often having more ambivalence 
about taking medications long-term, having other medical co-morbidities, and being 
followed up much less closely. 14 The resulting differences in medication compliance 
and disease outcomes between efficacy studies and naturalistic studies in primary care 
are often marked. 14 Some patients follow doctor's advice exactly but do not benefit 
from treatment, and others follow the advice incompletely, inconsistently, or not at all, 
yet improve or become well. 15 in addition, a person's condition can deteriorate or 
remain unstable even when the medications are taken as prescribed. Some studies even 
demonstrate that patients compliant with a placebo had better outcomes than poor 
compliers prescribed an efficacious treatment. 16-23 These suggest that factors related 
to compliance may operate independently or in combination with the drug to produce a 
treatment effect. For example, the act of complying may enhance feelings of well being 
or self-efficacy in a manner that may independently influence health outcomes and 
quality of life. 24 
4 
Table 1: Compliance and treatment responses 
Health Outcomes 
Good Poor 
A. Ideal outcome B. Inadequate therapy? 
Compliance 
Correct diagnosis Sub-optimal/incorrect diagnosis 
Good Correct treatment regimen Sub-optimal treatment regimen 
Good treatment compliance Good treatment compliance 
C. Unnecessary therapy? D. The target group 
Sub-optimal/incorrect diagnosis Correct diagnosis 
Poor Sub-optimal treatment regimen Correct treatment regimen 
Non-compliance Non-compliance 
Table 1 depicts various combinations of prescribing behavior and patient compliance 
on treatment outcomes that may be present in clinical practice and the need to 
distinguish one from another to initiate the appropriate intervention. The upper left cell, 
A, represents the most desirable state: good compliance with achievement of the 
treatment goal. Patients who fall into cell D (poor compliance and sub-optimal 
achievement of the treatment goal) are in need of efforts to promote compliance. 
Patients in cell B (good compliance without achieving the treatment goal) require more 
or better diagnosis and/or treatment. Those in cell C (attainment of the treatment goal 
despite poor compliance) need less treatment prescribed or reassessment of diagnosis or 
treatment regimen, and do not merit intervention to increase compliance. The aim of 
compliance assessment, along with other diagnostic tests, is to categorize patients into 
t 
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the appropriate cells. When it has been determined that patients occupy cell B, C or D， 
physicians may then review diagnosis, alter treatment or reinforce compliance to attempt 
to move patients into cell A. 
Besides, a definitive link between health outcome and compliance has yet to be 
established before there can be a care for allocating more health care resources to 
improve the utilization of medications in light of limited resources. 
1.3 Definition of compliance 
The first step in addressing the issue of compliance is to identify an underlying accepted 
definition of compliance. However within the literature, there is some dispute over the 
best method of defining the term 'compliance'. Many definitions have been offered with 
varying interpretations, 25-30 but the most widely accepted working definition by Brian 
Haynes was adopted in this thesis. 23 1979，Haynes stated that compliance is 'the 
extent to which a person's behavior (in terms of taking medications, following diets or 
executing other lifestyle changes) coincides with medical or health advice'. Non-
compliance is when a person's behavior does not coincide with medical or health advice, 
the extent of which is variable. 
When this term came into popular use in the 1970s, it was considered to be 
interchangeable with ’adherence' and was intended to be a 'non-judgmental' alternative to 
a previous understanding of patient behavior as characterized by 'recalcitrance' and 
'insensitivity'. 31 it has now become clear, however, that there are some critical 
differences between the two terms of'compliance' and 'adherence’. 
1' 3.1 Compliance 
'Compliance', when used outside of a medical framework, implies an obligation to yield 




When applied in a medical context, the implication is that the patient will submit 
to the prescriber's authority and will be obedient with treatment regimens. It suggests an 
asymmetric relationship between patients and health care providers, which assumes that 
health care providers, because of their training and expertise, know what is best for 
patients and those patients have an obligation to follow the advice once given. This is 
consistent with how the term 'compliance' is used in other aspects of medicine to 
connote acceptance or accommodation to a dominant force. For example, an artery or 
lung is 'compliant' to the extent that it accepts the pressure applied to it. The implication 
is that non-compliance is the patient's fault and is evidence of his/her willingness to obey 
advice. This diminishes the patient's autonomy when making decisions and reduces the 
possibility of joint problem solving based on mutual respect. 
Several authors have suggested that the term 'compliance' reinforces patient 
passivity and stigmatizes independent patient judgment about self-treatment as deviant. 
32-36 
1.3.2 Adherence 
An alternative term, 'adherence', has been offered by some investigators to denote a 
more active patient-physician treatment collaboration than compliance. 35,37-40 
'Adherence', when used in a non-medical context, suggests that an individual 
follows a plan or request (Oxford English Dictionary). It captures the increasing 
complexity of medical care by characterizing patients as independent, intelligent, and 
autonomous people who take active and voluntary roles in executing their medical 
treatment plan. Non-adherence may invoice guilt as the individual violates his/her own 
accepted standards of behavior. If adherence implies that the patient has made a choice, 
then the health professional can only rely on influence to alter or support the patient's 
decision whether or not to follow a treatment plan. This means that many doctors and 
nurses have to adapt the form in which their consultations are conducted and begin 
i 
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inviting patients into the decision-making process rather than dictating treatment plans. 
Despite the seemingly less judgmental nature of this term, it still shows a passive 
phenomenon as used in other aspects of medicine like platelets adhere to (stick to) blood 
vessels. 
In this article, 'adherence’ and 'compliance’ were considered to be 
interchangeable. 'Compliance' was the preferred term for consistency purpose, although 
it is recognized that 'compliance' may be interpreted as placing the patient in a passive 
role, whereas 'adherence' emphasizes a patient's active role in working with a health care 
provider to achieve a common goal. In addition, 'compliance' is the most widely 
recognized term describing this body of literature both currently and historically. It has 
also been chosen as the medical subject heading by the National Library of Medicine 
instead of'adherence'. 
1.3.3 Concordance 
'Concordance’ is a new approach to the prescribing and taking of medicines. It is a 
shared agreement reached after negotiation between a patient and a healthcare 
professional that respects the beliefs and wishes of the patient in determining whether, 
when, and how medicines are to be taken. 42 In this context, a doctor needs to develop a 
rapport with the patient, understands the illness in his or her terms, comes to a shared 
understanding and agreement about the diagnosis and imparts information about the 
proposed treatment and gives alternative choices. Also, a doctor provides the patient 
with alternative professionals for independent advice and allows time for the patient to 
decide on his or her future management. 43 
It is a good medical practice to discuss the pros and cons of drug treatment with 
the patient. However Milburn suggested that there were situations when treating the 
patient as a decision-maker, the backbone of concordance model, would fail. 
i 
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Firstly, if compliance is incomplete during the conduct of clinical trials of new 
drug, conclusions about the efficacy and dosing regimens cannot be made. Hence such 
trials require almost complete compliance to strict protocols. Incomplete compliance can 
set the dosage of new drugs at an unnecessarily high level and thus increase the risk of 
dose-dependent adverse effects which endanger those patients who adhere to the 
prescribed dose to toxicity. Moreover, it may otherwise lead to abandoning a useful 
treatment. 
Secondly, compliance and non-compliance are patterns of behavior resulting 
from complex interactions of many different factors. Attempts to change behavior with 
cognitive analytic psychotherapy are encouraging and suggest improvement in both 
compliance and clinical parameters in patients. 45 Thus, research into the human 
behavior of medicine taking is more related to compliance and does not fit the 
concordance model. 
Thirdly, in the case of an infectious and potentially lethal disease such as 
tuberculosis, doctors cannot ethically allow a patient the freedom of deciding which if 
any of the antibiotics he or she will take and how much. Patients with open pulmonary 
tuberculosis who decide not to take drug treatment will remain infectious and a hazard to 
others. Furthermore, patients who are selective about the antibiotics or erratic in taking 
the treatment are at risk of developing multi-drug resistant disease, a condition that is 
difficult and costly to treat and usually fatal to immuno-compromised people. 
Given the wide spectrum of diseases and the complexity of the interactions 
between patient, disease, medication and environment/society, the strategy to influence 




1.4 Definitions of satisfactory compliance 
Compliance is not a dichotomous variable, with either 'good' or 'bad', but represents a 
spectrum of variable administrations. 46 But what's the line to draw between it? 
Although this is particularly true for lifestyle changes and preventive practices, 
most drug regimens do allow for some flexibility and patient discretion in how and when 
the drugs are taken. While maintaining an adequate level of compliance is central to 
deriving benefit from any efficacious therapy, the degree of compliance necessary to 
achieve a measurable benefit from specific medications is variable and no quantitative 
standards for compliance performance in general clinical practice have been defined. 47 
Luscher and co-workers reported that 80% compliance was necessary to achieve a 
reduction in blood pressure from anti-hypertensive therapy, whereas 50% compliance 
was ineffective in lowering blood pressure. 48,49 On the other hand, Markowitz 
reported that children receiving only one third of their prescribed penicillin had 
substantial protection from recurrences of rheumatic fever. 50 The threshold of 
compliance for acceptable therapeutic effects is not known for most regimens. 
Compliance over long periods of time at a 100% level is clearly unrealistic and 
may not be necessary under normal circumstances. Ideally, one should define a level of 
treatment compliance for each disease that will maintain the patient in an adequate 
functional status. Unfortunately, such a level is often impossible to determine. Besides, 
the majority of patients with chronic diseases are on multiple medications. Hence, often 
compliance has to be defined arbitrarily. Common sense suggests that taking between 90 
and 110 per cent of doses is likely to produce the desired therapeutic effect for most 
categories of drugs; otherwise few patients can ever improve on drug therapy. However, 
90 per cent may be thought too high a level and 80 per cent is often adopted as 
acceptable. 51-55 An arbitrary compromise figure of 85 per cent has also been used. 56 
Some studies have defined compliance as between 80% and 120% of the prescribers' 
direction. 57-59 Furthermore, the main outcome measure in many of these studies was 
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the identification of severe non-compliance with essential medications as opposed to 
non-compliance of drugs with questionable clinical efficacy. 57,59 
The minimum compliance goal of 80% of prescribed dose can be justified as a 
standard since it is used conventionally in most clinical trials which collect safety and 
efficacy data to support new drug registration. Using data from subjects with this level 
of compliance, the dose-response function, and incidence of symptomatic and adverse 
side effects are usually determined. 60 Also, this level of compliance is 
pharmacokinetically sufficient to maintain steady state conditions that provide adequate 
therapeutic effect of many drugs, and is originally based on observations with anti-
hypertensive drugs.胡 
1.5 Importance of compliance 
The long-standing underestimation of poor compliance in drug trials has many 
implications for the interpretation of drug trials, for optimal dose estimation, for the 
interpretation of failed drug therapy, and for accurate labeling of prescription drugs. 61 
Undetected non-compliance can significantly reduce the power of the study to detect 
treatment effects in a clinical trial, thereby seriously diluting the reported effectiveness 
of the trial medication. It may also result in an overestimate of the dosage of the drug 
leading to unnecessary recommendation of high doses. Ironically, compliant patients 
may then have increased risk of developing side effects due to drug overdose. 
Medication non-compliance has been identified as a major public health problem 
that imposes a considerable financial burden upon modern health care systems. 33，62 
Approximately 10 percent of all hospitalizations and nearly one quarter of all nursing 
home admissions are attributed to a patient's inability to manage or follow drug therapy 
although this is almost certain to be an underestimation since compliance is often not 
assured or well documented. 28,37,62-70 j h e National Pharmaceutical Council 
estimates that medical costs related to prescription medicine misuse and adverse 
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reactions total more than $20 billion a year. 71 Non-compliance generates its own 
excess costs. When medications are used incorrectly or not taken at all, healthcare 
providers' time, effort, and expertise must be recycled and repeated. It can cause 
unnecessary diagnostic and treatment procedures with renewed rounds of testing, thus 
generating further costs. 72,73 when consequences such as lost productivity, premature 
deaths, and excessive treatments associated with non-compliance are included, annual 
costs are as high as $100 billion. 33,71,74 This issue requires serious attention and is 
particularly true for chronic diseases.乃 The economic burden of chronic diseases can 
put significant financial pressures on the health care system of any country due to the 
persistent nature of these conditions. The economic effects of non-compliance, when 
combined with the already high societal expenses on treatment of chronic diseases can 
be extreme. ^^ 
Not only does non-compliance add to the cost of medical care, it can lead to 
treatment failure with advancement of the disease states which are potentially avoidable. 
These can heighten the occurrence of adverse drug reactions due to uncontrolled 
diseases and worsen the quality of life. 77 For instance, missed doses of a glaucoma 
drug can lead to optic nerve damage and blindness; missed doses of a heart drug may 
lead to an erratic heart rhythm and cardiac arrest; missed doses of an anti-hypertensive 
drug can lead to stroke. 78-81 Non-compliance of immunosuppressive drugs can lead to 
rejection of transplanted organs or death. 82-84 Failure to take prescribed doses of an 
antibiotic can cause an infection to flare up and lead to the emergence of drug-resistant 
strains for infectious disease. On the other hand, surplus drugs may be used later without 
clinical guidance, leading to masking of infection and selection of resistant bacteria. 85 
All these can increase the infectious nature and this situation now seriously threatens the 
health of people worldwide. Drug-resistant strains of human-immunosuppressive virus 
(HIV) can replicate and mutate rapidly if patients do not maintain near-perfect (e.g. > 
95%) compliance rates. Less than optimal drug compliance most likely compromise 
the future effectiveness of those and related medications. This forfeits the opportunity to 
benefit from potentially life-saving therapies. Even if these patients later attain perfect 
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compliance, the virus will have developed resistance to the prescribed medications and 
possibly to other drugs in the same class.奶 
Abrupt discontinuation of medication can be risky in some situations, especially 
in patients with coronary artery disease taking beta-blockers. Indeed, it has been 
observed that hypertensive patients suddenly stopping beta-blockers had an immediate 
fourfold increase in the risk of developing new angina or myocardial infarction. ” 
When prescribed drugs are not taken correctly, health care providers and patients 
can be misled to believe that the therapy is ineffective or needs to be changed.幻 A 
failure to detect non-compliance often results in the prescription of excessive dosages of 
medicine and an increased cost of treatment due to health complications. ^^ If the non-
compliant patient becomes concerned about the lack of therapeutic effect and begins to 
take the higher doses, overmedication or drug toxicity may result. Early identification 
and remedies for patient non-compliance can be viewed as an investment in planning 
which will eventually pay high dividends to healthcare. 
1.6 Non-compliance as a behavioral disease 
Dr. Richard Levy of the National Pharmaceutical Council has proposed the analogy of 
non-compliance as a 'behavioral disease丨.Use of a disease model could be helpful in 
understanding and 'treating' non-compliance. 
1.6.1 Disease manifestation (Patterns of non-compliance) 
Taking medicine is a complex process necessitating a multitude of decision which 
include obtaining the prescribed drug and taking the right dose at the specified time, by 




Non-compliance can occur in many different ways. 89,90 八 patient may simply 
fail or refuse to get the prescription filled (non-starters). If the prescription is filled, the 
patient may take an incorrect dose or take the medication at the wrong time because 
he/she does not understand the physician's instructions (inappropriate users). Some may 
take a drug that is not prescribed, others may forget doses of their medications or stop 
taking the medication too soon (abrupt quitters). On the other hand, patients may self-
adjust the regimen due to side effects and toxicity or personal health belief systems 
(intermittent users). 
Hussey and Gilliland described two types of non-compliance: inadequate 
understanding of the disease or condition being treated (unintentional non-compliance) 
and a conscious choice by the patient to find another method of treatment or not to 
comply with treatment (intentional non-compliance). 91 
Some patients are found to have occasional major lapses of drugs lasting 3 or 
more days followed by sudden resumption, often called 'drug holidays'. 92 xhe 'holiday' 
pattern appears to recur approximately monthly in about 20% of patients，and less 
frequently in about half or more of patients. 15，93 The potential consequences of drug 
holidays include waning of drug actions during the drug free period, hazardous rebound 
effects when drug administration stops abruptly, and/or overdose effects when 
administration of drugs in full strength suddenly resumes. 77,94 Drugs that may have 
hazardous withdrawal or rebound effects include beta-blocking agents without partial 
agonist activity, clonidine and drugs that act on the central nervous system (opiate-
withdrawal syndrome) and cardiovascular disease. 94 Some rebound phenomena 
examples are rebound hypertension, rebound coronary insufficiency，and exacerbation of 
arrhythmia. 94,95 
A commonly observed phenomenon is that compliance improves several days 
prior to or a brief period after a scheduled medical appointment. 3,27,93,96-98 xhese 
higher compliance rates may be related to anticipation of the visit. John Urquhart 
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referred this temporary enhancement of compliance as 'the toothbrush effect': people are 
particularly likely to brush their teeth before going to the dentist. An alternative title may 
be 'white coat compliance', where the compliance is timed to meet the needs at 
consultation with the white-coated doctor. 96，99 it may also derive from the 
identification of 'white coat hypertension' - a phenomenon of blood pressure increase in 
doctor's presence, 96 
The above is a depiction of a continuum of compliance activities. However, 
patients who are taking multiple therapies may adopt several of these behaviors at the 
same time with several types of medications they may be consuming. 
1.6.2 Prevalence/Epidemiology (Rate of non-compliance) 
Non-compliance affects the course of many diseases and is prevalent even among people 
with serious and life-threatening conditions. 100-102 
About 6-20% of patients fail even to redeem their prescriptions. 103 For medical 
appointments, failure rates to attend between 19% and 28% are not uncommon. 104，105 
Low compliance with prescribed treatments is also very common. Typical compliance 
rates for prescribed medications for chronic illnesses tend to cluster around 50%. 
55,58,62,90,100,106-114 it varies from almost 0% to over 100% 
3,4,34,36,55,78,106,111,115 with an array of variable patterns of drug consumption with 
丨under-compliance' occurring more commonly than taking too many doses i.e. 'over-
compliance'. 46,75,116-118 Part of this variation is a consequence of the different 
definitions and measures of non-compliance and some are related to differences in 
patient populations, the illnesses studied and other variables or measurements relating to 
the treatment regimen. 106,114 
Electronic monitoring data in hypertension, glaucoma, seizure disorders, and 
other diseases indicated that only about 50% to 60% of patients achieved near optimal or 
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excellent medication compliance, that 5% to 10% displayed low levels of compliance, 
with long periods of taking no medications at all. Partial compliers, who represented the 
remaining 30% to 45% of patient, adhered to an intermediate but markedly variable 
degree, with day-to-day, week-to-week inconsistencies. 78 in some studies, workers 
concluded that the 'one-third rule' often apply to these patients - about one-third of 
patients are said to comply with recommended treatment, one-third sometimes comply 
and about one-third never comply. 7,24,26,119-121 The pattern for partial compliance 
may be erratic, or it may be consistent but different from what the physician prescribed. 
116 Patients who were partial compliers essentially had accepted their diagnosis and 
need for treatment. They made an effort to participate in their treatment, but they had not 
achieved consistency in their implementation to benefit from the full effect of their 
treatment. 78,116 
1.6.3 Diagnosis (Detecting non-compliance) 
It is important to distinguish between patients not complying with a recommended 
treatment and those not responding to a given treatment. 122 Therefore, as in the 
diagnosis of medical disorders, detection of non-compliance is a necessary prerequisite 
for adequate treatment. 
The standard criteria of the quality of a diagnostic test are sensitivity and 
specificity. Sensitivity here refers to the amount of non-compliant patients detected 
among all truly non-compliant patients and specificity, accordingly, to the amount of 
compliant patients detected among all truly compliant patients in a particular population. 
123 
The measurement of compliance has been a thorny problem. 124 There is a lack 
of agreement on the best method of a s s e s s m e n t . � Researchers will often choose a 
particular method due to ease and convenience. However, most of these methods have 
not been satisfactory in providing accurate measurements ^^ and none of the detecting 
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methods are without shortcomings or difficulties. 3，126 The use of various measurement 
techniques and calculation methods between studies has made it very difficult to 
compare compliance research findings. 
Current detection methods can be divided into direct and indirect. Direct 
methods are those by which the drug can be identified in the patient while indirect 
methods mainly take the form of assessments, either by the patient himself or some other 
individuals, as to whether the patient is likely to have taken the medication. Direct 
methods include direct measures, such as biological markers, tracer compounds, and 
biological assay of body fluids. Indirect measures, such as self-report, interview, 
therapeutic outcome, pill count, change in the weight of metered-dose inhaler canisters, 
medication refill rate, and computerized compliance monitors. In general, the direct 
methods of detection have a higher sensitivity and specificity than the indirect methods. 
Computerized compliance monitors are the most recent and reliable indirect 
methods. 
1.6.3.1 Direct methods 
Direct measurements usually involve the detection of a chemical (drug, metabolite, or 
marker) in a body fluid (blood, urine) and demonstrate that the medicine has been 
administered beforehand. The primary advantage for using direct measurements is that 
they are specific, reasonably accurate and less subject to bias than are indirect 
measurements. 127 in some situations, such tests offer the best means for compliance 
assessment. 
However, these are not available for all medications. Direct methods do not 
account for the large inter-individual pharmacokinetic variability of different 
medications. 127 Appropriate interpretations of these levels require fluid samples to be 
taken within specified time limits after administration of the medicine, which is rarely 
feasible under routine conditions. In addition, most therapies have to be administered 
repeatedly over time and thus fluid samples have to be taken repeatedly over time too, in 
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order to get a valid insight into the patients' compliance. These can be difficult to 
perform，inconvenient, and costly. Finally, some patients object to having blood 
specimens taken, regarding this as unnecessary, intrusive and thus unacceptable. 128 
Taken together, these factors limit the usefulness of direct estimations as a measure of 
compliance. It is practical only in single-dose therapy, intermittent administration and 
hospitalized patients. 23 
1.6.3.1.1 Use of biological fluids 
Therapeutic drug monitoring using blood and urine tests is well established as accurate 
and reliable method for many medications. The concentration of a drug or its 
metabolites in the blood will often give some indication of the actual dose being taken 
by the patient, provided that there is a clear relationship between dose and steady-state 
blood level. However, such methods may not be available for all drugs and entail high 
costs. 
Monitoring serum concentrations of selected drugs do not necessarily measure 
overall compliance. First, the plasma half-life of most drugs is only a fraction of a day. 
Thus, the plasma concentration reflects drug administration only during the last 48 hours 
at best, which is a small portion of the usual interval between clinical examinations. 
Little information can be derived regarding the use of medication over time. 129 Drug 
serum concentrations are therefore a reasonable method of evaluating compliance only 
for medicines with long half-lives. One example is the measurement of HbAic that gives 
a preceding three-month history of glucose control and thus in part may reflect anti-
diabetic medication compliance. The value of assessing compliance using direct 
measurement also depends greatly on the reliability of the method by which the drug is 
identified or quantified in the body fluids. Secondly, samples are usually obtained during 
clinic visits. There is good evidence indicating that compliance in the several days 
preceding a scheduled clinic visit is much better than at other times, allowing steady-
state serum concentrations within therapeutic range to be reached. 3,96,130 xhus these 
methods are not foolproof and can be misleading if the patient takes the medication just 
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prior to testing. A third problem is that because individual kinetics varies, the variability 
in levels may not fully reflect compliance. 
Urine tests are cheap and easy to administer but are only available for drugs or 
metabolites that are present in the urine e.g. the phenothiazines and tricyclic 
antidepressants. As with blood tests, one major disadvantage of these 'spot check' 
methods is that they pertain only to a limited time period and do not indicate what is 
happening during the rest of the interval. Both methods are also affected by individual 
variance in metabolic and absorption rates though they do provide some objective 
measures. 
In summary, the usefulness of data on drug concentrations in biological fluids is 
limited because: 
• They are affected by individual differences in absorption, distribution, 
metabolism, and excretion. Therefore, low or erratic drug concentrations do not 
necessarily indicate non-compliance; 
• They do not provide data regarding the timing of doses consumed and 
• Intake of rapidly cleared drugs right before testing can produce results that show 
adequate drug concentrations, erroneously suggesting regular medication use. 
Thus, some believe that the use of biological fluids is impractical in most 
ambulatory settings and give little information about the consistency of medication 
taking. Rather than as a measure of compliance, monitoring of serum drug concentration 
has been more important in increasing our understanding of the relationship between 
drug dosage and drug concentration in the blood. 
1.6.3.1.2 Biological surrogate (Drug) markers 
When it is too difficult to identify a substance in bodily fluids, an inert, nontoxic, 
absorbable, and kinetically similar compound can be co-formulated with the therapeutic 
agent or placebo and act as a marker to measure patient compliance with drug therapy. 
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131 This marker can then be subsequently detected in blood, urine, stool, saliva, exhaled 
air or even on hair (theoretically reflecting long term compliance with chronic therapy) 
and used for compliance assessment. 131-134 
Many types of markers have been proposed: 
Radioactive substances in tracer microspheres have seldom been used, since 
handling of radioactive substances in large trials involves hazards. 135,136 
Inert molecules, such as perfluorocarbon, dyes, pheromones and spin-labeled 
substances have only been hinted at. 
Pharmacological substances have been more extensively studied but only have 
historical value, e.g. phenol red, sodium bromide, fluorescein sodium and 
phenazopyridine. 98,131,137 
Stable isotopes (marker molecules enriched with ^H, '^C, ^^N or could 
provide a non-pharmacological, non-radioactive and non-invasive procedure. Heavy 
water, deuterium oxide (D2O), is relatively inexpensive and is a particularly interesting 
candidate, since the pattern of its metabolism reflects the theoretical ideal for a marker. 
133，138 D2O could be administered as a diluent for drugs administered as liquids (e.g. 
insulin) and deuterated glucose could be used as filler in solid drugs. 139 was 
detected in exhaled air, urine and stools. 1 卯 Technical difficulties in handling stable 
isotopes have hampered widespread use of this technique. 
Riboflavin was first used in large-scale trials, like the 1967 study of the Veterans 
Administration Cooperative Study Group on Anti-hypertensive agents. All candidates 
for the trial were rigorously screened for compliance, on the basis of their intake of 
riboflavin and its subsequent excretion in urine, which lead to discovery of the 
'toothbrush' effect. Riboflavin is a short-lived marker in doses of 3 to 15mg, and can be 
detected in urine within 12h or ingestion by its fluorescence. 139,140 
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To simplify the relation between marker dose and its concentration in plasma, the 
marker should have linear pharmacokinetics that displays minimal variability. These 
objective and accurate methods require modifications in formulations to incorporate the 
marker into the dosage form. However, often the marker methods do not reveal the time 
of administration of each dose and prove dose ingestion only within a limited interval of 
time (i.e. 2.5 to 3 plasma elimination half-lives of the marker substance) which is about 
3 to 7 days prior to blood sampling. 94 in the choice of a marker, a trade-off based on 
the rate of elimination of the marker must always be made. Short-lived markers are 
vulnerable to the 'toothbrush effect', are subject to big intra-individual differences and 
are susceptible to timing differences between intake and collection. These can often 
invalidate the interpretation of results from various detection methods (e.g. 
determination of drug concentrations in body fluids). Hence, drug concentration 
monitoring usually results in an overestimation of the usually prevailing degree of 
compliance, unless the drug in question has an exceptionally long plasma half-life, or 
blood samples are drawn at unscheduled times. 
1.6.3.1.3 Pharmacological indicators 
Digoxin in doses of 2.2mcg per tablet has a half-life of about 60h (longer than the half-
life of the therapeutic dose - 0.25mg per day). 141 it has proven to be a valuable urinary 
marker, suitable for categorical discrimination between poor and good compliance, and 
it may also give some indication of dosage reduction. It serves to reveal non-compliant 
patients who resume medication on the day of or the day preceding the control visit. The 
occurrence of 'drug holidays' (stopping all medications for more than 2 consecutive 
days) can be detected only if they occur less than 3 days before the control visit. 
Phenobarbital have long elimination half-life (tl/2) of 99 hours and thus have the 
advantage of indicating compliance for the preceding few weeks, rather than days. With 
either drug, good compliance cannot be simulated by ingesting a few doses immediately 
before assessment and are relatively free of bias introduced by white coat compliance. 
They are markers which can produce quantitative data, unlike other markers which only 
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provides qualitative data. 141,142 Consequently, its developers, Pullar and Feely, coined 
the term 'pharmacologic indicator' rather than simply 'marker'. 143,144 
In addition to its long half-life, low dose phenobarbital (LDP) displays relatively 
little inter-individual and intra-individual variation in plasma concentration after 
allowances are made for weight and age. 142 in the dosage used (1 to 2mg/day) to 
measure compliance, it has no enzyme inducing properties and no apparent sedative 
effect. 142,144,145 Furthermore, at this low dosage, there is a good direct linear 
relationship between dose and steady-state concentration in plasma. 
However, as with all markers, either patient has to take separate capsules, or 
special dose-forms incorporating the markers have to be prepared. 142 por practical 
implementation, the low dose marker method requires a special formulation (e.g. 
standard tablet plus marker in an opaque capsule) and strict quality control to minimize 
variance in the amount of marker added to each dosage form. 141,142 Furthermore, 
bioavailability of both drug and marker must be validated and careful chemical analysis 
is demanded. A further disadvantage is that blood samples must be taken. 
Although the marker methods provide unambiguous evidence of drug ingestion 
and have been invaluable research tools, their uses in routine care are limited in clinical 
settings where unchecked non-compliance is responsible for serious clinical problems. 
There are also biological parameters which reflect the efficacy of the treatment e.g. 
decreased serum cholesterol level with a hypocholesterolemic agent; adequate 
therapeutic range for the International Normalized Ratio with warfarin therapy; 
normalization of glycemia with a hypoglycemic agent; decreased level of angiotensin 
converting enzyme with ACE inhibitors. 
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1.6.3.2 Indirect methods 
Indirect measurements include process measures such as patient self-report, self-
monitoring by patient diaries, pill count, prescription refill, and impression of the 
physician or therapeutic outcome. Several studies have shown that indirect methods 
provide only low to moderate sensitivity and specificity in the detection of non-
compliance (Table 2). More recently, electronic medication monitors have emerged as 
a particularly promising alternative to traditional measures, which provides a high 
degree of sensitivity to detect partial compliance. As with direct measurements, each 
indirect means of measuring compliance has inherent advantages and disadvantages. 
Most are incapable of directly confirming actual consumption of the medication, and 
frequently distant in time and space from the actual medication-taking event. Despite 
their limitations, indirect measurements of compliance are the most frequently and 
widely used methods in the literature, possibly due to the relative ease by which these 




































































































































































































































































































































1.6.3.2.1 Self-report / Direct questioning 
Self-report is the most widely applicable method to evaluate compliance with therapy. 
143,144,151,152 Patients and/or their relatives are asked, verbally or by questionnaire, 
to what extent the patient has been complying with the treatment. It is the most direct 
source of information and also the best measure for collecting information about patient 
beliefs, attitudes, concerns,' experiences with medication regimens and possible reasons 
or explanations for non-compliance. The instant attainment of this valuable clinical 
information can allow prompt re-evaluation of the current regimen. It is essential to take 
into account that even if the patient admits to missing any medication during the 
previous day or week, he or she still tends to overestimate the actual rate of compliance 
(by an average of 17% in one study), 153 
Unfortunately, inadequate compliance coupled with inadequate reporting is 
ubiquitous across medicine. 149,153-155 One major pitfall of this method is that 
patients often tend to overestimate their level of compliance because of embarrassment, 
forgetfulness, recall bias 122,156,157, fear of losing their physician's trust, desire to 
please the provider and avoid criticism. 130,158 Even Hipprocrates remarked that 
patients often lied to have taken certain medicines to please the clinician or to avoid 
disapproval. 23 These observations reflect the strong social desirability of appearing to 
be compliant. Few patients have the temerity to admit that they are not taking their 
medications. However, it is always worthwhile to ask, because the substantial numbers 
of patients who do admit to non-compliance are rarely trying to mislead their doctors. 
7,23,125,130,145,156,159 Stephenson et al claims that careful questioning identifies 
more than half of those who are non-compliant without falsely labeling them as 
c o m p i l e r s .湖 
How the question is asked also affects the accuracy of the response; simply 
altering the phrasing may lead to different reports. 161 Questions about non-compliance 
should not be threatening, accusative, or embarrassing. The sympathetic question can be 
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prefaced with a remark such as: 'People often have difficulty taking their pills for one 
reason or another' or 'Everyone forgets to take his or her medications from time to time, 
that's natural. I do myself. Do you forget sometimes too?' 153 skilful phrasing is a 
necessity. The question must also be asked in a particular way: 'Have you ever missed 
any of your pills?' If the answer is affirmative, the patient is asked to estimate how many 
pills he or she has missed during the previous day and week. Patients should be asked to 
indicate, without prompting, exactly what medications they are taking and when they are 
taking them. This may reveal a different understanding of compliance to the regimen 
than was prescribed. For patients who report a generally correct understanding of their 
prescription, the details of any non-compliance should be sought. 
Similarly, Morisky and colleagues 162, have reported success in the use of a 
four-item scale as a predictor of future medication compliance as well as a measure of 
current compliance. The scale was shown to be a reliable and valid predictor of 
compliance. The four questions in the scale are: 
Do you ever forget to take your medicine? 
• Are you careless at times about taking your medicine? 
•:• When you feel better, do you sometimes stop taking your medicine? 
Sometimes if you feel worse when you take the medicine, do you stop taking it? 
In other words, the reliability of data from interviews also depends on the quality 
of the relationship between the patients and the interviewers. 
1.6.3.2.2 Pill counts 
Pill counts are another common method used to measure compliance and is frequently 
used in clinical drug studies. Since some patients cannot be relied upon to report their 
own drug consumption, attempts have been made to follow drug use by monitoring the 
amount of medications which remain unused. A patient's compliance to a medication 
regimen can be assessed by the difference between the number of dosage units initially 
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dispensed and the number remaining on the patients' return visit or during an 
unscheduled home visit. With this method, the patient is asked to return a medication 
container at regular intervals. The amount of medication not used is counted and 
provides a basis for an assessment of compliance. 
Counting returned tablets or weighing returned aerosol canisters to determine the 
number of actuations are often used in prospective studies to monitor compliance over a 
period rather than at a single time point. Any tablets remained in the bottle clearly 
cannot have been taken. 126 But when compared against other methods, tablet counts 
often over-estimate true patient compliance because the patient might adjust the number 
of tablets in the bottles. 3,57,145,157,163,164 Patients quickly become aware that the 
doctor checks the number of pills they are returning and thus throw away some pills in 
order to achieve the perfect number. This is so called 'pill dumping'. On the other hand, 
patients might see the drugs dispensed as their personal belongings and were unwilling 
to return unused medications. 165 The reliability of pill count is undermined whenever 
the patient chooses to discard or hoard untaken doses. 
Pill counts can only give a very imprecise evaluation of compliance rate for a 
given period. Nothing can be said about daily treatment schedules or about time 
intervals between doses. Such counts do not measure what days the medication was 
actually taken; whether the appropriate numbers of pills were taken; or whether pills 
were discarded before the visit to give the appearance of compliance with the prescribed 
regimen. The patient could regularly underdose and then overdose himself, yet appear to 
be compliant. Poor compliance should be suspected when the count is surprisingly 
accurate, especially if the patient is casual about other details of the treatment. 
Pearson 126 concluded that pill counts were useful, providing their limitations 
were recognized. Steps that can be taken to maximize their validity are: 
• Not giving the patients any clues that there would be a tablet count; 
• Telling the patients not to use any drugs already at home; 
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• Giving the patients more medication than required for the period under study and 
counting the tablets left in the bottle when returned and 
• Visiting the patients at home to minimize the number of missing bottles. 153 
1.6.3.2.3 Diaries 
Diaries and various kinds of charts and records have been used to track compliance. 166-
170 Patients' diaries have been successfully used in clinical practice to improve 
c o m p l i a n c e .腳 For each dose, patients record in diaries the time and quantity of 
medication used. The diaries constitute a reference for patients and investigators that 
facilitate discussion about treatment history. Use of these techniques may have the effect 
of reminding some patients to take their medicine. On the other hand, the patient must 
remember not only to take his or her medicine, but also to record the event, introducing 
yet another potential error. It is also difficult to sustain diary keeping for long periods of 
time and it gives only an illusion of objectivity, for it is impossible to know when the 
records were filled out or how truthful a representation of reality they are. Of course 
many patients simply never write anything on the diary. 
1.6.3.2.4 Electronic monitoring 
Computerized compliance monitors are the most recent, innovative, sophisticated and 
reliable indirect-detection methods. Devices are available for a variety of packages 
(bottle, blister, nebulizer) such as the Medication Event Monitoring System (MEMs) 
(APREX, Menlo Park, CA), the MDI Chronolog (Medtrac, Lakewood, CO), and the 
Medtrac Electronic Management System (Medtrac, Lakewood, CO). 171,172 This 
technique was first used in the 1970s, but became commercialized only in 1987 after the 
size and power requirements of the electronic device and cost of micro-circuitry had 
fallen drastically. At the same time, the memory capacity of these devices had grown to 
permit continuous monitoring for several months or more. 173 The principle of 
electronic monitoring of compliance was pioneered by Kass et al, with the development 
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of an electronic eye-drop dispenser in which the time- and date-stamped events were 
coincident with cap removal and bottle inversion. 130 
For oral solid dosage forms, several approaches have been taken. Simple cup-
type drug containers have micro-switches or optical sensors within the closure that 
activates recording of the time and date that the container is opened or closed. Thus, the 
medication event is the pair of opening and closing times. 130 Those for blister packages 
have been designed so that a signal is generated when the blister is broken into 27, or 
when an extracted tablet drops through a slot in the device holding the blister card. 口4 
For inhalational drugs, micro-switches are activated by the drug dispensing mechanism. 
171 
The MEMS has been adapted to measure compliance with solid dosage forms. It 
consists of a microprocessor housed in the cap of the medication container. Each time 
the patient removes the cap of the container; the time and date are recorded with each 
opening counted as a presumptive dose throughout periods of many months at a time. 
3,24,99，130 After the patient returns the compliance monitor, data is retrieved by 
connecting the microprocessor unit and downloading to a personal computer to show a 
calendar plot of the number of openings for each day. An exact time and date of every 
bottle opening is recorded, which gives a very good understanding of drug usage and 
dosing interval. Detailed reports on the percentage of days with the correct number of 
doses taken can be produced and displayed. The patient's pattern of usage can be 
compared with the prescribed regimen to determine how many doses were taken on 
schedule, too late, too early, or not at all. 3，96 Such data not only provides an indication 
of individual dosing patterns, but also allows correlation with clinical events which 
might be useful in understanding why treatment has not been fully successful. 
Although electronic monitoring approaches are not entirely foolproof, they are 
vastly superior to any other available monitoring approach. As compared to tablet 
counting, it would seem a more reliable measure of compliance. 3,175 Unlike someone 
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who discards pills before a periodic pill count, a patient who wants to fool the 
monitoring circuit would have to trigger it according to the appropriate schedule each 
day. There is no assurance that patients actually consume their medication, but they 
would have to open and close the bottle at prescribed intervals on a daily basis to create 
a false pattern of compliance. Though not impossible, it is an arduous task and such 
patients will be wrongly classified as drug non-responders. However, a study by 
Urquhart suggests that few- patients open the device and discard the medication. 176 
After going through the trouble of opening the container each time to do this triggering, 
the patient might as well take the pill. Other problems include patients taking out several 
doses at one opening, patient on multiple drugs who may swap bottle caps, and the 
possibility of patients leaving the cap off altogether. 71 In addition, the device is 
expensive and is slightly different in appearance from a normal cap, meaning that 
patients need to be informed about it. This may change their behavior to a certain extent 
because they know they are being watched. Finally, medication compliance may not 
always correlate to beneficial patient clinical outcomes. 71 Patient misuse, device 
failure, or computer hardware/software problems can also cause failure of the electronic 
devices. 177 Clinicians or researchers who use such devices must be careful to develop 
quality control procedures that ensure the ongoing monitoring of device performance 
and validity. 
Overall speaking, MEMS detect pill dumping, drug holidays and white coat 
compliance. They can also detect poor compliance preceding the occurrence of a clinical 
endpoint. 24,97 This technique is reliable because most of the errors in drug 
administration are errors of omission (delayed or omitted doses). 178 in addition, these 
devices offer the opportunity to extend our understanding of compliance in an individual 
patient from simply being a yes/no or adequate/inadequate phenomenon to one that 
recognizes compliance has dimensions of both time and quantity. Medication monitors 
are thus the only compliance measuring method that allows accurate assessment of the 
timing of doses. Studies have demonstrated that MEMS is more accurate than other 
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available methods and is therefore frequently considered the 'gold standard' of 
compliance measurement. 3,27,164,172’ 173,179-184 
Although the recorded patterns will allow physicians to recognize patients who 
are fully compliant or totally non-compliant, the results are particularly important for 
identifying partial compliance. Partially compliant patients take enough doses to indicate 
that they accept the principle of treatment, but they delay or omit too many doses to let 
the drug have its full effect. Such patients are the ones who may be helped by additional 
encouragement or by special modification of either the regimen itself or their rituals in 
trying to maintain it. ^^^ 
The printout of the electronic compliance pattern has many advantages. It offers 
a specific written record that provides feedback to the patients and the basis for a frank 
discussion to take place between doctor and patient. It will prevent doctor's tendency to 
prescribe bigger doses or switch to different drugs if the prescribed drug is not 'working' 
because it is not taken properly. 24 By eliminating conclusions based on the toothbrush 
effect (or white-coat compliance), physicians can avoid false overestimates of 
compliance that may have led in the past to such therapeutic paradoxes as glaucoma 
occurring despite normal ocular tension or left ventricular hypertrophy developing 
despite normal blood pressure in the doctors' office. 
The era of technology has led to a proliferation of efficacious drugs in clinical 
trial settings but whose actions and effects in day to day clinical practice are difficult to 
evaluate. With the development of electronic monitoring for compliance, the effective 
use of these drugs can be enhanced due to better monitoring by patient's doctor. 
However, to date such devices are still too expensive to be used in large studies 
or routine clinical p r a c t i c e .赐 To my knowledge there have been no reports of 
pharmacists using electronic compliance monitoring devices for patients with chronic 
diseases in Hong Kong. Nonetheless, with more widespread use, the economies of scale 
in production and cost will apply. With such instrument in place, more quality data on 
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compliance can be collected leading to greater emphasis on monitoring compliance so 
that a more rational approach could then be adopted to identify individual patients who 
are most likely to derive benefit from interventions designed to improve compliance. 
1.6.3.2.5 Physician estimates 
One of the earliest methods,of measuring non-compliance involved physician estimates 
of patients' drug taking behavior. Findings revealed that this method was no more 
accurate than chance alone since physicians have a tendency to overestimate the degree 
of compliance in their patients. 127,137,187-190 
In some studies, primary care physicians were asked to give compliance 
estimates only for patients they felt they knew well. The sensitivity of clinical judgment 
for detecting non-compliance was an embarrassing 10%, and overall performance by 
clinicians was not better than if they had flipped coins instead of applying their 'clinical 
judgment丨.137，188 physicians should not trust their unaided judgment regarding drug 
compliance by individual patient. 
Mushlin and Appel reported that less than one-half of a physician's predictions 
correctly discriminated between compliers and non-compliers, while three quarters of 
their predictions of non-compliance were inaccurate. 191 Other studies have shown that 
physicians have no more than a 50% chance of identifying whether their patients are 
complying with the prescribed medication, m Paterson and colleagues compared actual 
patient compliance to physicians' predictions of patient c o m p l i a n c e .旧 Compliance 
was defined as taking at least 80% of the prescribed medication dose. Compliance was 
measured with the Medication Events Monitoring System (MEMS). MEMS records 
each time the container is opened, document precise time of medication use，as well as 
drug holidays and extra doses as explained in Diagnosis. This study revealed that 
physicians incorrectly classified the patients' compliance ability 41% of the time. Often 
health care providers believe that low socioeconomic status, lack of education and 
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poverty predicted non-compliance. However, predictors of compliance vary greatly and 
no one single factor has been constantly to be associated with non-compliance. 
While most physicians recognize the possibility that patients may not follow 
instructions, the knowledge does not help them to assess accurately the behavior of 
specific patients. 
1.6.3.2.6 Outcome measurement and clinical judgment 
In theory, if an efficacious drug has been taken correctly, there should be an observable 
improvement in the condition being treated, which will not be evident if patient has poor 
compliance. However, there are a number of weaknesses in this hypothesis. Firstly, the 
diagnosis may not be correct. Secondly，the selected drug may not be appropriate. 
Thirdly, patients do improve for reasons other than following the prescribed regimen. 
And lastly, there may be other confounding factors, such as socioeconomic reasons or 
lifestyle factors which may influence the drug taking process. In fact, the patient's 
response to therapy has only been shown to be weakly related to compliance for many 
treatments. 153,192 Failure to achieve a therapeutic response may be the first sign that 
the patient is not complying with the prescribed treatment. However, such an analysis is 
both over-simplistic and flawed; in that it presumes the efficacy of treatments is the 
same for all patients. 126 So outcome measurement may tell us nothing about 
compliance. 
Despite these arguments, for certain types of drug treatment, there is reasonable 
assessment between clinical outcome and compliance. For example, non-compliant 
patients who are on anti-convulsants will be more likely to have seizures than those who 
are complying. However, for many types of treatment, this approach may not be 
sufficiently sensitive, because even when patients comply, this does not necessarily 
ensure a satisfactory outcome due to the fact that there are so many other factors that 




Another method of assessing compliance is to identify drug-related effects that 
indicate the medication has been ingested although this may still not correlate with 
clinical outcomes for previous arguments. Clinical markers of compliance which relate 
to the mechanisms of action of the experimental treatments are: 
• Normalization of blood pressure in hypertension, 
• Disappearance of fever with antibiotics and 
• Decreased intra-ocular pressure in glaucoma 
Examples of clinical markers related to other effects of the drugs are colored 
urine (rifampin, rifabutin), bradycardia (beta-blockers), and increased micturition 
frequency (diuretics). Researchers have also used laboratory tests, blood pressure 
readings, and other physiological measures for detecting non-compliance 125,188,193； 
however, these methods are not always available or feasible. Another concern is that 
these techniques only reflect drug taking in the day or two before the test. 26 This is an 
important drawback due to the white coat phenomenon where patients increase drug 
intake a few days before coming to the clinic and give a false impression of compliance. 
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1.6.3.2.7 Presence of side effects 
With certain drugs, side effects occur consistently when the patient is taking a 
therapeutic dosage. Assessment of these side effects may give an indication as to 
whether the patient is complying with the treatment program or not. Some regimens 
produce telltale side effects, the absence of which suggests low compliance; for 
example, increased urinary frequency with the initiation of diuretics, dry mouth with 
anti-cholinergics, slow heart rate with beta-blockers, dark stool with oral iron and 




The limitation of this method is that patients are often unreliable in reporting side 
effects, as shown by the occurrence of many side effects when patients are taking 
placebo in double-blind controlled trials. In addition, although the absence of common 
side effects may be an indication of non-compliance, the link between compliance and 
side effects for most medications is either unknown or relatively tenuous. For example, 
for patients prescribed with diuretics, the sensitivity for non-compliance of reductions in 
serum potassium was 82%'but the specificity was only 48%. 153 Nonetheless, some 
studies suggest that patients might be willing to endure adverse side effects 
unnecessarily, blindly believing that this drug might decrease their risk of developing 
future health problems. 115,131,195 
1.6.3.2.8 Keeping of appointments 
Keeping appointments does not mean that the patient is compliant with the regimen. 
Some patients may develop good relationships with his/her doctors with regular clinic 
attendance, but may remain non-compliant. Physicians should not assume that good 
attendance equal to good treatment compliance. Although attendance is not an assurance 
of compliance with medications, non-attendees are frequently poor compliers. 102,122 
According to Stephenson et al, 'you can detect most non-compliant patients by watching 
for non-attendees, watching for non-responders, and asking them about their 
compliance； 160 o f patients keeping more than 60% of their scheduled clinic 
appointments, 40% were found to be non-compliant with medication by urine metabolite 
measurement, while 95% of patients with lower appointment attendance demonstrated 
low compl i ance .舰 
1.6.3.2.9 Prescription refill rates 
The validity of prescription refill dates depends on the completeness of the pharmacy 
database which the pharmacy computer systems are capable of displaying information 
indicating how long it has been since the prescription was last refilled. Knowing the last 
refill date, the quantity supplied, and the daily dose, pharmacist can assess how many 
t 
35 
days late-or early-the patient is for a refill. Pharmacy refill records provide relatively 
objective, unobtrusive, and inexpensive estimates of compliance in large populations 
over extended periods of time. 196-199 However, these methods only provide a gross 
measure of compliance and cannot be used for short-term regimens. Similarly, the 
use of prescription refill rates to estimate medication compliance patterns is not a 
reliable measure of compliance. Some patients order refills automatically without using 
their supply, while others might have had a dosage reduction, making it appear that they 
are delinquent in obtaining a refill. Still, delayed refills of prescriptions can be a useful 
sign of partial compliance. 116 
1.6.3.3 Direct observation 
Directly observed treatment has been successfully implemented in several settings and 
found to be associated with substantial improvements in rates of compliance and 
reduction in emergence of drug resistance. 153,154,200-205 this scheme, patient 
takes the drugs in the presence of a healthcare provider or other designated person. 
Medicine administration in residential homes and in hospitals involves direct 
observation that the patient actually takes the medicine. This approach is routine in the 
pharmacology unit when subjects are hospitalized for the entire study. For oral dosing, 
the mouth should be checked after swallowing to ensure that pills are not hidden in the 
cheek or under the tongue and later discarded. 131 induced vomiting is a potential 
source of non-compliance. 
Direct observation is a useful tool when a level of skill is required to use a 
medication successfully, such as eye drops, various inhaler devices and use of buccal 
tablets. Here, direct observation can help patients acquire the skill to comply, rather than 
to measure their level of compliance. 
Although direct administration by a health care professional is more difficult for 
long-term oral therapy, this method may represent the only solution when poor 
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compliance creates major medical and social concerns. 206 Poor compliance with anti-
tuberculosis treatment is associated with a growing number of therapeutic failures and 
emergence of drug-resistant bacterial strains. 207 Despite the increased burden on 
resources, direct observation of drug administration effectively reduces primary and 
acquired drug resistance as well as relapses. 203 Directly observed therapy is also 
recently adopted for HIV infection 208 which a near perfect compliance is required to 
inhibit rapid replication and mutation of drug resistant strains of HIV (refer to section 
1.3 Importance of compliance). 
Although this approach is often used as part of a comprehensive care plan effort 
to improve tuberculosis services, it is generally impractical to adopt this strategy in the 
majority of clinical trial setting or day-to-day clinical practice. Also, it has been argued 
that in this care situation, the patient is being coerced into taking the medicine, rather 
than being allowed freedom of choice. 
1.6.3.4 The ideal detection method 
The ideal detection method is to measure compliance at the time and place of the 
medication-taking event. This will give perfect sensitivity (the proportion of patients 
with imperfect compliance identified by the measure) and specificity (the proportion of 
patients with perfect compliance identified by the measure). Perhaps the closest to this 
way is the use of direct observation via closed circuit television to validate electronic 
monitoring methods, but this method is not representative and furthermore would be 
impossible to implement for routine use which also violate human right and 
confidentiality. 
To help overcome limitations of various assessment methods and to collect 
corroborative information, it is recommended that at least two different detection 
methods be used to measure compliance xhe researcher and practitioner should be 
aware of the limitations unique to the technique they have chosen and interpret data 
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cautiously. A gold standard to measure adherence to therapy does not exist: the best 
method likely depends on the intended use of the data. 
1.6.4 Risk factors (Related factors of non-compliance) 
The drug defaulter, just like the placebo reactor, is not a consistent or readily identified 
person. 209 whether or 'not a particular patient complies with the physician's 
instructions depends on a variety of factors that may change with time. 3,57,173,179 
Those who are unreliable in one situation may not be in another. A family physician 
who studied this problem in detail concluded that it has not proved possible to identify 
an uncooperative type. Every patient is a potential defaulter and compliance can never 
be a s s u m e d . � 
One of the first studies on compliance, by Brian Haynes and David Sackett, 
explored factors associated with non-compliance, focusing on the understanding, 
measurement and resolution of non-compliance. 33 More than 200 variables have been 
studies since 1975, but none of them can be considered consistently predicting 
compliance: neither socio-economic nor pathology-related factors. 23,33,42,154 
Compliance research is so complex that it is inevitably fragmented. Even so, it remains 
possible to identify a constellation of factors that are sometimes associated with non-
compliance. Many correlations are weak but the possibility of a casual relationship is 
often suggested. Such factors may be found in relation to the patient, illness, physician, 
medication regimens or treatment milieu. Identification of these factors may alert the 
physician to situations where patients' non- or partial compliance may occur. 
1.6.4.1 Patient related factors 
1.6.4.1.1 Understanding and comprehension 
Many patients are simply not given correct information on how to take medications, 
such as taking drugs at regular intervals or at certain times of the day. These patients are 
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often left to follow in their parents' footsteps or learn on their own. Chronic medications 
for asymptomatic disease such as hypertension, diabetes, or hyperlipidemia are new 
medical technology. The lack of public education through societal mean e.g. mass media 
which many patients now on therapy have never seen their parents take it and the often 
ineffective education by health care professionals have led to inappropriate use of these 
new techniques. Besides, patients may not understand their condition and the reason for 
taking medications. They misunderstand physicians' intentions regarding drug therapy. 
210-213 丁hey may have inadequate and inaccurate cognitive or intellectual abilities to 
understand complex regimens and their potential complications. Some patients simply 
fail to master the necessary skills such as those required for effective actuation to 
inhalation coordination while using inhalers. Others may see the reduction of symptoms 
as improvement or 'cure' of the condition and do not appreciate the need to finish the 
prescribed amount of medication. 214 For example, patients might stop their antibiotics 
prematurely after fever subsided before all bacteria were adequately eradicated as 
mistakenly believing that the infection has been sufficiently treated. Some misinterpret 
their chronic conditions can be 'cured' by drugs and may therefore stop taking their 
medicines after they feel better or are symptoms-free. 36,215 This may also occur in 
situations where patient acknowledges physician's diagnosis, but consider the disorder to 
be mild especially in the absence of symptoms such as glaucoma and high blood 
pressure. A similar situation arises with prophylactic or suppressive medication, for 
example, anti-malarials, where the individual may see no advantage in taking a medicine 
with its associated risks. 
When relapse is immediate or severe (as with heart failure), the patient is less 
likely to deviate. For example, patient experiencing asthmatic attack usually experiences 
dramatic improvement after using an inhaled medication. In this case, the benefits of 
taking medication are immediate and quantitative. However, patients with illnesses 
which have low responses to treatment may decide to stop it. ^^^ They may feel angry 
and betrayed if they do not observe immediate benefits and, consequently, stop taking 
the treatment. This situation is common with some medications with delayed effects 
such as anti-depressants, which may take up to three weeks to become effective. If the 
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patient is not well informed about this delayed effect and advised to gauge the drug's 
effectiveness by comparing with how he feels prior to drug taking, he may discontinue 
therapy before the medicine has a chance to work. As a rule, immediate consequences 
are more powerful than delayed consequences in changing behavior. 100,131 This 
explains why health-related behaviors e.g. drug taking, dieting or increase exercise can 
be difficult to adopt, because their immediate effects are often 'aversive’ e.g. side effects 
of treatment or self regulatron or discipline, while their beneficial effects may be long 
term and probabilistic. 
On the other hand, some patients may intentionally take more than the prescribed 
dose of a medication in the mistaken belief that more drugs will expedite recovery. 
These patients may live by the adage 'if a little works, a lot will work a lot better'. 214 
Such deliberate non-compliance may be based on prior experience with rapidly acting 
drugs or in the hope that their symptoms will resolve sooner resulting in a net reduction 
in drug costs because of incorrect concept. 
Fear of dependence on drugs is a frequently given explanation for ceasing 
medication prematurely or omitting some doses. Some patients do not comply with 
medication because they fear of becoming 丨immune, to the treatment or even become 
'dependent' on the drug. 
In many of these cases, the doctor may not have explained the purpose of 
prescribing, immediate effect of the treatment, the intended duration of action and 
expected benefits of the treatment. He may not have discussed the unwanted effects 
adequately. Importantly, doctors need to explain to patients when they may modify the 
regimen themselves, and when they should ask the doctor first. 
1.6.4.1.2 Health beliefs 
Health behavior includes any action taken by a healthy person for the purpose to remain 
healthy or stay asymptomatic. It differs from illness behavior. Examples of health 
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behavior include brushing teeth, vaccination, going to body check-ups, eating healthy 
diets, wearing a seat belt, avoiding tobacco products, exercising regularly, avoiding 
high-risk behaviors and the list goes on. People engage in these behaviors for several 
reasons, including habit, fear, attraction, and health. They usually develop these 
behaviors and then associated beliefs from a variety of sources. Parents teach their 
children not to touch the stove and to look both ways before crossing a street. The 
parents' own behaviors concerning health are important sources of information for 
children. Teachers, peers and media, are other sources of information. These sources, 
like all others, can provide either positive or negative influences. Perhaps, more 
powerful than any of these sources is one's own experience. A child or adolescent who 
has been told of the dangers of particular behaviors may experiment and discover that 
the threatened outcomes did or did not materialize. Such experience will then reinforce 
or influence the person's subsequent health beliefs and behaviors. 
People often have different values and resource allocation to areas of their lives 
and all depend on the priority ranking of each area. If health is a low priority to a patient, 
little energy will be expended to improve a condition. Some patients fully understand the 
risks associated with their disease state and intend to be compliant later in their lives. 
They care about immediate convenience but not long-term health. In essence, they enjoy 
now and pay later. If patients care about their health but do not accept, disagree with, or 
deny their physician's diagnosis, it is unlikely that they will follow the physician's 
prescribed therapy. As a result, the condition remains untreated. Patients may also opt 
not to follow medical treatment regimens in an effort to conform to social 'norms', such 
as the stigma of diabetes (e.g. embarrassment about taking insulin injections and the 
awkwardness of taking pills in front of other people). Additional constraints include 
competing on alternative approaches to treat the illness, difficulties in navigating the 
medical system, conflicting ideologies about illness and treatment, or socioeconomic 
limitations. 
Some patients may use non-compliance as a form of passive manipulation to 
control their relationships with others, to satisfy needs, or to avoid changes. Thus, 
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patients may choose not to comply in order to get attention or a secondary gain, such as 
avoiding school, work, or the legal system and do not want to get well. 214 in addition, 
some patients may be reluctant to improve if the illness has become part of their self-
concept, such as in disorders related to identity e.g. anorexia nervosa. 
Religious beliefs can also affect compliance. In addition, some cultures may 
associate disease with spiritual causes and therefore do not see the relevance of physical 
treatments. Perhaps the most significant is the Muslim observation of Ramadan, where 
medicine should not be taken between dawn and dusk throughout the month of the 
Ramadan intermittent fasting. Ramadan is the ninth lunar month of the Islamic year and 
fasting during the month is one of the five pillars of Islam. The changes in dietary habits 
during Ramadan present problems for patients with diabetes. During daylight fasting 
hypoglycemia may occur, while excessive food intake in the evening results in 
hyperglycemia. 216-218 
All in all, patients' perceived severity is more important than the actual illness 
and their perceived importance of the drug is more important than the drug itself. On the 
contrary, patients who perceive their illness as serious and susceptible to complications, 
usually believe in the efficacy of treatment develop an insight into their illness and 
therefore will be more likely to comply. 
The social science literature on non-compliance with medication has identified 
eight ways in which patients commonly think about medicines 84: 
• They may test the efficacy of their medicines by not taking them (perceived efficacy 
of medicines). 
• They perceive the danger of becoming 'immune' to the medicine, which is an 
important problem where antibiotics have been prescribed. 219 
• They beware of 'unnaturalness丨 of manufactured medicines. 220 
• They worry about the danger of addiction and independence, 115 such that many 
epileptic patients saw their medication as a symbol of reduced control in their lives. 
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• They may hold 'anti-drug attitude' 221 such that one-third of patients with chronic 
illnesses (e.g. asthma, chronic pain and hypertension) spontaneously described their 
medicines as poisons. 
• They may balance the risks and benefits of medicines, which may lead to non-
compliance. 幻 
• They may find daily events have stronger influence on how they take treatment than 
their doctors' advice. 11 ^ 
• They may have different perceptions on the risks of treatment compared to that of 
doctors. 222 
Many theories have been formulated to identify which factors influence a 
person's compliance with a treatment regimen. Two popular models of health behavior 
change are the health belief model and the trans-theoretical model that are useful in 
explaining non-compliance behaviors. They increase knowledge about patient 
compliance and have application for clinical practice. 34 
Health belief model (HBM) 
The HBM is perhaps the most well known and compelling of the behavioral models 
because it is intuitive and easily understood. All health actions a patient undertakes are 
based on perceptions rather than actuality. A key to understanding patients is then to 
identify their perceptions and beliefs. The model as originally developed states that a 
person is motivated to carry out some action by his or her perceived threat to health. 
This threat is determined, in turn, by each patient's 
• Perceived value of good health 
• Perceived susceptibility or re-susceptibility to a particular disease 
• Perceived seriousness of a disease condition 
According to Becker (1976)，people must first believe that they are susceptible to 
an illness due to poor lifestyle habits or non-compliance with health routines before they 
are motivated to change their behavior. Next, they must believe that the illness could 
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have serious consequences with regard to health and daily functioning if contracted. 
Further, people must believe that the treatment prescribed will reduce the severity of the 
condition and lastly, the benefits of the regimen prescribed outweigh the perceived 
disadvantages and costs incurred. 
The beliefs of patients about their illness and their medicines need to be elicited 
if individualized patient education on the importance of compliance is to be effective. 
220,223 
Stages-of-change model (Trans-theoretical model) 
Perhaps the best known and most thoroughly validated theory of behavior change is the 
stages-of-change model (trans-theoretical model) developed by Prochaska and 
DiClemente and their colleagues 224，which can be directly applied to consultations in 
several fields. The model is called trans-theoretical because it integrates multiple 
perspectives in order to describe and explain a continuum of behavior change and can be 
applied to medication compliance. The model describes different stages through which a 
person needs to go through before changing his or her behavior. 
Prochaska et al 224 proposed that behavior changes occur through a series of 
five stages in which an individual may fall into any point in time. Instead of progressing 
through these stages in a linear fashion, people may fail in their efforts to change several 
times before they finally succeed; they may remain in a particular stage for an extended 
period of time, or they may pass through that stage, only to return back later on. In other 
words, behavior change is conceptualized as a dynamic process that is influenced by 
different variables, depending on the stage in which the person happens to be. 
The five stages of change are (1) pre-contemplation, (2) contemplation, (3) 
preparation, (4) action, and (5) maintenance. People in the pre-contemplation stage have 
no intention of changing their behavior. They may be unaware of their problem. They 
may even deny a problem exists. They simply do not want to change. In the 
contemplation stage, people are aware a problem exists and start to think about 
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changing; however, they have not yet committed themselves to a plan of action. A 
person may remain in this stage for years and never move beyond it. During the 
preparation stage, the person intends to change and is beginning to take small steps in 
that direction. If they progress to the action stage, they have committed themselves to 
change and are now taking active steps to modify their behavior and overcome the 
problem. Maintenance is the stage at which people integrate the new behavior into daily 
life and learn to prevent relapse from occurring. 
The stages-of-change model is useful for examining compliance problems 
because it describes different stages through which a person passes before changing his 
or her behavior and suggests the use of different approaches at different stages to 
improve patient compliance. The possibility of a patient at the pre-contemplation stage 
to change their behavior is exceedingly remote. However, appropriate discussions which 
leaves such patients with a sense that his or her decision has been understood and 
respected minimizes the chances of entrenching their resistance and might open the door 
for change in the future. Similarly, providing non-compliant patients in the 
contemplation stage with information about the importance of taking their medication as 
prescribed may help them move on to the next (preparation) stage. However, this type of 
information would be of little value to someone who is already in the preparation stage, 
or beyond. Here, people who have committed themselves to a plan of action are more 
likely to benefit from learning specific skills or techniques which will help them change 
their behavior, while in the maintenance stage they primarily need relapse prevention 
strategies (e.g. psychological and peer support). Based on this theory, specific 
interventions work best when they are matched to the particular stage of change the 
person is in. 
1.6.4.1.3 Socio-demographic factors 
It is often difficult for a clinician to readily identify inadequate compliers and to 
distinguish them from poor responders or non-responders. This is not surprising as there 
is considerable evidence to indicate that compliance with a treatment regimen is not 
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determined by socio-demographic factors 25，122，160 such as age 27，75,130,225， 
gender 114, race, intelligence 130，education 36,114，115,130，marital status 36,115,226 
and socio-economic status " 4 . The above comments should not be interpreted to mean 
that socio-demographic characteristics are always irrelevant; rather, the point is that they 
do not lead to a general understanding of the compliance phenomenon. However, in 
specific instances, one or another of these variables may be related. 227 
Several investigators have identified the positive influence of social support on 
compliance along with the negative effect of social isolation. 228 Social isolation (living 
alone) is a major contribution to non-compliance among general practice patients on 
chronic m e d i c a t i o n . � Irrespective of the disease or disorder studied, self-administered 
treatments are associated with poor c o m p l i a n c e . � 
The expense of the therapeutic regimen also can interfere with compliance (e.g. 
cost of medications, blood or urine monitoring supplies, special foods, and 
transportation to physician's office). 23,229 
1.6.4.1.4 Forgetfulness 
Among the many reasons people give for not complying with a treatment plan, 
forgetfulness is the most common. 230 Medication to be taken in the morning was a 
problem for some, as they rushed to get to school or work. Being away on holiday or 
temporary lifestyle changes were other reasons given for forgetfulness. The importance 
of incorporating the medication regimen into the daily routine (e.g. meal- time, bedtime 
or tooth brushing) was stressed in this context. It was when the daily routine or the 




The illness (e.g. mental disorders) may compromise patient's ability to cooperate or 
affect his/her attitude toward disease and treatment. Some patients may find it difficult 
to open child-resistant medication bottles especially patients with arthritis or 
Parkinson's disease. Problems arise when dementia or depression is present, which may 
interfere with memory. A skin condition may require application of a cream to a part of 
the body, which the person cannot reach. Having difficulty in swallowing tablets or 
capsules is another example illustrating the effects of illness on non-compliance. 
Except for the above specific conditions, disease factors including the type, 
duration and severity have generally been shown to be poor indicators of compliance 
25，36,114,115,122,160 except in a few studies. 23 xhe only association between 
diagnosis and non-compliance is with a psychiatric diagnosis. 160 Compliance has been 
reported to be low amongst schizophrenic patients, especially those with paranoid 
features. These patients pose particular problems because the illness itself may erode the 
capacity to cooperate such as in the case of schizophrenia when a patient lacks insight 
about his illness, ceases medication leading to relapse when treatment is needed most. 
Similarly, a patient suffering from bipolar affective disorder can become manic and 
grandiose and no longer entertains the idea that treatment is needed for his psychiatric 
disorder. Among patients suffering from terminal illnesses or cancers 131，despair, 
depression and lack of conviction regarding the effectiveness of treatments not 
uncommonly lead to poor compliance. 131 
1.6.4.3 Therapeutic regimen 
The majority definers of complexity of a regimen are the number of medicines being 
taking daily and the frequency of dosing. Compliance decreases as the number of drugs 
taken rises. 23,75,114,232-235 
/ 
47 
Elderly patients are more likely to be non-compliant because they generally take 
more drugs, often have multiple chronic illnesses and, therefore, have complex 
medication regimens. 65,75,236-239 Elderly patients also appear to be particularly 
vulnerable to the adverse consequences of drug non-compliance. 75,240,241 They have 
deficits in physical dexterity, cognitive skills and memory. 242 Their age-related 
changes alter pharmacokinetic and pharmacodynamic profiles particularly with regard to 
increases in drug distribution, decreases in drug elimination, decreases in metabolic rate, 
alteration in receptor sensitivity and changes in tissue and organ functions. All these 
age-related changes can compound the problem. 239,243,244 Together with impairment 
of homeostatic mechanisms and the effects of coexisting disease, these changes place the 
elderly at heightened risk for adverse effects and drug interactions. 245 
Polypharmacy 
In recent years in developing countries, war, poverty and environment remain the main 
hazards to health and survival. On the other hand, medical advancement has further 
prolonged life expectancy through prevention, diagnosis, and treatment of diseases in 
most developed countries where socio-economical reasons are relatively less important. 
However, this was led to a rising aging population with its associated chronic diseases 
and increased prevalence of polypharmacy and multiple medications. 239,243,244 
Montamat and Cusack (1992) 246 have defined polypharmacy as the prescription, 
administration, or use of more medications than is clinically indicated in a given patient. 
Beers and Ouslander (1989) 247 on the other hand, defined polypharmacy as a medical 
regimen which includes at least one unnecessary medication. Kruse and associates 
( 1 9 9 1 ) 248 developed the criteria for polypharmacy at 5 or more concomitant drugs. At 
present there is no generally accepted definition of polypharmacy except to indicate that 
it represents the use of multiple medications by a single patient. 249 
Elderly patients with multiple medical problems often require three or more 
medications to control their disease states. Combination drugs, particularly anti-
hypertensives, have long been marketed to take advantage of this principle, and 
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combining all drugs prescribed for an individual into one tablet or capsule is the 
extension o f this process to its ultimate end. However , f ixed dosage combination drug 
products lack commercial feasibility owing to their limited flexibility of composite 
ingredients and problems with physicochemical incompatibility. 
Polypharmacy is a common worldwide problem in many health care settings. 
Our local studies have shown that the prevalence of polypharmacy, arbitrarily defined as 
5 medications or more, ranges from 16% to 38% in different hospitals. 58,113 
Simultaneous use of multiple drugs (polypharmacy, PP) has been associated with many 
undesirable consequences including increased rates of adverse drug reactions, drug 
interactions 239,245,250^ patient non-compliance and treatment failure all of which can 
lead to hospitalization, increased health care costs 232,244,251-253 and unsatisfactory 
clinical responses 254 increased dosages or number of drugs may follow these. Increase 
compliance can help to disrupt the cycle of escalating drug therapy. 
Apart from types and number of drugs, dosing frequency of a regimen may also 
lead to confusion. The more frequently a medication is prescribed, the less regularly it 
may be taken. The fewer the daily doses, the fewer doses there are to forget. Dosing 
frequencies of three or four times a day cause a larger percentage of missed doses than 
dosing frequencies of once or twice a day. 3,27,111,182,255 addition, the more 
complex the daily dosage schedule, the greater the interference with the patient's 
lifestyle and daily routines and hence, the less likely the patient is to comply with 
treatment. 34,256 
1.6.4.4 Patient-practitioner relationship 
Conflicts between patients and doctors 
Patients inquire about their diagnoses, their diseases, and prescribed therapies. Their first 
opportunity to ask questions occurs in the physician's office. All too often the necessary 
dialogue between the patient and their doctor does not occur. This is largely due to the 
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medical education system which has taught physicians to view patients as disease puzzle 
to be solved rather than to listen to patients. 257 
A survey has shown that while a patient came in with two or three complaints, 
the doctor interrupted 12 seconds on average 258 after the first problem was presented. 
The doctor then grilled the patient on the symptoms, using a series of closed-ended 
questions to be answered either yes or no. This was followed by the formulation of a 
diagnosis and the writing of a prescription which was handed to the patient as a signal 
that the visit was over. However, the patient might not have mentioned his most serious 
complaint. 
Another study indicated that only one of every four physicians discussed a 
patient's medication with the patient. 258 AS a result, patients often leave a physician's 
office with unresolved concerns, which may become barriers to compliance. 
Patients spend a minute portion of their lives in the doctor's office and physicians are 
simply not central to patients' lives. Furthermore, patients and physicians tend to use 
different information during their interactions. The patient presents with a medical 
problem for which there is a potentially helpful treatment. What the doctor brings to the 
consultation - scientific evidence and technical skill - is classed as the solution. Doctor 
understands the regimens in terms of the way it will affect the patient's health and tend 
to refer to facts and technical knowledge. By contrast, patients understand the regimen in 
terms of the way it will affect his life and use more personal information pertaining to 
their lived experiences - 'health beliefs' based on experience, culture, personality, family 
tradition, and so on. The doctor sees these as the impediment to the solution. The 
doctor's task is to overcome the impediment. 230,259 
May be in part due to their academic excellence and societal status, doctors not 
uncommonly expect respect from patients. Physicians expect a patient to fill the 
prescription and to take the medicine as indicated. They also assume that their patients 
will call to discuss adverse events or lack of response rather that adjust or discontinue 
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the medicine without the professional medical advice. When faced with the high 
prevalence of non-compliance, physicians easily become despondent and pessimistic 
about the effectiveness of their efforts to improve compliance rate. Some may sigh 
wearily and assume that they have done their best. Others who are more cynical view 
non-compliance as intrinsic to the patient and beyond their influence and rationalize that 
their patients are not the only ones who do not listen to their physicians. 
Patients often are reluctant to ask questions for fear of being perceived as 
ignorant or of wasting the doctor's time. This is true even if they have consumer-oriented 
attitudes and a formulated list of questions. 260 
Importance of patient-physician communication 
The circumstances surrounding a patient's visit with a health care professional, as well as 
the quality and effectiveness of the interaction between the health care professional and 
the patient are major determinants of the patient's understanding of and attitude toward 
his or her illness and therapeutic regimen. 228 inadequate communication and 
counseling by health care professionals can result in patient misperception of 
information, distrust of caregivers, and negative attitudes toward treatment. Patient 
satisfaction is found to be crucial for compliance with treatment. 260,261 This includes a 
friendly manner rather than business-like, with the doctors spending time to discover 
patients' concerns and expectations and to discuss them as well as to give information 
and ask questions. 
1.6.5 Treatment (Interventions) 
There are currently 4 major strategies that improve compliance with a medical regimen. 
They include education, dosing regimen planning, clinic scheduling, and 
communication. These approaches are pertinent to all types of patients regardless of 




Numerous studies have shown a direct relationship between compliance and patients' 
understanding either of the illness or treatment regimens. 262-264 The educational 
interventions are based on the assumption that inadequate information is the main cause 
of poor compliance. There are 2 types of information that patients need: 
•How to,: How should the drug be taken, and when? What times during the day 
should the medication be taken? What about meal times? What should be done if a dose 
is missed? What other drugs or foods should be avoided and why? Any self-monitoring 
is needed? 
'What': When the patient leaves the pharmacy with a new prescription, he or she 
should have a good understanding of what the drug does, why it is prescribed, and how 
it works in the patient's disease state. Is the drug used for prevention, symptomatic relief, 
or cure? What are the possible side effects? Are they serious? Will they disappear? How 
can they be managed? What should the patient do if they occur? 
^How to, information 
It has been shown that more than half of such information is forgotten immediately after 
the visit. Hence, apart from verbal counseling 265-267，written instructions on dosing 
should be provided. 264,268-271 Elderly and patients with low literacy may be 
disadvantaged because they are unable to read medication labels. Since patients often 
remember only the first few instructions presented, they should be provided exactly the 
right amount of information at the right time with emphasis on the essential points of 
therapeutics. 90 
There is a wide range of different designs of memory aid devices that can help 
patients self-administer their prescribed drugs, largely by regularly reminding the patient 
to take the medication. 53,77,90,176,272-275 They may be used when initiating the 
routine of compliant behavior, for the maintenance of the compliant behavior, or for 
recovery from an episode of non-compliance. One way to combat forgetfulness is to link 
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administration of medicines with specific daily routines to which most patients can 
relate. 53,272,273,276 These activities include brushing teeth, shaving, meal times, or 
attendance at class, personal toilet, radio or TV programs, or bedtime. The physical cue 
is the medication container placed prominently in the center of the daily activity cue. 
Pills can be set next to a razor for a man who shaves every morning or near the coffee 
for those who eat breakfast. Inexpensive wristwatches with alarms and small electronic 
memories to record brief messages can be programmed to cue the time for a dose or 
remind the patient about special instructions for therapy. Almost all patients will be able 
to denote something in their lifestyle that will work for them. Developing cues to remind 
the patient when to take a dose requires only a few minutes of careful planning to mesh 
with the individual's lifestyle. If one type of cues does not work, another cue or 
combinations of cues should be tried over time. The drawback to all these reminders is 
that unless the patient remembers and takes the pills immediately, the cue is quickly 
forgotten. 
Some patients manage well with a simple pillbox with a compartment for each 
day of the week in which a full day's dose can be inserted once a week or several weeks. 
The Dosett box has compartments for four doses daily for 7 days and can be filled 
weekly by a pharmacist to assist patients who take multiple medicines in frequent doses. 
Studies have shown that higher compliance can be achieved when patients used these 
aids. 276-279 xhe size of the box, however, made it inconvenient to carry for most 
ambulatory patients. Medication containers with a variety of clocks, timers, or reminder 
alarms are also available and are useful for those who are forgetful or have complex 
medication schedules. 276 
The picture schedule uses simple line drawings to represent various daily 
activities, such as time of awakening, meals, and bedtime. Each drawing has a picture of 
a clock and several lines next to it. The lines are for placement of colored dots. Each 
colored dot represents a medication, and the medication bottle is color coded with the 
same color. A proper number of dots are placed next to the picture, indicating the 
number of tablets to be ingested. 262 
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A self-administration of medicines (SAM) program that enables patients to keep 
and administer their own medication while in hospital facilitates patient to learn and 
practice self-care for taking drugs from early on which can increase drug knowledge in 
supervised conditions. 280,281 
Self-monitoring is often a measure which can lead to changes in behavior 282 
The data generated act as feedback to help patients determine the need for an 
intervention or increase their awareness of their health status. Self-monitoring can take 
many forms, including charts with blood glucose values, peak expiratory flow rate 
measurements, number of seizures, or number of cigarettes smoked. It is also useful if 
the monitoring includes an annotation of the patients' interventions and their efficacy. In 
this way, the patient receives feedback, and if the intervention is effective, it serves as 
positive reinforcement. Patients should be encouraged to record their findings at the time 
of observation rather than waiting. They should be trained in skill requisition and 
positively reinforced for success. Finally, periodic assessments of the self-monitoring 
program by both care providers and patients help further refining the program and keep 
the patient interested and involved in the educational process. This will ensure that these 
data are used as tools for further improvement and not simply a recording exercise. 
'What, information 
It is especially important to explain to patients the expected actions and possible side-
effects of medication. One such example is to advise that patients prescribed a 
monoamine oxidase inhibitor to avoid eating cheese which may place their lives in 
jeopardy due to possible adverse effects of severe hypertension. Rather than simply 
giving a list of side effects, patients should ideally be explained and given written 
instructions on what to do if side effect occurs: whether they should stop taking the 
medicine and contact a doctor, take a simple remedy, or persevere with the treatment. 
264,268-270 Explaining to patients that side effects of a medication may be transitory 
and should diminish with regular，continuous use is also helpful in providing 
encouragement and increasing compliance. 
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Fear tactics, with warnings to patients about the dire consequence of less-than-
perfect compliance, frequently had little benefit and may occasionally backfired, 
producing worse compliance compared with baseline levels. 283,284 
Assessment of knowledge and skill, patient's attitudes and beliefs is important so 
that the information provided can be tailored to the patient's needs. The most effective 
way to correct patient's attitudes and beliefs is to help patients discover their own beliefs 
may be incorrect. This can be done by providing educational material or helping patient 
collect data that refute their belief. For instance, an asthmatic patient may report that 
his/her meter dose inhaler does not work and thus stop using it. The health care provider 
on discovering that they are not using the device properly will take steps to teach them 
how to do so. If the patient can then self monitor and record the results of the peak flow 
rate, it is likely that they will see the effect of treatment and continue to use it. Involving 
patients in a problem-solving approach and having them adopt positive self-statements 
can help change their beliefs. 
It is also helpful to involve patients in the goal-setting process. Goals should be 
individualized, specific, reasonable and attainable using an incremental approach. There 
are both short- and long-term goals to be set. Short-term goals should have a high 
likelihood of success，as this serves as positive reinforcement to motivate the patient to 
comply even more. Goals should also be attached to a reward system if they are attained 
(e.g. fewer acute episodes or hospitalizations, reduced frequency of visits and blood 
sample taking). 282 Although some may use monetary reward as an inducement to 
comply with medical advice, it usually works only in the short term but can be 
problematic. 200,201 
Clearly, individuals must understand the basis of therapeutic regimens in order to 
comply with them. Information must be stored as knowledge before appropriate 
decisions can be formulated and behaviors performed. However, knowledge alone does 
not change behavior. Educational strategies using 'knowledge only' approach to increase 
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medication compliance have shown variable results. 275,285 Therefore, although giving 
knowledge of medication care plans is necessary, it is not a sufficient step by itself to 
improve compliance. ^86 
1.6.5.2 Dosing regimen planning 
It is well established that lower compliance rates are associated with more drug-taking 
inconveniences, such as dosage intervals and different drugs to be taken each day. 
Simplification can take the form of: (a) decreasing the number of medicines being taken; 
(b) reducing the frequency of dosing; (c) increasing synchronization of the dose times of 
the various medicines in the regimen. Simplifying a regimen makes it easier to 
understand, remember and more compatible with a patient's lifestyle as well as reduces 
the cost of the therapy. 287 jh i s is likely to be followed by a reduction in the occurrence 
of drug interactions, therapeutic duplication, side effects or treatment failure due to non-
compliance. 
Decreasing the number of medicines being taken 
Various studies have shown a negative relationship between the number of doses to be 
taken and compliance. 3,75,120,144,152,180,233,288,289 in many clinical situations, a 
second drug is added instead of increasing the dosage of the first drug to a therapeutic 
level, although some workers argue that several drugs with different actions can be 
given in small therapeutic doses to get maximal effect and reduce side effects. Such a 
combination treatment approach is often used in patients with complex medical 
conditions such as hypertension, diabetes and thyroid problems which can lead to 
multiple medications taken by the patient. 
Actually, one can try to reduce the number of medications by substituting a 
single drug with multiple actions with two or more separate agents with single action. 




Drugs prescribed on 'as needed' basis should be limited and with regular 
monitoring to assess the frequency of their use. 246 The almost routine addition of 
vitamins, analgesics, hypnotics and anti-anxiety drugs are common examples of drugs 
prescribed on 'as needed' basis which can lead to overuse or drug wastage. 
Every medication should be started as a trial and they should be discontinued if 
they are found to be ineffective or intolerable by patients developed. If this philosophy is 
adopted, medications will then not be continued beyond their usefulness, which add to 
the problem of polypharmacy. Patients should undergo a regular drug regimen review (at 
least yearly) to evaluate all their medications in light of all current medical conditions. 
This process has been termed the 'brown bag review' where the patient brings in all their 
medications, both prescribed and over-the-counter, to their pharmacist or physician. 
232,291 The purpose of this review is to ensure that all medications are necessary and 
are being used properly. This process has also been termed 'therapeutic debridement'. 
292 
Reducing the frequency of dosing 
Compliance rates fall off dramatically which drugs are prescribed beyond two or three 
doses per day. Simplifying regimens often entails selecting medications that permit less 
frequent dosing regimen, e.g., once to twice daily versus three or four times daily with a 
view to increase compliance. 3,27,111,143,182,282,288,293-295 The use of longer 
acting drugs in a therapeutic class or dosage forms that are specially designed e.g. 
sustained-release or controlled-release formulations allows less frequent administration 
and may facilitate this regimen simplification. 
Synchronizing the dosing frequencies of the whole treatment regimen 
Synchronizing doses for patients on multiple drug therapy is also important. If regimens 
can be coordinated so that doses are only taken at one or two points during the day, then 
compliance may be further improved. Patients often ask whether different medicines can 
be taken at the same time. The answer is almost always 'yes', and this can simplify the 
regimen considerably. For instance, most once daily medicines can be taken in the 
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morning. If they are labeled 'at morning' rather than 'daily', this indicates to the patient 
that doses of the medicines can be taken together. Synchronization is aided by the use of 
a reminder chart and the use of events such as mealtimes to describe dose frequencies on 
the label. 
1.6.5.3 Clinic scheduling 
The first clue that a patient may be non-compliant is failure to attend a scheduled 
appointment. Compared to patients with infrequent review visits, patients who are 
offered a high level of medical supervision with frequent follow up appointments are 
more likely to comply with medical advice, particularly if compliance is explicitly 
assessed in these interviews. 296 Every follow-up visit should be carefully planned to 
assess potential adverse reaction and clinical efficacy of the treatment and health care 
provider should respect the patient's time by avoiding lengthy delays in seeing the 
patient to enhance the patient's willingness to return for examinations. 
1.6.5.4 Communication 
Perfunctory casual questioning about drug taking behavior at each visit may lead 
patients to assume that the doctor does not place high priority on this aspect of 
therapeutic plan. Clinicians may simply assume patient's compliance and see any 
continuing symptoms as indicating the need for more or a different medication. 297 
Indeed, clinicians often spend his/her time on diagnosis and hand over a prescription slip 
as the closing act of a consultation which signals the end of an interview rather than the 
beginning of an alliance to ensure patient compliance to attain therapeutic benefits. 
On the other hand，improved physician-patient relationship has been shown to 
enhance patient's knowledge, satisfaction, and compliance. 275,286,298 Factors such as 
warmth, caring, sincerity, confidence, trust and empathy on the part of the physician, 
adequate time spent with the patient, providing explicit information about a diagnosis, 
and meeting the patient's expectations of an encounter provide a strong positive 
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influence. 73,296,299 it is particularly important for health care providers to assess 
patients' current understanding about the seriousness of their illness, their risk factors 
and vulnerability to illness, the effectiveness of various treatment strategies and the 
obstacles in the implementation of treatment strategies. This information will allow 
advice tailored to match patients' preferences. 296,300 Consultations concerning 
behavioral change are more likely to succeed if they address patients' own 
interpretations of the pros and cons of change, enhance patients' sense of control, focus 
on acceptable and attainable targets for change and take careful account of attitudes 
toward change. 
Clinical studies affirm that the more information patients are given, the greater 
the percentage of the total message is forgotten. Patients tend to remember the first few 
items at the beginning of the conversation. Therefore presenting the information and 
instructions as clearly, precisely and simply as possible facilitates understanding and 
recall. The most important aspect of the treatment regimen should be stated first and its 
importance should be stressed and emphasized. Patients should be given specific rather 
than vague instructions concerning their treatment and they are more likely to remember 
what they have been told if it is repeated in their own words. 301 It is also important for 
patients to demonstrate any techniques that they have been taught, such as injecting 
insulin (practicing needle sticks using an orange), using a meter dose inhaler, obtaining a 
blood sample for glucose monitoring or using a peak flow meter. 
Most studies have discovered almost inevitable decay in responsiveness over 
time，even when interventions are sustained. Therefore, an ongoing assessment of a 
patient's understanding and recall as well as continuing or periodic reinforcement is 
critical to long-term success. Educational interventions should be given in small 
segments, continuing through subsequent visits, rather than overwhelming the patient at 
once. A simple set of written instructions should be provided if patients have to follow 
complex treatment regimens. Most patients appreciate regular praise or other positive 
reinforcement for their extra efforts, especially when prescribed treatment requires major 
lifestyle changes or other behavioral sacrifices. 302 Future compliance is improved by 
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praising patients with optimistic assurances that the patient would benefit by following 
the prescribed treatment regimen. 
When ever possible, patient should participate in decision-making regarding their 
therapeutic regimen. The compliant patient sees himself or herself as an active member 
of the team involved in his or her care, not as a passive victim of a disease and the health 
care system. Involving patient in the development of his/her treatment plan will help 
his/her patient view the regimen as something that increases his or her control and 
options, rather than something that imposed on him/her. This sense of 'ownership' is 
associated with a greater commitment to decide on or comply with treatment. This is a 
two-way communication between health care providers and patients which is basis for 
the recently and actively promoted 'concordance' (Please refer to Section 1.3 Definition 
of Compliance). 
To increase compliance, verbal explanations often have to be repeated to a 
family member or carer. Although a patient may comprehend the details during the 
interview, he or she often forgets or is unable to repeat the instructions after leaving the 
office. Health care professionals should involve the family or patients' carer wherever 
possible and acceptable to the patient, and encourage them to provide emotional and 
physical support. 275,283,296,303 However, it is important to be aware that family can 
also exert a negative impact on patient's willingness to undergo/continue treatment. The 
health care professional should evaluate cautiously the attitudes of the supporters in the 
patient's treatment program and attempt to maximize its potential constructive 
contributions and minimize its potential destructive influences such as over-involvement 
and negative attribution. Finally, for many chronic diseases, there are support groups 
which comprise of people with similar problems, and this mode of low cost peer 
counseling has also been proven to be valuable. 201 
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1.6.6 Intelligent non-compliance 
Inherent to all the definitions of compliance is the assumption that medical advice is 
good for the patient or that rational patient behavior means following medical advice 
precisely. 
As discussed in the previous section, many theories about compliance locate the 
source of non-compliance'in the doctor-patient relationship, patient knowledge or beliefs 
about treatment. An alternative perspective is to consider the patient's experience of 
illness, and the meaning of medication in people's everyday lives. 1 
Patients define compliance in terms of apparent good health and seek treatment 
approaches that are manageable, tolerable and, in their view, effective. Although 
compliance may be a priority for health professionals, for the person, especially with a 
chronic health problem, concerns such as controlling symptoms, preventing medical 
crisis, maintaining financial comfort or enjoying a quality of lifestyle may take 
precedence. Patients do not view all recommended treatments as necessary for their best 
interests. ^29 
Little attention has been paid to patients' ideas about medicines, and such ideas 
might well have relevance for understanding non-compliance to medication. Perceived 
properties of medicines and patients' general preference for taking or not taking 
medication are important themes. Patients have many fears and powerful negative 
images of medicines. 222 [f measures are to be taken to improve compliance, these 
should primarily be based on a closer understanding of the patients' experience of their 
illness and medication, rather than the perceptions and expectations of health care 
professionals. Because non-compliance is traditionally defined as a lack of compliance 
to recommendations, most research in the field of compliance does not take into account 
the deliberate discontinuation or alteration of a medication by a patient. 
The patient has a right to non-compliance. Intelligent non-compliance can be 
defined as a rational act of intentionally altering or not taking prescribed therapy by 
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patients who do not suffer adverse consequences as a result. 222 Some examples are 
misdiagnosis, inappropriate prescribing, the patient experiences adverse reactions or side 
effects, or the patient with a chronic condition becomes aware that the disease has 
changed. 222 
In the majority of cases, the dose of medication for an individual patient is based 
on published reports of the average dose for groups of people under ideal conditions. 
There are only a few drugs such as digoxin and beta blocking drugs, whose dosages can 
be titrated against a biologic response, such as heart rate. Yet, the correct dose for an 
individual may be much higher or lower, depending on that person's absorption and 
metabolism of the drug, disease severity, and other factors. There is also enormous 
variation in the dose-response curve from person to person, which are larger than that 
due to inaccurate medication taking. If a patient takes less than the prescribed dose, and 
that dose happens to be too high for him/her, he or she may in fact be getting the right 
amount and be spared toxicity which may be associated with the prescribed dose. 
Second, the dose of many drugs is chosen because of the drug's half-life in body 
fluids, rather than its biologic half-life - which is the duration of actual effects intended. 
For example, the serum half-life of many anti-hypertensive medications (such as 
thiazide diuretics) is short, measured in hours to days, but the anti-hypertensive effects 
of these medications are much longer. In recognition of this fact, the recommended 
frequency of many anti-hypertensive medications has been reduced in recent years. 
Third, there is good evidence that partial doses of many drugs yield partial 
effects. Thus if the patient does not take all that was prescribed, much good could still 
have been done. Part of the reason may be that the biologic half-life is longer than the 
serum half-life. Thus the net effect of partial non-compliance may be, in some 
circumstances, beneficial to the patient. When non-compliance is prompted by side 
effects, the patient's choice not to take all that was prescribed may be particularly wise. 
Unfortunately, some of these seemingly rational decisions may not be appropriate. For 
example, patients want to have blood pressure controlled to prevent the consequences of 
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uncontrolled hypertension. However, he or she may stop taking the anti-hypertensive 
medications because he or she feels well. 
Fourth, for some drugs and disease states, intermittent periods of 'sub-
therapeutic' drug levels are necessary to enhance patient's clinical course. For example, 
optimal treatment of angina with nitrates may require periods of absent drug levels to 
prevent tachyphylaxis. Similarly, treatment of rheumatoid arthritis with methotrexate 
requires regular medication-free intervals of several days to minimize the risk of adverse 
drug levels. The omission of occasional doses of medication in the treatment of 
moderate hypertension or seizure disorder also may not necessarily alter the morbidity 
or mortality associated with these diseases. 
Fifth, full compliance may not follow if patient is in doubt of: (1) that the 
diagnosis is correct, (2) the physician has chosen the correct dose of medication with 
proven clinical efficacy for the disease diagnosed and that (3) the therapy prescribed 
must do more good than harm. 152,304 if any of these factors does not apply, full 
compliance by the patient is likely to be unnecessary and can be detrimental. 
From patient's point of view, non-compliance may not be seen as a deviant 
behavior but rather a reasoned decision-making process aimed at mitigating the 
unpleasant effects of drug. They may also believe that this behavior will have little or no 
unfavorable long-term impact on their health. 
The implication here for the health care professional is to develop a therapeutic 
relationship with the patient and to monitor compliance behavior and periodically 
evaluating the need for therapy. By helping patient to respect and accept a relationship 
with health care professionals can promote a patient's personal growth and improve his 
or her health. Therefore, physicians should respect patients, regardless of whether 
patients follow their physicians' advice. In fact, patients may decide not to comply with 
their physicians' advice after they subconsciously and consciously weigh competing 
values. 305 Helping patients make informed decisions that are best for them is in 
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keeping with an adult-to-adult style of physician-patient relationship, whereas trying to 
dictate lifestyle decisions (however politely) is a parent-to-child style of interaction. 
Older people are particularly at risk from the dangers of non-compliance as the 
illnesses and conditions they suffer often require multiple and long-term therapy. In 
addition poor memory and sensory impairment often complicate drug-related problems. 
With increased awareness'of compliance theories and the variety of interventions that 
are available to increase compliance, nurse and other health care providers can begin to 
incorporate additional interventions into their daily clinical practices. A therapeutic 
pharmacist-patient relationship is repeatedly cited in the literature as the most important 
factor influencing patient compliance with medication regimens. Other key interventions 
include involving the patient in clinical decision-making 154，simplification of complex 
medication regimens 75，236 and reducing the cost of medications by prescribing generic 
drugs and avoiding unnecessary or over the counter medications. 2,75,229 Although 
patient knowledge about medication alone has not been shown to increase compliance 
significantly, some degree of knowledge is necessary for the patient to make an 
informed decision and better patient education should decrease non-compliance. 
1.6.7 Overview of problems with compliance studies 
In my extensive review of the literature, it becomes apparent that there are a number of 
problems with compliance studies. To date, the quality of most of the compliance 
research has been generally poor ^^^ mainly due to inconsistency in definitions and 
methodology despite the availability of sound theoretical background. There are few 
studies to prove or disprove many of the hypotheses. These shortcomings make it 
difficult for the reader to critically assess the validity of the conclusions. 306 
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1.6.7.1 Complex and not effective 
Many compliance interventions for long term medications were exceedingly complex 
and labor-intensive. 307 They are given in isolation or in combination of directly 
observed therapy, counseling, tailor made reminders, self administration medication 
program, self-monitoring, reinforcement, family therapy, and other forms of additional 
supervision or attention. '153,154,200-205,308 However, these complex strategies for 
improving adherence with long-term medication prescriptions are not very effective 
despite the amount of effort and resources they c o n s u m e .皿 They may be in part due to 
the inadequate statistical analysis and small sample size. Further, inconsistent 
application of learning and behavioral change principles and a lack of systematic 
planning limited the potential effectiveness of health education interventions. 309，310 
No single intervention is totally effective for all patients and it is not yet possible 
to predict which individual or subgroup actually needs a given intervention. ^^ It is also 
difficult to design and evaluate interventional strategies in a non-research setting, 
particularly in the current era of cost-containment and staff reductions. Yet given the 
large amount of evidence supporting the efficacy of many treatments on clinical 
outcomes or surrogate endpoints in clinical trial settings, clearly, there is a need for more 
studies using innovative approaches to assist patients to follow medication prescriptions 
to ensure they obtain benefits from these treatments. 
1.6.7.2 Lack theoretical framework 
A major review of compliance studies found that only just over half of these studies had 
defined compliance. 53 This gross insufficiency in methodologies bedevils compliance 
research, causing difficulty in determining its true extent and implications, and in 
detecting real improvement. 
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For those with defined ones, different definitions have been used, and there is no 
consensus on the 'amount' of non-compliance allowed before the patient is labeled as 
non-compliant. Compliance as an outcome measurement has been defined as 'the 
number of doses not taken or taken incorrectly that jeopardize the therapeutic 'outcome丨， 
or 'the point below which the desired preventive or desired therapeutic result is unlikely 
to be achieved.' 127 Both of these definitions recognize the possibility that taking less 
than 100% of the medication can result in a desired health outcome. Outcome-oriented 
definitions differ from the process-oriented definition in their emphasis on the end result 
or outcome of the actions taken. For example, Luscher and co-workers reported that 
80% compliance with an anti-hypertensive regimen lowered blood pressure to a normal 
level while that of 50% or less was inadequate in reducing blood pressures. 48,49 j h e 
absence of a singular conceptual basis of compliance is problematic. Comparative 
assessments of the compliance literature cannot be done across studies using different 
definitions of compliance. Strategies to improve compliance can be evaluated only 
within the context of a given definition. Furthermore, a major difficulty in interpreting 
the data on compliance is the different design methods between various studies in 
addition to different criteria for identifying non-compliance. 114 Data collection 
methods differ in objectivity, accuracy, reliability, and sensitivity causing difficulties in 
comparing the studies across the board. 101 
1.6.7.3 Fragmented studies 
A few meta-analytic reviews assess the nature and relative effectiveness of compliance 
interventions across the broad spectrum of patient conditions and compliance measures. 
The reviews infrequently described the interventions in more than the most general 
manner, and the compliance outcomes have been summarized in either very narrow or 
widely inclusive terms. 310 The many published studies tend to be fragmented. They 
differed in patient sampling, methodology, and types of intervention, clinical setting or 
outcome measures. For instance, different diagnostic categories and disciplinary 
perspectives i.e. with a special disease or with a particular chronic condition; particular 
aspect of compliance such as appointment keeping; or a specific type of intervention 
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such as financial incentives; in a specific practice setting; or are receiving a single drug 
or classes of drug. 53,202,309-315 it is difficult to control variables within studies and to 
generalize findings since a wide range of specific specialties or interventions or classes 
of drugs etc have been used. Groups of patients may have different motivations for 
adhering to medication regimens, and these motivations may affect compliance. All 
these variables make comparisons between studies difficult to interpret " 4 and the 
results obtained may not apply to other patients or conditions. For instance, insight into 
the compliance difficulties of hypertensive patients may not be totally applicable to the 
management plans of diabetic, asthmatic, or arthritic patients, although there is clearly 
common ground. It is difficult and sometimes inappropriate to derive general 
conclusions from such heterogeneous data. 
1.6.7.4 Lack high quality compliance study 
Most of the studies had small number of patients and lacked power to detect clinically 
important effects and the possibility of a false-negative (beta) error would be quite high. 
As a general guide, studies with a single intervention group and control group would 
need to include over 60 participants per group if they are to have at least 80% power to 
detect an absolute difference of 25% in the proportion of patients judged to have 
adequate compliance. The largest trial in compliance studies reported had fewer than 
500 patients. 
While there have been numerous studies which aimed to quantify the degree of 
non-compliance in various groups of patients, results from these studies are open to 
criticism regarding their validity due to methodological problems. Sackett and Snow 
(1979) reviewed 537 original studies and found that less that 40 of these studies satisfied 
their strict methodological requirements for the following factors: 
• Study design 
• Sample, selection and specification 
• Description of illness 
• Description of therapeutic regimen 
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• Completeness of definitions of compliance 
• Adequacy of the measures of assessing non-compliance 
More recently Haynes et al. (1996) conducted the Cochrane Database of 
Systematic Reviews evaluating the published, unbiased, randomized controlled trials of 
interventions to improve medication adherence. This review identified only 13 studies 
out of over 1500 citations which met the stringent criteria set by the reviewers, namely 
that: 
• Both compliance and treatment effects were measured; 
• There was at least 80% follow-up of each group studied; and 
• At least 6-month follow-up period for long-term treatments with initiative 
positive outcomes. 
It is surprising to note that there are so few rigorous studies of compliance 
interventions in spite of the many thousands of published reports on the efficacy of 
many drugs and treatment regimens in clinical trial settings. Indeed, there is very little 
evidence if any, to support the notion that medication compliance can be improved 
consistently, within the resources usually available in clinical settings, and that this will 
lead predictably to improvements in treatment outcomes. 
1.6.7.5 Without long term follow up 
Claims of increased compliance within the literature relating to self-medication were 
frequently made without long-term follow-up, the longest being 18 months and are thus 
incomplete. Further, most studies failed to assess compliance after the intervention had 
been discontinued, thus making assessment of the durability of the effect of 
interventions impossible. More substantial trials are needed to document clinically 
useful effects and important outcomes, interventional programs as well as their 
feasibility in usual practice settings, and their durability. 308 
/ 
‘ 6 8 
1.6.7.6 Correlation between compliance and desired therapeutic outcomes 
Since non-compliance can lead to treatment failure, it is often assumed that 
improvements in treatment outcomes will follow improved patient compliance and that 
non-compliance will result in excess morbidity and early mortality. 15，197 However, 
there has been a lack of positive, definitive studies relating patient outcomes to non-
compliance or a link of non-compliance to deleterious effects in published literature. In 
fact, research has demonstrated that the correlation between compliance and desired 
outcomes from prescribed therapeutic regimens is not always a positive one. 316 
It is expected that patients who receive active medication in a trial and comply 
will do better than those who do not comply. Likewise, it is assumed that outcomes in 
the placebo group to be independent of compliance. Some studies, however, have found 
that patients who adhered to treatment, even when that treatment was a placebo, had 
better outcomes than patients who showed poor compliance. 19 
In 1980，The Coronary Drug Project (CDPRG) investigators issued a report that 
challenged our understanding of the relationship between compliance and its effects on 
disease outcome. 16 The study was a well-controlled trial evaluating the effectiveness of 
clofibrate in reducing lipid levels and mortality for men who survived a myocardial 
infarction. It showed that clofibrate provided no clinical benefit: 5-year mortality was 
20% in 1,100 men treated with clofibrate and 21% in 2800 men given placebo. As 
anticipated，those patients in the treatment group who took at least 80% of the prescribed 
clofibrate had a low mortality rate than those who were less compliant (15% versus 
25%). However, the investigators found nearly identical results in favor of good 
compliance in patients who received placebo (15% mortality for those with good 
compliance and 28% for those with poor compliance). 
There were contradictory results from the Lipid Research Clinics-Coronary 
Primary Prevention Trial (LRC-CPPT). 61 in that trial, the investigators found an 
association between compliance with cholestyramine and reductions in coronary heart 
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disease (CHD). However, the LRC-CPPT investigators found no significant association 
between compliance with placebo and incidence of coronary heart disease. 
However, investigators participating in the Beta Blocker Heart Attack Trial 
(BHAT) 17 again found a relationship between compliance with placebo and outcomes. 
They studied more than 2000 patients randomly assigned to receive either propranolol or 
placebo. For patients receiving propranolol, mortality rates were 4.2% for those with 
poor compliance and 1.4% for those with good compliance. For patients assigned to 
receive placebo, mortality rates were 7% for those with poor compliance and 3% for 
those with good compliance. 
Horwitz et al 18 re-analyzed the BHAT and found that poor compliers were 2.6 
times more likely to die within a year of follow up after a myocardial infarction than 
good compliers. This was an independent effect on whether the patients were in the 
treatment group or in the placebo group. 
Results from the BHAT and the CDPRG suggest that compliant behavior may be 
a marker of some unidentified health care behavior that directly or indirectly linked to 
good prognosis and survival benefit or alternatively that compliance confers a protective 
effect on patients with coronary heart disease compared with non-compliers. 16,17,20,95 
Possibly，patients demonstrating good compliance in the BHAT trial may have been 
more likely not only to treat their hypertension but also to lower their cholesterol level or 
engage in more physical activity and care about their diet. Also, they may adapt better to 
the stress associated with their illness. 18 if this is the case, compliance strategies and 
interventions may not produce the desired outcomes. Therefore, it is important to 
measure compliance to medications, including placebo, and link compliance to 
important clinical outcomes. 
Indeed, the past compliance literatures have focused on documenting the 
problem of non-compliance than on showing feasible and effective remediation. Also, 
most of the compliance research works have focused on measuring intermediate 
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outcomes such as pill counts, blood pressure control, reduction in cholesterol levels, 
patient knowledge, patient satisfaction and levels of compliance. 127,317-319 Increasing 
compliance is not a justifiable end of itself. 308 Attempts to increase compliance must 
be judged by their clinical benefits, not simply their effects on compliance rates. 308,320 
Nevertheless, studies addressing the impact of medication compliance on more clinically 
important clinical endpoints, such as morbidity and mortality, are scarce. 95 
The costs of not taking drug treatment in terms of persistent disease and 
increased mortality rate are thought to be enormous but are largely unreported. 44 
Similarly, although some research studies have correlated compliance with 
clinical outcome, no attempt has been made to examine the relation in detail. This was in 
part due to the relatively crude measures of compliance that are currently available. 
Moreover, studies of medication compliance often fail to offer an adequate description 
of their measures and methods to allow replication by others. 306 Indeed, the 
compliance intervention studies conducted or reported so far have been much too narrow 
and limited. The field would benefit from a broader outcome context, that is, 
interventions should be designed not only to improve compliance but also to address the 
broader spectrum of patient outcomes. The latter will need to evaluate parameters such 
as patient satisfaction, patient empowerment, comprehension and understanding, as well 
as markers of clinical significance including quality of life, functional status, and 
enhancement of emotional health and well-being. 
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2 Hypothesis and Objectives 
Compliance according to the most widely accepted definition was the extent to which a 
person's behavior (in terms of taking medications, following diets or executing other 
lifestyle changes) coincides with medical or health advice. The term 丨adherence丨 denotes 
a more active patient-physician treatment collaboration than compliance. 'Concordance' 
is a new approach to the prescribing and taking of medicines. It is a shared agreement 
reached after negotiation between a patient and a healthcare professional that respects 
the beliefs and wishes of the patient in determining whether, when, and how medicines 
are to be taken. 42 However, 'compliance' is still the most widely accepted terminology 
in literature and is adopted in this dissertation. 
The lack of a valid method for measuring non-compliance is by itself a major 
barrier to compliance research. 62，321 Although a wide variety of methods have been 
used, there are serious problems with each method for generating valid and reliable data 
to give an accurate estimate of the extent of compliance. Current detection methods 
include indirect measures, such as self-report, interview, therapeutic outcome, pill count, 
change in the weight of metered-dose inhaler canisters, medication-refill rate and 
computerized compliance monitors; and direct measures, such as biologic markers, 
tracer compounds, and biologic assay of body fluids. In general, the direct methods of 
detection have a higher sensitivity and specificity than the indirect methods, making the 
direct methods more reliable for the assessment of compliance. However, direct methods 
such as analyzing blood drug levels are not practical because they are expensive, time-
consuming, and not standardized, and have not been shown to encourage compliance. 
Indirect methods such as pill count and direct questioning vary in degree of convenience 
and effectiveness. Still, all of these methods have their limitations. To help overcome 
limitations of the assessment methods and to provide corroborative information, it is 




Research into the determinants of non-compliance has been largely inconclusive 
322 but the possibility of a casual relationship was often suggested. Such factors may be 
found in relation to patient, illness, physician, medication regimens or treatment milieu. 
They may be used to alert physician but not to identify non-compliers as every patient is 
a potential defaulter and compliance can never be assumed. 
As discussed in the previous chapter, only improved compliance should not be 
enough, it was also important to address on patient clinical outcomes. It has always been 
postulated in the literature that improved drug compliance leads to better clinical 
outcomes. Many drugs have proven efficacious in clinical trial settings where patients 
received intensive care with drug compliance being monitored according to study 
protocol. However, in real clinical practice in which compliance may be far from 
satisfactory, the response to drugs is not often reproducible. 15 Despite this wealth of 
literature on compliance, well-designed studies to examine the effects of medication 
compliance on clinically important endpoints such as morbidity and mortality have been 
lacking. 
Studies showed a significant correlation between the number of medications 
prescribed and the incidence of inappropriate medication compliance. For many patients, 
treatment with two to four drugs was appropriate and necessary. However, when the 
number of simultaneously drugs used increased to five or more, there was a pronounced 
risk of medication errors, especially when the drugs had to be taken at different times of 
the day. 323 Some papers have suggested the association of polypharmacy with non-
compliance in addition to the increased risks of adverse drug reactions and drug 
interactions. 58,113,232 At Hong Kong Hospital Authority hospitals, patients attending 
medical specialties had the most number of drugs prescribed, averaging 3 items per 
patient and 16-38% of medical patients were prescribed 5 drugs or more. 58,113 in view 
of the asymptomatic nature of chronic diseases and the frequent need for polypharmacy, 
these patients were my target group for studying their compliance levels and reasons for 
non-compliance. In this study, polypharmacy has been used simply to mean multiple 
4 
73 
drug use and did not carry connotation regarding its appropriateness. And our data did 
not allow us to draw any conclusions about the justification for polypharmacy. 
There are currently 4 major strategies namely education, dosing regimen 
planning, clinic scheduling and communication that improve medication compliance. 
They are complementary to each other but their use must be tailored to individual needs 
in order to be effective. Pharmacists are conventionally involved in a wide range of 
patient education activities from the more intensive, face-to-face interview to the more 
time-limiting telephone call. They are recognized as important members of the health 
care team. The ability of clinical pharmacists to assist in the management of a variety of 
disease states, including hypertension, diabetes mellitus, hyperlipidemia, and anti-
coagulation therapy, has been documented. 324-328 Although studies have 
demonstrated the improvement of patient compliance following pharmacist's 
interventions 53,311,329-333^ the effects of the latter on clinical outcomes remain 
inconclusive. To my knowledge, their role as health care providers among polypharmacy 
patients on reducing premature morbidity and mortality has not been evaluated. 
The objectives of this study are to: 
1. To identify the patterns and to examine the reasons for non-compliance of Hong 
Kong polypharmacy patients. 
2. To investigate the association of drug compliance and telephone counseling by 
pharmacist on clinical outcomes: 
• Primary outcomes: the time from the first visit to death 
• Secondary outcomes: the change in frequency of emergency room (ER) 
attendance, hospitalization rate and length of hospital stays within 2 years before 
versus after the first visit 
• Tertiary outcomes: medication compliance and blood pressure control 
The hypotheses of this study are 2 folds: 
1. Poor medication compliance at baseline associates with poor clinical outcomes and 
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2. Periodic telephone intervention by a pharmacist, as a compliance-enhancing strategy, 
is linked to reduced morbidity and mortality. 
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3 Methods 
The study was a 2-year, prospective, open-label, randomized study conducted at the 
medical clinics at the Prince of Wales Hospital (PWH), a regional hospital serving a 
catchment population of over 1 million inhabitants from all social classes. It comprises 
of 22 outpatient medical clinics for the ambulatory management of a wide variety of 
medical conditions under the subspecialties of geriatrics, rheumatology, gastrointestinal, 
renal, hematology, hepatology, endocrine, diabetes, respiratory, hypertension, asthma, 
thyroid and cardiology. The weekly attendance exceeds 2000 patient visits and each 
patient has on average 2.3 clinic visits annually, i.e. -45,000 patients per year 
(2000x52/2.3). The medical record of each patient contains a list of the patient's current 
medications and is shared by all health professionals involved in the patient's care. This 
list is reviewed and updated at each clinic visit and becomes part of the medical note 
dictated on the day of the patient's visit. It is also updated whenever prescriptions are 
renewed (e.g. hospitalized or discharged) or added outside the office visit (e.g. ward 
follow up). All these data are systematically kept as hard copies at the Central Record 
Office and as soft copies in the Hospital Authority (HA) central database. Hong Kong 
HA acquires powerful computer system and comprehensive databases including Hong 
Kong Patient Master Index (HKPMI), Clinical Management System (CMS) and 
Medication Order Entry (MOE) as well as Corporate Drug Dispensing History (CDDH) 
which support overwhelming patient visits for A&E admission, hospitalization and 
outpatient discharged plus follow up. These systems are inter-related and support each 
other to give a full picture on patients' demographic data, telephone number(s), 
laboratory data, prescribing and dispensing details, A&E admission and hospitalization 
records as well as live/dead status. 
Hong Kong lacked a long-term health care financing policy with no government 
or third party insurance scheme. Many patients with chronic diseases, including those 
from the middle class, were managed in hospital clinics where patients paid a flat fee 
that covered consultation, investigations and drug costs. Therefore, Hong Kong health 
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care system is unique in the way that it captures the complete information of the 
prescribing and dispensing details of each patient in the HA database. 
3.1 Study design 
Patients were included if they attended any medical clinics at PWH and receiving 5 or 
more chronic medications at the last visit as documented on the medical records. As our 
study was a pragmatic instead of an efficacy trial, we have allowed minimal exclusion 
criteria to increase the generalizability of our study results to the general patient 
population. 
Exclusion criteria 
• Non-Cantonese dialect or language speaking patients 
• Patients who had conditions that prevented their participation in patient education 
and follow-up (e.g. deaf, mute or had marked dementia or another psychological 
disorder) 
• Patients currently residing in residential home 
The protocol was approved by the institutional review board. Patient enrollment 
started in Oct 1998 and finished in Jun 1999. Each day, patients with scheduled medical 
clinic appointments were initially screened for study eligibility through reviewing of the 
medical records. Patients fulfilling all inclusion and had no exclusion criteria were 
selected and telephoned by me, as a research pharmacist, one to several days in advance. 
They were asked to bring along all remaining drugs (prescription and over-the-counter) 
including inhalers to the office visit to allow a more reliable assessment of their 
compliance. At the first visit, a 15-20 minute face-to-face interview provided by me was 
conducted to eligible patients with informed consent while they were waiting for their 
scheduled medical consultation. The carer(s) or 'significant other(s)' accompanying these 
patients were also welcomed to join the interview with patients' prior consent. A private 
area near the consultation room at the patients' waiting area was used for interview and 
counseling where privacy was ensured. On average, 5 to 6 patients were interviewed in a 
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half-day session (-2.5 hours). Altogether, I have attended 6 half-day sessions per week 
to interview patients (Appendix 1) and used the remaining time for patient 
recruitment, data collection, data entry and conducting telephone intervention at a later 
stage. 
During the interview, patients were asked to read out simple instruction printed 
on the medication label to demonstrate their ability to read labels. Even though a person 
might possess adequate reading skills, understanding and interpretation was not 
guaranteed. Based on a structured checklist (Appendix 2), I asked patients to indicate, 
without prompting, exactly what medications they were actually taking, how and when 
they were taking or using them as well as their understanding of the purpose of each of 
the medications. A drug chart showing all medications available from the pharmacy was 
shown to patients for drug identification or confirmation in case they forgot to bring 
their medications along. These were then compared to the list of medications recorded in 
their medical records to see whether the patient had omitted any, taken wrongly or taken 
additional medications. Afterwards, open-ended questions were asked to evaluate factors 
determining medication usage and to elicit patients' concerns and comments about their 
medications and any barriers to medication compliance. 
The level of drug compliance was assessed by direct questioning and pill counts. 
Questions that might sound threatening, embarrassing or accusative were avoided in this 
study. Sympathetic questions were prefaced with remarks such as: 'People often have 
difficulty taking their pills for one reason or another, have you ever missed any of your 
pills?’ or 'Everyone forgets to take his or her medications from time to time, that's 
natural. I do myself. Do you forget sometimes too? Do you have medicines for which 
you sometimes miss taking a dose?. If the response was positive or affirmative, then the 
patient was asked to estimate how often the medication was omitted. These open-ended 
questions did not specify a time frame for response (e.g. 'over the previous week' or 
'within the previous 24 hours') so as to detect infrequent non-compliance. For example, 
if a patient indicated that she rarely missed doses of drug X (one tablet once daily) and 
estimated only missing one tablet a month, then the self-report compliance was 
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estimated to be 29/30 or 97%. If the patient indicated that routinely, every Thursday, she 
did not take frusemide (1 tab or 40mg daily), the self-report compliance rate was 
estimated to be 6/7 or 86%. 
A tablet count was also used to verify compliance, as it was the only practical 
method to quantify compliance of patients taking several drugs with wide variety. To 
maximize the count's validity, patients were given no overt clues that their tablets would 
be counted. Instead, patients were told not to use any drugs left at home as they might 
probably be expired and their new drug supplies were enough since prescriptions were 
rewritten at successive clinic visits, which lasted till the next clinic appointment. 
A patient was considered compliant with a particular drug if he/she remembered 
the regimen correctly and had taken 80-120% of that drug persistently based on self-
report and tablet count. The patient was considered compliant if he/she was compliant 
with all of his/her prescribed chronic drugs, and vice versa. A compliance score, defined 
as the number of medications with which a patient complied taken over the total number 
of medications prescribed expressed as a percentage, was calculated for each patient. 
Based on the assessment, a patient was classified as compliant if he/she complied with 
all the prescribed chronic drugs (thus giving a compliance score of 100%) and vice-
versa. Take for an example, a 80% compliance score means 4 out of 5 or 8 out of 10 
prescribed drugs were taken correctly and persistently and patient achieving this was 
classified as a non-compliant patient. 
Apart from checking on drug compliance, I also made a broad range but tailor-
made counseling. Elderly are not a homogeneous group and consequently, rather than 
teaching everything about a particular disease, education programs must be tailored to 
acknowledge individual levels of interest, prior knowledge and ability to absorb new 
information. I explained the purpose of each drug and the importance of complying with 
the prescribed regimen. 
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Patients with asthma were counseled on inhaler technique (including the use of a 
spacer); obese and hyperlipidemic patients were given an advice on exercise and low-fat, 
low cholesterol diet; patients with depression or anxiety were given information on 
stress reduction. Patients prescribed with sublingual nitrate (TNG) were given 
information on correct administration and proper storage. Smokers or alcohol drinkers 
were encouraged to gradually reduce their consumption of cigarettes or alcohol in an 
attempt to achieve smoking cessation and alcohol abstinence. Booklets for anti-
hypertensive drugs, coronary heart disease, and diabetes mellitus were given to 
appropriate patients or caregivers for reference or education purposes. Patients were also 
taught or encouraged to conduct self- monitoring at home e.g. blood glucose, blood 
pressure and peak expiratory flow rate. 
A drug box with compartments for pill taking was introduced to patients whose 
regimen was more complex (e.g. different medication dosages to be taken at different 
times of the day) and have difficulty in sorting them appropriately. Patients were also 
taught to put the correct daily doses in a pocket-sized pillbox that holds a 1-day supply 
of medication. I also reviewed with patients and caregivers, the general principles of safe 
medicine use such as how to cope with side effects or missing dose, proper drug storage 
etc. The importance of discussing their medications or health-related problems with their 
physicians was also emphasized. Patients were given the opportunity to ask the 
pharmacist questions regarding their drug therapy. Before each telephone ended, patients 
were told to repeat the key messages they received which provided an opportunity for 
clarifying misunderstandings, mental rehearsing, and reinforcing commitment. 
All intervention activities and information regarding patient's levels of 
compliance, patterns of drug taking behavior, reasons for non-compliance and other 
medication-related problems were documented. 
Patients classified as compliant at initial interview received standard instructions 
on how to take prescribed medications, along with an explanation of precautions and 
adverse effects but without further education. One-fifth of these compliant patients 
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identified at the first visit were randomly selected and reassessed for drug compliance at 
their second doctor visit (8-12 weeks after the first visit) and at the end of the 2-year 
study. 
Patients considered non-compliant at the first visit were followed up at their 
second clinic visit usually 8-12 weeks later with their drug compliance reassessed. 
Further individualized patient education was provided. They were then reclassified as 
’compliant (C)’ and 'non- compliant (NC)’. Depending on their show up sequence at the 
second visit and within the C and NC groups, patients were randomized into intervention 
(T+) or control (T-), giving a total of 2x2 thus 4 treatment arms; namely compliant-
control (CT-), compliant-intervention (CT+), non-compliant-control (NCT-) and non-
compliant-intervention (NCT+) groups. For example, for those reclassified as compliant, 
the first to show up at their second visit would be assigned to CT- while the second one 
would be assigned to CT+. The third one was again assigned to CT- and so on. Patients 
who remained non-compliant were randomly assigned to NCT- or NCT+ based on the 
same principle above. Thereafter, patients allocated to the intervention groups (CT+ or 
NCT+) received a telephone call from the pharmacist between doctor visits for the 
whole period of 2 years. Each telephone call lasted for 10-15 minutes and served to 
remind patients of their next clinic appointment and reinforce drug compliance. The 
counseling was individualized but essentially followed the same structure which the 
pharmacist has adopted at the first visit. Patients in the control groups (CT- and NCT-) 
did not receive any interventions. 
After 2 years sustained periodic telephone intervention，the above 4 groups of 
non-compliant patients identified at the first visit were given a final reassessment on 
their medication compliance through a face-to-face interview (Figure 2). 
3.2 Outcome measures 
The primary endpoint was the time from the first visit to death. The secondary outcome 
measures were the change in hospitalization rate, length of hospital stay and the 
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frequency of emergency room (ER) visits within 2 years before versus after the first 
visit. Other outcome measures included blood pressure and the level of drug compliance. 
Data on demographics, patterns of medication* use and the social aspects of patient 
characteristics (living arrangement, drug administration method and patient's ability to 
read drug labels) were documented by the pharmacist upon the first visit and these data 
captured were considered baseline. Drug compliance was assessed at the first visit, 
second follow up and at the end of the 2-year study. The blood pressure readings at each 
clinic visit, hospitalization rate, length of hospital stay and frequency of ER visits were 
documented retrospectively for the previous 2 years before the first visit, and 
prospectively until the end of the 2-year study or the last visit for patients who died 
before the study ended. Drug utilization data and blood pressure readings were available 
from medical records. Hospitalization, ER and mortality data were obtained from the 
hospital administrative database. 
•Medications prescribed were classified as in the British National Formulary 42 
except that aspirin was grouped under anti-platelets or anti-coagulants but not grouped 
along with analgesic drugs in the central nervous system (CNS), or non-steroidal anti-
inflammatory drugs (NSAIDs) used for musculo-skeletal and joint diseases. 
3.3 Statistical analysis 
Socio-demographic characteristics were summarized using means and standard 
deviations or frequencies and percentages. To examine differences in baseline 
characteristics between patient groups, Chi-square test was used for categorical data, 
Student's t test was used for normally distributed continuous variables and Mann-
Whitney U test for continuous but not normally distributed variables. 
The primary endpoint, 2-year all cause mortality, was analyzed using the COX 
regression model with the following covariates: age (continuous), gender, hospitalization 
rate for the past 2 years (times/year), frequency of ER visits for the past 2 years 
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(times/year), baseline compliance score and the baseline number of concomitant 
medications. This regression model was chosen because patients were followed up for 
varying periods of time. Time to death was defined as the dependent variable. Patients 
were censored if they died or reached the end of the 2-year follow-up period. The 
forward stepwise regression model was built by considering statistical significance (P < 
0.1) for entering variables and likelihood ratio for removing variables. After the best 
fitting model was determined, the hazard ratio and the corresponding 95% confidence 
interval (CI) were computed for the regression coefficient of each variable that was 
determined to be a significant predictor. Kaplan-Meier curves were plotted to describe 
the hazard function and they were compared by log-rank test. 
The COX regression model was also used to assess the effect of pharmacist's 
periodic telephone intervention on the primary outcome after adjustment for the change 
in age, hospitalization rates and frequency of ER visits during the course of the study. 
The secondary and other outcomes measures (frequency of ER visits, 
hospitalization rates, length of hospital stays, mean clinic systolic and diastolic blood 
pressures and mean compliance score) were analyzed with one-way analysis of variance 
(ANOVA). The Least Square Method was used to adjust value for multiple 
comparisons. A 2-sided P value <0.05 was considered statistically significant. 
I performed all statistical analyses using the Statistical Package for the Social 
Sciences (SPSS version 9.0 for Windows). 
3.4 Power analysis 
Power analysis determines the chance of detecting a true-positive result and reduces the 
risk of committing a type II error which accepts a false null hypothesis. 334 There are no 
empirical definitions of clinically meaningful intervention exist, such as in the 
percentage reduction of death for a given intervention. There is neither clinical 
consensus nor empirical evidence to guide definitions of clinically important effect. 
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Therefore in this study, a natural history was examined in order to detect the effect of 
compliance on mortality rate. Assuming a mortality rate of 7% per year with reference to 
a local high-risk diabetic cohort 335, 845 patients were calculated and required for this 
study to have 80% power to detect a 7% reduction in the absolute risk with a 2-sided 
alpha level of 0.05. This did not account for patients who were lost to follow up. A more 
modest reduction in risk or patients defaulted follow up would require a larger sample 


















































































































































































































































































































































































































































































































































































A total of 1011 patients taking five or more chronic medications were recruited 
during the 9-month period and their drug compliance levels were assessed by direct 
questioning and pill counts. These patients were interviewed by me for about 15-20 
minutes as previously described with careful documentation of their knowledge 
about their disease, treatment regimens, drug taking behaviors and health beliefs on 
their clinic visit days. Over 90% of patients highly appreciated the services of this 
patient education section for their detailed counseling and 'extra' care. 
4.1 Patient demographics 
Of the 1011-polypharmacy patients recruited, the mean age was 71 ± 10 years with a 
range of 34-96 years, 49% was male. The mean drug item number received by each 
patient was 5.9 土 1.2 (range 5-14). The mean total number of daily doses was 12.4 士 
6.1 (range 4-40). For example, if the patient's regimen required 2 tablets to be taken 
twice daily and three capsules to be taken three times daily, then the total number of 
daily doses equaled 2x2 + 3x3 = 13. Over 90% of patients lived with family 
members, 87% could read out labels and 13% had their drugs sorted and/or 
administered by caregivers. 
4.2 Clinic attended and drug usage 
Figure 3 illustrates more than half of the polypharmacy patients were recruited from 
general medical clinics (Firm 1, Firm 2, Firm 3 and Firm 4). Over 25% of the 
recruited patients came from Cardiology clinic and another 13% attended Geriatrics 
clinic. 
Table 3 shows the patient chronic drug usage at baseline classified according 
to BNF 42. Nearly all polypharmacy patients recruited were taking cardiovascular 
drugs (97%), and about 41% of patients were taking anti-diabetic agents. The most 
commonly prescribed cardiovascular agents were anti-platelets or anti-coagulants 
/ 
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(69%), diuretics (56%), angiotensin converting enzyme inhibitors or angiotensin II 
antagonists (51%) and nitrates (49%) as illustrated in Table 3. 
4.3 Non-compliant rates and its patterns 
At the first visit, 502 (50%) of 1011 patients were identified as non-compliant with a 
mean compliance score of 60% (median 67%). In other words, one out of two 
polypharmacy patients interviewed got compliance problem and only about 60% of 
their prescribed regimens were taken within 80-120%! Of these non-compliant 
patients, 81%, 16% and 3% had problems of under-compliance (i.e. taking <80%), 
over-compliance (i.e. taking > 120%) or a combination of both, respectively. The 
patterns of non-compliance were modified frequency (27%), dose omission (24%), 
premature cessation (20%), altered dosages (17%) and adjustment of both frequency 
and dosages (12%). 
4.4 Reasons for non-compliance 
Insufficient knowledge (65%), forgetfulness (16%), problems with health beliefs 
(10%) and experience of side effects (9%) were the main reasons for non-
compliance. Further reasons for insufficient knowledge included lack of knowledge 
on their medications e.g. did not know the indication or were afraid of side effects 
(42%), were not aware that the regimen had been changed (39%), deliberately altered 
the regimen due to a decrease or disappearance of symptoms (9%), claimed the drug 
was not dispensed though the dispensing record confirmed otherwise (6%) and 
stepped up their dosage and/or frequency because of worsened condition perceived 
(4%) . 
4.5 Relationship between drug class and medication compliance 
Respiratory drugs were found to have the highest non-compliant rates (40%) 
amongst all drug classes and were almost double the second one which was drugs for 
central nervous system (Table 4). Cardiovascular drugs were shown to be the best 
compliant drug class (Table 4). For individual drug class, the compliance with 
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diuretics, calcium channel blockers, beta-blockers, angiotensin converting enzyme 
inhibitors or angiotensin II antagonists and anti-diabetic drugs were 80.6%, 83.8%, 
84%, 84.1% and 82.6%, respectively (Table 4). 
4.6 Relationship between dosage frequency and medication compliance 
In these 1011 patients, there were altogether 5920 dosage regimens and their 
distributions were shown in Figure 4. Once daily was the most common dosage 
schedule (54%) and was followed by twice daily (32%) and thrice daily (9%). Four 
times a day regimen accounted for only 5% of the total number of treatment 
regimens. 
There was a linear decline in compliance rates with increasing number of 
frequency per day. The greatest decline occurred when dosing increased from three 
to four times a day (Figure 5). The same applied to the maximum daily dosing 
frequency and when it reached four times a day, significantly more patients (almost 
three fold) were considered non-compliant (p<0.001) (Figure 6). 
4.7 Clinical characteristics of compliant and non-compliant patients 
Compliance was neither related to age (P=0.161) nor gender (P=0.801). Those who 
could not read out labels for drug administration (P=0.032), lived alone (P<0.001) 
and self-administered medications (P<0.001) were more likely to non-comply 
(Table 5). Compared to the compliant patients, the non-compliant patients were 
receiving significantly more concomitant medications (P=0.017) and had a greater 
number of total daily doses (P<0.001), and more frequent emergency room (ER) 
visits for the past 24 months (P=0.012) (Table 5). Also the non-compliant patients 
were found to have higher hospitalization rate and (P=0.549) longer duration of 
hospital stays (P=0.972) in the previous 2 years but these were not statistically 
significant (Table 5). 
Comparing the individual drug class prescribed for compliant and non-
compliant patients identified at the first visit, patients taking respiratory and gastro-
/ 
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intestinal drugs were more prone to non-comply. On the other hand, patients taking 
drugs for endocrine system and cardiovascular drugs especially anti-platelets or anti-
coagulants, lipid-regulating drugs and beta-blockers were more likely to comply 
(Table 6). 
4.8 Comparison of non-compliant patients identified at baseline during the 
second reassessment 
Among the 502 non-compliant patients identified, 442 came back for follow up at the 
second visit while 60 patients defaulted (Figure 7). Of the 442 non-compliant 
patients who had their drug compliance reassessed at the second visit, 236 (53%) 
became compliant (C) whereas 206 (47%) remained non-compliant (NC) despite 
pharmacist's initial counseling (Figure 7). For the compliant patients identified at 
baseline (i.e. compliance score = 100%), 93% remained compliant and 7% 
deteriorated (Figure 7). 
Within the C and NC groups, patients were randomized to CT- (n=l 19)，CT+ 
(n=l 17)，NCT- (n=104) and NCT+ (n=102). The 4 arms were well matched in terms 
of age, sex, and ability to read labels, living arrangement, as well as drug 
administration method. They were also similar regarding the number of regularly 
scheduled medications, total number of daily doses, the frequency of ER visits and 
hospitalization, and the length of hospital stays for the past 2 years (Table 7). 
However, NCT- and NCT+ had a significantly lower compliance score at the first 
visit and a greater total number of daily doses than CT- and CT+ (Table 7). There 
were no significant differences in the class of drugs prescribed between the 4 groups 
except that more patients in CT+ were taking lipid-lowering drugs (Table 8). 
4.9 Effects of pharmacist's telephone intervention on tertiary outcomes 
4.9.1 Medication compliance 
The effects of pharmacist's telephone reinforcement on medication compliance are 
shown in Figures 8 and Figure 9. Patients in all 4 groups demonstrated a 
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significant improvement in compliance score at the end of the second year compared 
to the first visit (P<0.001) (Figures 8). On the other hand, the mean compliance 
score in patients classified as compliant at the first visit reduced significantly at 2-
year compared to the first visit (P二0.006) (Figures 8). The percentages of patients 
became fully compliant increased from 0% to 81.7%, 92.7%, 57.7% and 80.7% for 
CT-, CT+, NCT- and NCT+ respectively (P<0.001) (Figures 9). Whereas the 
percentages of fully compliant patients decreased from 100% to 88.3% for compliant 
patients identified as baseline (Figures 9). 
By study design, all patients in NCT+ and NCT- were non-compliant at the 
second visit but at 2-year, significantly more patients became compliant in NCT+ 
than in NCT- (80.7% vs. 57.7%, P<0.001) (Figures 9). In contrast, all patients in 
CT+ and CT- were compliant at the second visit. At the end of 2-year, significantly 
less patients in CT+ than CT- turned non-compliant (7.3% vs. 18.3%, P=0.038) 
(Figures 9). 
4.9.2 Blood pressure 
The mean values of all blood pressure readings measured during the 2 years before 
the first visit and that during the 2 years after the first visit were collected and 
analyzed. 
Except NCT-, all other groups of patients showed significant decrease in mean 
systolic blood pressure comparing to their own mean levels in the previous 2 years 
(F igure 10). The mean changes in systolic blood pressure from the 2 years before 
and after the first visit were -4.79 士 1.27, -6.58 土 1.26，-2.59 土 1.49 and -3.87 土 1.28 
(mmHg) for CT-, CT+, NCT- and NCT+ respectively (F igure 11). The reduction 
appeared to be the greatest for CT+. However, the mean reduction was not 
significantly different between the 4 groups (P=0.186, ANOVA). It was noted that 
about 60% of these polypharmacy patients still got a mean systolic blood pressure > 
140mmHg. 
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F i g u r e 13 illustrates that all groups of patients got significant reduction in 
mean diastolic blood pressure and again with CT+ achieved the greatest extent, while 
NCT- acquired the fewest improvements. Using patients as their self-control, the 
mean changes in diastolic blood pressure for the 2 years before the first visit versus 
the 2 years after were -2.38 士 0.62, -4.32 士 0.58，-1.71 土 0.84 and -3.19 土 0.69 
(mmHg) for CT-, CT+, NCT- and NCT+ respectively (P=0.043, ANOVA) (F igu re 
14). CT+ showed a significantly greater decrease in mean diastolic blood pressure 
compared to CT- (P=0.039) and NCT- (p=0.007). However, no significant difference 
in the mean diastol ic blood pressure reduction was found between NCT+ and NCT-
groups (P=0.141). 
Similarly, there was a trend that patients receiving pharmacist intervention 
achieved better blood pressure control than their control counterparts. 
4.10 Effects of pharmacist's telephone intervention on secondary outcomes 
In all patient groups, irrespective of their compliance status at the first visit and the 
assigned groups after randomization, there was an increasing trend regarding the 
frequency of ER visits, hospitalization rate and duration of hospital stays during the 
2-year study period using their previous 2 years as control (Table 9). 
Using patients as their self-control, the mean changes in the frequency of ER 
visits for the 2 years before the first visit versus the 2 years after were 0.59 士 0.44, 
0.50 土 0.37，1.56 土 0.51 and 0.72 土 0.41 (times/year) for CT-, CT+, NCT- and N C T + 
respectively. Although NCT- apparently showed the greatest mean increase in the 
number of visits, no significant difference in the change in frequency of ER visits 
was noted between the 4 treatment groups (P=0.299) (Figure 14). 
Regarding the mean increase in hospital admission rate, CT-, CT+, NCT- and 
N C T + got 1.93 士 0.72，0.89 土 0 . 3 7，U 9 ± 0.31 and 1.44 土 0.36 (times/year) 
respectively. No significant difference was noted between the groups but CT+ 
showed the smallest increase (P=0.463) (Figure 15). 
91 
The mean changes in the length of hospital stays were 16.8 土 4.23，4.33 土 
2.70, 17.3'士 4.73 and 9.80 土 3.51 (days/year) for CT-, CT+, NCT- and NCT+ 
respectively. All groups also showed significant increase in the lengths of hospital 
stays during this 2-year study period except the change in CT+ was statistically 
shorter than CT- (P=0.019) and NCT- (P=0.017) but not for NCT+ (P=0.141) 
(Figure 16). 
4.11 Primary end-points of compliant versus non-compliant patients 
The overall 2-year mortality rate for compliant and non-compliant patients based on 
the first assessment was 12% and 19% respectively (F igure 17). F igu re 18 presents 
the Kaplan-Meier curves for the compliant and non-compliant patients identified at 
the first assessment. The graph shows that the Kaplan-Meier mortality curve 
representing the non-compliant group is consistently above that of the compliant 
group. This difference explains that medication compliance had effect at all points of 
follow up. This figure also indicates that non-compliant patients had poorer 
prognosis in terms of survival than compliant patients. Moreover, as the number of 
months increased, the two curves appears to get farther apart, suggesting that the 
beneficial effects of compliant over non-compliant patients were greater the longer 
one stayed in good medication compliance status. The relative risk of all cause 
mortality in the non-compliant group (compliance score < 100%, n=502) as 
compared with the compliant group was 1.63 (i.e. 63% increase) (95% CI 1.18-2,24, 
P=0.0029) (Figure 18). 
Regarding the baseline compliance score, for those achieved less than 33% 
mean compliance score, the relative risk to die within 2 years was 2.9 times 
compared to those who attained 100% mean compliance score (P<0.001) (Figure 
19). The hazard ratio was 1.8 for those who only obtained a mean compliance score 
between 34-66% compared to compliant patients (P=0.0098) (Figure 19). However, 
there was no statistically significant difference in mortality rate was found between 
those achieving a mean compliance score of 67-99% and those of 100% mean 
compliance score (Figure 19). 
/ 
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4.12 Best predictors of mortality rate for the studied population 
Upon stepwise COX regression modeling, older age [RR (95% CI): 1.05 (1.03-
1.07), P<0.0001], more frequent hospitalization within the previous 24 months [1.19 
(1.14-1.25), P<0.0001] and baseline compliance score less than 66% were 
independent predictors of 2-year mortality (Table 10). Compared to the compliant 
patients (i.e. 100% compliance score, n=509), the adjusted hazard ratio of 2-year 
mortality for patients who achieved <33% (n=81) and 34-66% (n=159) baseline 
compliance score were 2.87 (95% CI 1.8 — 4.6，PO.OOOl) and 1.61 (95% CI 1.1-2.7, 
P=0.029) respectively. 
4.13 Effects of pharmacist's telephone intervention on primary outcomes 
Over the 2-year study period, the mortality rate was the highest for NCT- (19.2%), 
the lowest for NCT+ (10.6%), and similar for CT- (15.1%) and CT+ (12.0%) 
(Figure 17). Both the mortality function curves of patients who received 
pharmacist's intervention (CT+, NCT+) are continuously below their control 
counterparts (CT-, NCT-). This explained that the former group had better survival 
rates than those without periodic telephone follow up by the pharmacist (Figure 20). 
Upon Stepwise COX regression modeling, older age [RR (95% CI): 1.06 
(1.024-1.088)，P=0.0005], male [1.99 (1.118-3.331), P二0.0089]，more frequent 
hospitalization within the previous 24 months [1.16 (1.074-1.258), P=0.0002] and 
without pharmacist intervention [1.66 (1.002-2.757), P=0.049] were independent 
predictors of mortality (Table 11). Variables not being selected into the regression 
modeling included the frequency of ER visits for the past 2 years, number of 
concomitant medications and compliance status at the second visit (Table 11). As 
patient compliance at the second visit was not a significant predictor of 2-year 
mortality, data were pooled to compare the intervention group (CT+ and NCT+ 
combined) and control group (CT- and NCT- combined). Over the 2-year study 
period, significantly fewer patients in the pooled intervention group (n=25, 11.4%) 
than the control group (n=38, 17.0%) died (unadjusted RR=1.63, P=0.028) (Figure 
21). After adjusting for other covariates, the hazard of 2-year mortality for those 
/ 
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without pharmacist's telephone intervention was increased by 40% (95% CI, 1.002 
to 2.757; P=0.049). Using this result, the number of patients who would need to be 
treated (NNT) for two years with a pharmacist's telephone intervention to prevent 
one death was 14.1. 
4.14 Clinical characteristics of non-compliant patients with / without second 
follow up 
Among the 502 non-compliant patients identified, 442 were reassessed for drug 
compliance at the second visit while 60 patients defaulted (Figure 7). Compared to 
patients who had attended the second visit, the defaulters had similar characteristics 
in terms of age, sex, and the number of concomitant medications, living arrangement, 
drug administration method and their ability to read label (Tab le 12). Nonetheless, 
the defaulters had a significantly lower compliance score (P二0.019) and greater total 
number of daily doses at the first visit (P=0.037). They also had a significantly 
higher rate of hospital (P<0.001) and ER admissions (P=0.007) and a significantly 
longer length of hospital stays (P<0.001) within the previous 2 years before the first 
visit (Table 12). 
Table 13 summarizes the baseline chronic drug profiles between patients 
with or without second reassessment and pharmacist's additional counseling. It was 
concluded that there was no statistically significant difference between these two 
groups of patients in terms of different drug classes prescribed. However, within 
cardiovascular drugs, patients taking alpha-blockers (P=0.049), anti-platelets or anti-
coagulants (P=0.014), beta-blockers (P=0.029), calcium channel blockers (P=0.027) 
and lipid-regulating drugs (P=0.006) were more likely to keep appointments. 
4.15 Clinical outcomes of defaulted patients at the second visit 
The non-compliant patients who defaulted the second visit (n=60) were not 
randomized into any of the 4 groups. At the end of the 2-year study, they had a 
significant and marked increase (P<0.0001) in the frequency of ER visits (8.65 土 
1.90 times/year), hospitalization rate (8.88 土 1.80 times/year) and the length of 
/ 
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hospital stays (119.08 土 20.08 days/year) compared to their previous 2 years (Table 
9). Moreover, 32 died (Figure 17) and the hazard ratio was 6.8, (95% CI, 4.4 to 
10.4, PO.OOOl) compared to those who kept the second visit and were subsequently 





































































































































































































































































































Table 3: Patterns of drug class prescribed for the cohort of 1011 patients 
assessed at the first visit 
l ^ u g Class* % 
Cardiovascular system 97.4 
Anti-platelets or anti-coagulants 69.0 
Diuretics 55.5 
Angiotensin converting enzyme inhibitors or Angiotensin II antagonist 50.9 
Nitrates 48.9 
Calcium channel blockers 45.3 
Other cardiovascular drugs 34.0 
Beta-blockers 30.9 
Lipid regulating drugs 18.5 
Alpha-blockers 8.0 
Endocrine system 44.4 
Anti-diabetic drugs 40.8 
Nutrition & Blood 35.1 
Respiratory system 19.8 
Musculoskeletal & joint diseases 16.1 
Gastrointestinal system 16.0 
Central nervous system 5.6 
Others 3 .0 
*The drug class was classified according to BNF 42 3 3 6 
97 
Table 4: Non-compliant rates amongst drug classes of 1011 patients 
assessed at the first visit 
^ u g Class* % 
Respiratory system 40.2 
Central nervous system 24.3 
Gastro-intestinal system 24.0 
Musculoskeletal & joint diseases 23.0 
Nutrition & Blood 20.4 
Endocrine system ^ 17.1 
Anti-diabetic drugs 17.4 
Cardiovascular system 16.0 
Diuretics 19,4 
Nitrates 18.9 
Other cardiovascular drugs 17.7 
Alpha-blockers 17 J 
Calcium channel blockers 16.2 
Beta-blockers J 6.0 
Angiotensin converting enzyme inhibitors or Angiotensin II antagonists 15.9 
Anti-platelets or anti-coagulants 11.6 
Lipid-regulating drugs J 1,4 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Low compliance is a growing concern, seriously undermining the benefits of current 
medical care. Lack of compliance to medical advice is also a source of ongoing 
frustration to doctors. 337 in many chronic diseases, the weakest link is helping the 
patient to manage his own disease. Patient education is an added value to medicine, 
and contributes to therapy and to the quality of life of patients. This study aims at 
studying the relationship between compliance and patient outcomes, also whether a 
pharmacist's periodic telephone intervention can help to improve compliance or 
patient clinically important outcomes. 
5.1 Study design 
Without similar reference to base on, I have recruited a larger sample size (n=1011) 
than the calculated number (N=845) in order to detect a smaller difference between 
the estimated mortality rates of compliant and non-compliant patients. Under a well-
planned study method, there were concurrent control groups and nearly identical 
number of patients amongst the control versus intervention groups after 
randomization. Besides, I conducted all interviews and telephone reinforcement 
myself and this could rule out any possible between-observer differences. This study 
design made the results reliable and useful. The response rates to the study were 
good，with no patient refusing to participate, i.e. 100% accountable. This may be 
because patients were provided with free 'extra care' and they were just required to 
pay a flat fee for the whole health care service. Patients in intervention groups 
received a telephone call between each doctor visit that was around 3-4 months apart 
and therefore on average, the number of telephone calls received by each of these 
patients in 2 years was about 6-8 calls. 
5.2 Compliance assessment method 
The method used for assessing compliance in this study was not as accurate one 
would expect from that measured using electronic devices which will tell the exact 
time that each medication container was opened. Amongst the various methods of 
127 
assessing compliance as discussed in Section 1.6.3 Diagnosis, the most simple and 
practical means which can be used in day to day clinical practice was by self-report 
and pill count. Using a combined approach including tablet counting and direct 
questioning, I have attained reasonable estimates of the extent of medication 
consumption (and hence, compliance) amongst these polypharmacy patients. 
Furthermore, for most medications, it was more important for the patient to take the 
drug according to the specified number of times per day rather than at specific times 
during the day. 
It was well recognized that self-reported compliance was probably a gross 
underestimate of actual non-compliance particularly due to its low sensitivity. 
144，145,155,338 Nevertheless, it could sometimes out-perform several direct and 
indirect measures of compliance. 7,57,153,158 Probably because patient interview 
was the best method to collect information about patient beliefs, attitudes, and 
concerns, experiences with medication regimens and possible reasons or 
explanations for non-compliance. Moreover, it was most appropriate for assessing 
the varied forms of treatment characteristic of a primary care setting. The learning 
and change built upon the learner's existing knowledge and know-how. The 
availability of this important clinical information also facilitated health care 
providers to re-evaluate the current regimens promptly and offered tailor-made 
counseling. 
The high self-reported non-compliance rate found in this study population 
(50%) suggesting that patients were cooperative in reporting their non-compliant 
behavior if asked in a non-judgmental manner. This positive response rate had high 
specificity in detecting true non-compliance. Pill count was also employed to 
supplement direct questioning to improve its sensitivity (uncovered non-compliance) 
and its specificity (verified compliance). 
Huge drug wastage was found during the counseling as reflected by the 
enormous amount of drug surplus either brought back by patients or left at home as 
claimed by them. I remembered an old lady who brought back 68 weeks (duration � 
4 clinic visits) surplus supply of simvastatin tablet just because she did not know its 
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indication and this together cost approximately $3285 (US$421)! This case 
demonstrated that doctors did not teach well and infrequently suspected that their 
patients were not taking their drugs exactly as prescribed; patients rarely volunteered 
this information to their doctor, and doctors did not often explicitly ask. 
5.3 Patient demographics and drug prescribing pattern 
As expected, our chronic polypharmacy patients were relatively old with a mean age 
of 71 years but no gender difference. The mean total number of daily doses was 12.4 
while the mean drug item number received reached 5.9. When the former was 
divided by the latter, one can estimate that the average daily frequency of each 
treatment regimen was twice daily (12.4 + 5.9 « 2). Besides, the drug profiles 
suggested our patients were mainly suffering from cardiovascular diseases like 
myocardial infarction, heart failure, coronary artery disease, hypertension, angina 
and diabetes mellitus. It is not difficult to imagine the difficulty faced by the old and 
ill patients who needed to take these multiple medications correctly, persistently and 
in a timely manner. This difficulty is even more obvious for those living alone, who 
could not read labels and had no carers to help sorting or administering medications 
for them. 
Most of our polypharmacy patients recruited were attending the Cardiology 
clinic, which was almost double that of the other clinics in terms of the number of 
patients recruited per clinic basis. Two possible reasons were that patients with 
cardiac problems tended to be more frequently prescribed with multiple medications 
and probably they were more compliant than those attended other clinics so that the 
counseling time required was comparatively lesser, as a result more patients could be 
recruited (Appendix 5). 
5.4 Extent and pattern of non-compliance 
Half of the polypharmacy patients were considered non-compliant during the first 
visit and this figure was quite profound since one in two polypharmacy patients got 
troubles in taking prescribed medications! Their 60% mean compliance score gave us 
an idea that on average they failed to take two-fifth of their prescribed regimens 
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within 80-120%. That signified the non-compliant patients identified were really 
poorly compliant! In accordance with other studies 75,117,118,339, this study found 
that patients reported under-compliance substantially more than over-compliance 
(81% vs. 16%). Also，in accordance with other studies 78，92,340-342, the 
predominant type of non-compliance was dose omissions, which included premature 
cessation of therapy. 
5.5 Reasons for non-compliance 
Insufficient knowledge, forgetfulness, problems with health beliefs and experience of 
side effects were the main reasons for sub-optimal compliance found in this study. 
Hong Kong lacked a long-term health care financing policy with no 
government or third party insurance scheme. Many patients with chronic diseases, 
including those from the middle class, were managed in hospital clinics where 
patients paid a flat fee that covered consultation, investigations and drug costs. 
Therefore, it was not surprised to observe that cost was not a main concern in this 
study population for their non-compliance. 
In agreement with other studies 73,343,344，lack of knowledge remained a 
major barrier to compliance with medication regimens and was the main reason in 
two-third of the non-compliant behaviors found in this study. The following 
examples illustrated some of these confusions: 
5.5.1 Lack of knowledge 
5.5.1.1 Dosing instructions 
A doctor prescribed, "500mg twice daily" and told patient, "take one tablet twice a 
day". The pharmacist, after contacting the doctor, dispensed a lower (250mg) 
strength clearly labeled "take two tablets twice a day"; the patient might be uncertain 
as to whose instruction to follow. With frail elderly patients, it might be a carer who 
/ 
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collected the prescription, so that the pharmacist would not see the patient. If the 
instruction was vague or ambiguous, confusion might arise. 343,345 
The instruction "take one tablet three times daily with meals" raised the 
question of what to do if a meal was omitted. Some patients might take two in 
lunchtime and one at night or designed his/her own regimen if they were used to 
have two meals a day only. 
Many patients in this study did not read labels before drug administration. As 
a result, many still took the old regimen despite there being a change in regimen. It 
was very important to remind patients reading drug labels before administration 
especially after a clinic visit because regimen might change according to their latest 
signs and symptoms. 
After a change in their 'feelings' towards the severity of their diseases, some 
patients were afraid that their regimens would be 'too strong' or 'too weak'. They 
simply altered the dosage or frequency arbitrarily in order to avoid over-doses or 
under-doses perceived by them. 
5.5.1.2 Drug identification 
In the past, the taste, smell and color of medication might all influence compliance. 
346 With improved technology, most medicines could be flavored and colored to 
minimize the impact of these factors. However, a related problem arose with color, 
size and shape where generic products were being used. Since for most generic 
compounds, there were no standards on color, size and shape, patients might get 
tablets that were different in appearance each time a prescription was dispensed. If 
patients were not given adequate explanation, this could lead to patients' uncertainty, 
confusion, or even rejection of the tablets. Medications might even be taken twice if 
the patients had supplies of both branded and generic products and hence non-
compliance was resulted. Real examples included Zyloric versus Milurit or Capoten 
versus Apo-capoten ... 
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While the same drug with different appearances generated compliance 
problems, different drugs with similar appearance could also complicate this matter. 
For instance, 'small white pills' could be analgesics, anti-gout products, oral 
hypoglycemic agents, respiratory drugs, diuretics or other anti-hypertensive drugs. 
Some patients prescribed a combination of such drugs become confused about which 
tablet to take and when, because of drug similarity. 
5.5.1.3 Storage 
Many patients had enormous surplus of drugs and some were found to be taking 
some brands that were discontinued over years. Some were frequently admitted to 
hospitals with different medications on discharge and yet still have surplus of drugs 
dispensed from previous clinic visits. As a result, they just mixed them up and some 
might overdose while others might underdose. 
The aforementioned situations were further aggravated by patients who put 
all of their loose pills or even removed all tablets from their blister packs into a large 
and empty glass bottle, milk can or biscuit box. These were not uncommon in our 
study population and all instruction labels were put aside that could not be referred to 
if they forgot those at a later stage. 
Some patients might even drop their medications and claimed that they were 
never dispensed with them despite it was clearly recorded in the dispensing history. 
5.5.2 Forgetfulness 
Poor compliance was also frequently attributed to forgetfulness and failure to have 
the drug handy (16%). Changes in routine occurred on weekends, holidays, during 
the travel or their sick period, which led to doses being missed. Some patients might 
spend time regularly at office, home of a significant other or family member, and it 
was a good idea to recommend that they kept a duplicate set of medications at these 
locations. For these patients, improved knowledge of the medication regimen did not 
guarantee compliance but a memory device would help. This could be solved by 
developing cues (refer to Section 1.6.5 Treatment), rationalizing the drug regimen 
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and linking administration times to daily events of the patients as a reminder to take 
their medication as prescribed. 
5.5.3 Problems with health beliefs 
Compliance with long-term treatment was generally worse than that in short-term 
therapy. 160,294 a s much as 10% patients were found to have health belief problems 
in this study population. Some patients claimed that they just got tired on 
taking/applying medications and lacked motivation to comply. Some patients did not 
get serious about compliance until their disease began to affect their lifestyle. Then 
they got religious about it. The lists below were some common misconceptions 
which I came across with these patients during the study period: 
5.5.3.1 Common myths or misconceptions 
These refer to patient's subjective perceptions rather than medical or objective 
estimate of how serious the illness may be. 
• I needed to give my body some 'rest' from the medicine once in a while 
otherwise my body became dependent on it or immune to it. 
• Medicines caused 'heat' and might be harmful to the body if taking non-stop. 
• Medications resulted in a general dullness and somnolence 
• Some of the old-fashioned remedies and Chinese herbal medicines were still 
better than drugs because they did not produce habit or dependence. 
• Medication concealed the real cause of the illness. 
• I only took medicines when I was ill, not when I was better. Besides, I must 
stop the medicines while I caught a cold or got some other illnesses. 
• You were the professional but I knew my own body. 
• My cigarette-loving uncle who did not use respiratory drugs regularly lived to 
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• Mistakenly believed that more drugs would speed their recovery and thus 
self-adjusted the dosage and frequency according to their 'self-monitoring'. 
• Mistakenly believed that the smaller the tablets, the more powerful and potent 
they were. Similarly, the more vivid their color, the more toxic the drugs 
were which was better avoided. 
• Medicines were harmful and not for the body. Treatment could be worse than 
the disease itself as in the case of chemotherapy for cancer. 
• Medicines lowered the body's resistance to infection and disease. Drugs 
might reduce the body's ability to combat infection naturally by preventing 
the body's own immune system from working or they might actually damage 
the body's immune system. 
• Medicines were seen as dealing with symptom and not cause, leading to 
partial treatment and that dosage or frequency was just arbitrarily defined. 
• Reluctant to split the tablets into half due to inconvenience. 
• Medicines were perceived as an offer of uniform treatment for all problems, 
and not tailored to the needs of the individual. 
• Preferred not to take medication if this was possible. Some said they would 
not take medication unless it was absolutely necessary. Some refused to take 
medication at the first symptom of pain and others regarded medication as a 
last resort. 
• Sometimes patients independently chose to temporarily stop taking their 
medications in response to anniversaries, holidays or stress. 
5.5.4 Presence of side effects 
Side effects constituted one of the most commonly predicted causes of non-
compliance. However, it was surprisingly that only 9% of patients mentioned side 
effects as a reason for non-compliance. Patients often gave side effects as a reason 
for stopping treatment, especially when they were alarming or unexpected. They 
might reduce their drug intake or even stop their medication regimen to diminish its 
side effects or to discover the lowest effective drug dosage so as to improve their 
quality of life. 
/ 
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It was not simply the development of side effects that interfered with a 
patient's compliance. Rather, it was the inability of patients to tolerate or manage the 
side effect which reduced compliance levels. Patients who claimed to experience side 
effects would need counseling on how to differentiate illness from drug-induced 
effects as well to balance short-term sacrifices for long-term health benefits. The 
explanation of adverse effects should address what might happen, how to best 
overcome the problem, how long the effect could last, whether it was a severe 
problem, and whether or not the patient should contact the physician or pharmacist. 
The pharmacist must judge how much emphasis to place on providing this 
information, and this would depend on the patient. A well-informed patient might 
want to know all the possible adverse effects, while someone who appeared 
frightened and confused might be able to handle only minimal information on the 
first visit. Patients must be taught on the potential of developing a side effect and its 
severity weighed against the actual occurrences of the disease and benefits of 
therapy. Unless this risk benefit ratio was explained and patient's perspective was 
taken into consideration, patients might decide that the risk of taking the medication 
was too great and discontinued therapy at the first occurrence of a minor, transient 
adverse event, which might or might not due to the medication. 
Half of the polypharmacy patients were non-compliant with one or more of 
their prescribed medications for different reasons with different patterns. 
Interventions to combat non-compliance must be individualized based on the 
underlying causes. 
5.6 Predictability of non-compliance 
5.6.1 Socio-demograph ics 
In my study, compliance was not related to age and gender as widely reported 
elsewhere. 3,23,47,122,160 However, patients who had difficulty in reading 
instructions on labels (p二0.032) were less compliant than those who could read 
labels. This was not surprising, as many patients got the instruction on dosage and 
frequency wrong due to their poor eyesight or illiteracy and thus continued with the 
old regimens which might have been changed several times already. When patients 
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were counseled, they might not be listening, had hearing difficulty or mild confusion. 
This situation would be aggravated if patients lived alone (p<0.001) or self-
administered medications (p<0.001) instead of having emotional and physical 
support or care by family members or other caregivers. All these were in accordance 
with other studies 131,228 that there was a negative influence on compliance if 
patients were having physical or mental disabilities or lacked social support. These 
data verified that stability and support of the patient's family were important in 
promoting and maintaining compliance. Also, effective clinical decision-making 
required that physician skillfully addressed not only the biomedical aspects of 
diseases and their management, but also the socio-behavioral characteristics of 
patients. 
5.6.2 Polypharmacy 
It had previously been shown that the complexity of the medication regimen was 
inversely proportional to adherence. 7,347 The polypharmacy patients recruited in 
this study required a complex regimen involving about six different medications with 
an average of 12.4 tablets to be taken each day. The results agreed with other studies 
showing that patients who took more medications had decreased compliance. 
149,153,348,349 xhe incidence of adverse reactions appeared to increase 
exponentially rather than linearly with the number of drugs administered, indicating 
that the effects of multiple drug use were not simply additives. 250 w h e n two drugs 
are prescribed, the potential for interaction is 6%. This potential increases to about 
50% when five drugs are administered and to 100% when eight or more drugs are 
given together. 250 Because adverse reactions increase exponentially with the 
number of drugs being taken, it is imperative that as few drugs be used as possible. 
By carefully evaluating the need for each prescription and non-prescription drug, a 
physician may be able to discontinue some with no apparent untoward effect on the 
patient. 
Polypharmacy had complex determinants and there was no easy solution to 
reduce its incidence. Physicians should be aware of whether a new drug was 
efficacious and that it did not duplicate or antagonize current drug therapy. In fact, 
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reducing the number of drugs may be therapeutic in itself. A prudent approach is to 
use a 'rule of five.' 250 That is, give no more than five drugs, at the lowest effective 
dose, to prevent drug interactions and increase compliance. The regimen should be 
periodically reassessed to prevent the domino effect suggested by Carlson. ^^^ An 
example to illustrate the domino effect was as follow: 
A patient received hydrochlorothiazide to treat mild hypertension. Several 
weeks later the patient developed hydrochlorothiazide-induced hyperuricemia and 
hyperglycemia and he was then treated with allopurinol and glibenclamide. Then the 
patient developed hypokalemia and required potassium supplementation. 
Subsequently, the patient developed hyperkalemia due to overzealous potassium 
supplementation and required treatment with sodium polystyrene sulphonate at a 
local emergency room to control the hyperkalemia. This scenario could have been 
avoided by changing the anti-hypertensive agent to an angiotensin converting 
enzyme inhibitor or a calcium channel blocker. 
Moreover, greater attention must be paid to the physicians' attitudes and 
motivations concerning drug prescriptions if educational programs were to succeed 
in achieving more rational clinical decision-making. Schwartz and coworkers (1989) 
had documented several motivations for non-scientific drug prescribing. The 
most common reasons offered by doctors was that the patient demanded the drug 
(46%), the medication was used for a placebo effect (24%) or in their clinical 
experience the drug was efficacious (26%). Physicians had also been shown to be 
reluctant to discontinue medications for the elderly. For instance, Kroenke and 
Pinholt (1990) 323 conducted a prospective, controlled trial to reduce polypharmacy 
in patients 65 years or older in the residents' clinic of a teaching hospital. 
Recommendations to discontinue medications or to simplify regimens were 
formulated for 79 polypharmacy patients. While physicians complied with 100% of 
recommendations to simplify a dosage schedule and 62% of recommendations to 
substitute a new drug for the old one, only 40% of the recommendations to stop a 
medication were accepted. The two most common reasons for not accepting regimen 
changes were that another physician had prescribed the medicine, and that the patient 
refused to accept the regimen change. Nevertheless, pharmacotherapy should be 
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based on sound scientific reasoning and that patient should be appropriately educated 
regarding their expectations. 
5.6.3 Dosing frequency 
5.6.3.1 Little difference between daily, twice daily and thrice daily dosing 
Patients who were prescribed several medications tended to take all types of drugs 
together (e.g. four types of drugs, eight pills with breakfast) or forgot all of them 
when they missed that dose. ^ Therefore it was suggested that the number of 
medications was not as important as the number of times per day drug taking must be 
remembered. 
Data from the literature seemed to be dominated by claims that once daily 
dosing would optimize compliance. 175，180，181,288 However, in one of the most 
frequently quoted studies (Galley's study 288), the once a day regimen group 
consisted of only 3 patients and the twice a day group, only 6. Nonetheless, this was 
a retrospective study, and no attempt was made to match the different dosage 
regimens for diagnosis or classes of drug used. Waebar et al 180 showed superior 
compliance with once daily regimens but also showed that switching to once daily 
led to a 15% increase in the number of patients with multi-day lapses. The results of 
the study by Paes et al and Kruse et al 92，183 also supported this. 
In addition, numerous studies had found no worthwhile or significant 
difference in levels of compliance between once daily and twice daily regimen. 
3,27,111,144,182,183,294,353-356 MEMS studies had also shown that compliance 
with once-a-day, twice-a-day and three times daily did not differ significantly but 
was significantly higher than that observed with four times a day dosing. 3,92,182 
Accordingly, a similar trend was observed in this study, showing that 
compliance with once daily regimen was found to be 85.8%; twice and thrice daily 
regimens were associated'with 78.4% and 74.4% compliance respectively, and only 
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52.8% demonstrated good compliance with four times a day regimen. A linear 
decline in compliance rates had also been shown in this study when maximum daily 
dosing frequency increased from one to four. It was noted that the ratio of non-
compliant to compliant patients was still less than one if the maximum dosing 
frequency equaled one, two or three. Nonetheless, when it increased to four times a 
day, the number of non-compliant patients were three-fold that of the compliant 
ones! This further confirmed that four times daily dosing should best be avoided. 
5.6.3.2 Importance of drug property in determining the impact of usual dosages 
A dosage frequency of once daily was not always the best choice. 356 Even highly 
motivated patients could forget once daily treatment. 3,82 Levy 355 w .Icn 
elegantly pointed out the advantage of once-a-day dosing was often illusory because 
the number of missed doses was not a good index of the consequences of poor 
compliance. It was a product-specific issue whether one long lapse caused more 
problems than the equivalent in many brief lapses. A missed dose of a drug given 
once a day usually is more likely to compromise therapeutic effects than a missed 
dose of the same daily dose of the drug given four times a day. Drugs should be used 
at the limits of their duration of action: a drug with an intermediate duration of action 
was better taken twice a day than stretched to once daily by taking a higher dose. The 
efficacy of drugs that were eliminated slowly and accumulated in the body was least 
impaired by partial compliance. 
In reality, the optimal dosing frequency should not be conceptually separated 
from the shape of the concentration-response relation. Although most medications 
exhibited first-order metabolism in a linear manner after reaching peak plasma 
concentration, the slopes varied greatly for decreasing response with decreasing 
concentration. For drugs with steep slopes, the response decreased rapidly, even to 
sub-therapeutic levels, if the intervals between dosing were long. 
Certain drugs, notably amlodipine, appeared to be more 'forgiving' than 
others of the same class were. Their duration of action was more than twice the 
prescribed interval between doses, allowing action to continue when one or more 
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doses were o m i t t e d .湖 Patients could miss taking it for up to 48 hours and still 
maintained therapeutic coverage. Forgiving drugs had low m/ti/2 values, where m 
was the slope of the intensity of effect versus the logarithm of drug concentration in 
plasma, and ti/2 was the half-life of the drug. ^ These indexes imply that forgiving 
drugs had a relatively long ti/2 or low m value or both. A drug with a long im would 
not forgive lapses in compliance if its effect-concentration relationship was steep. 
Among drugs with similar Xm values, some might be more forgiving than others did. 
Beta-adrenergic receptor antagonists like pindolol and propranolol had almost 
identical Xm values but they differed considerably in the rate of decline of their beta-
blocking effect, reflecting different m values. 79 a particularly striking example of 
the importance of the m value was bopindolol, a beta-adrenergic receptor antagonist 
with a ti/2 of 4 to 5 hours. It could be taken as an anti-hypertensive at 1-week 
intervals because of its very low m value. 79 Urquhart 79，358 argued that the most 
forgiving drug in a class was the preferable agent for patients who exhibited poor 
compliance, because it stood the best chance of being able to maintain effects in the 
face of dosing lapses. 
5.6.3.3 The impact of missed dosage on clinical condition 
Levy 355 argued that unless the incidence of non-compliance was reduced by more 
than two thirds when a medication was taken once daily rather than three times daily, 
the resulting increased compliance might be of limited advantage. The degree of 
benefit depended on whether optimal dosing and realistic dosing frequencies 
permitted sustained drug concentrations in the therapeutic range. The increased 
compliance obtained by reducing dosing frequency might actually be 
counterproductive if it increased the occurrence of sub-therapeutic drug 
concentrations. 
Variations in compliance had medical and economic consequences that were 
specific to each drug, to the disease and its severity, and to co-morbidity. Thus, the 
consequences of variability in compliance could range from trivial to catastrophic. 
For example, poor compliance with a diuretic prescribed for mild hypertension 
created a very low risk of serious problems, but if the diuretic was prescribed for 
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moderate to severe heart failure, a few days of missed administration could 
precipitate life-threatening fluid retention. Furthermore, the patient's ability to 
tolerate hypoxia during pulmonary congestion would depend not only on the severity 
of the heart failure, but also on the coexistence of respiratory disease. In contrast, if 
the same patient complied poorly with a prescribed laxative, instead of the diuretic, 
the consequences would probably be negligible, irrespective of concomitant disease. 
Consequences of unrecognized missed doses were easily misattributed to 
pharmacological non-response or worsened disease. Thus, any meaningful analysis 
of therapeutic failure required data on compliance not only for scientific reasons, but 
also because non-compliance was a principal reason for therapeutic failure 121,142 
and usually evaded clinical detection 3,121 Modem therapeutics unavoidably 
required integration of a patient's medication-taking behavior in assessing the clinical 
response to treatment. 
5.6.3.4 Practical issues regarding dosing frequency 
Designing a degree of forgiveness into the product could offset short lapses but that 
approach had its limits, as the longer lapses would necessarily interrupt the actions of 
even the most forgiving products. 357 Another problem created by dosing lapses was 
the occurrence of hazardous rebound effects with some drugs with economic 
consequences that depended on the clinical consequences of lapsed action. 94,357 
Thus helping patients understood the importance of taking drugs as prescribed was 
still of paramount concern. 
Although patients preferred simple, once-daily medication regimens for 
convenience, some of the newer formulations carried a high probability of producing 
sub-therapeutic drug concentrations if inter-dosing intervals increased due to dose 
omissions or delays. Only some medications were sufficiently forgiving that modest 
deviations from the prescribed dosing frequency carried no danger of loss of 
therapeutic efficacy. These new formulations that offered the patient once-daily 
dosing or a combined dosage form could help simplify the regimen and might 
improve compliance. It ‘ should be noted that reducing dosing frequency would 
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increase compliance only if regimen complexity was the primary barrier and the 
patient was motivated to be compliant. If miscommunication or unresolved concerns 
were the major problems, changing the patient's dosing schedules would not improve 
compliance. 
5.6.4 Drug Profiles 
Respiratory drugs were found to be the poorest compliant drug class and patients 
taking these drugs were more likely to be non-compliant in this study. Patients were 
found to stop taking them after a few days because they felt better or the condition 
did not worsen and thus assumed that they had recovered before they actually were. 
The lack of symptoms also acted as a disincentive for patients to remain compliant 
with their medication regimens as prescribed. Treatment with delayed benefits (e.g. 
long acting beta-2 agonist inhaler) or prophylactic treatment (e.g. steroid inhaler) 
also fostered non-compliance. Patients had not experienced symptoms prior to 
beginning treatment but must continue to take medication for years to avoid adverse 
sequelae such as airway obstruction. To some of these patients, these intangible, 
delayed benefits did not always outweigh the inconvenience and cost of taking 
medication daily. Especially many treatment regimens like short acting beta-2 
agonists required frequent administration as many as four times a day. Moreover, 
self-monitoring was rarely taught to patients e.g. peak expiratory flow rate (PEFR) 
using peak flow meter for asthma patients, not to mention that for those patients with 
chronic obstructive airway disease. In view of the absence of an immediate payoff, 
and/or the presence of an immediate annoyance due to drug taking, they were less 
likely to comply with medication regimens. 
It is surprising to know that this study population complied with 
cardiovascular drugs the most. Maybe due to the poor co-morbidity of these 
polypharmacy patients who had already experienced myocardial infarction, major or 
minor stroke, angina attacks，or had been treated with coronary artery bypass graft 
(CABG) or percutaneous transluminal coronary artery ( P I C A ) etc. Through different 
advertisements and TV programs from mass media, patients generally learned and 
accepted the severity of different cardiovascular diseases. Moreover, the dosing 
frequencies for these treatment regimens were mostly once to three times daily and 
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thus were comparatively easier to manage. In addition, they could self-monitor 
themselves simply by measuring blood pressures, pulses or frequency of angina 
attacks. These patients were mostly in the Preparation, Action or even Maintenance 
stage according to the Trans-theoretical model (refer to Section 1.6.4.1.2 Health 
Belief) and as a result, they were more likely to comply. 
5.7 Outcomes measure 
This study establishes that telephone counseling by pharmacist, apart from improving 
patient compliance, reduces mortality in patients with a variety of medical condition 
and who were treated with 5 or more chronic medications. The risk of death was 
reduced by 40% and the number needed to treat (NNT) for two years was calculated 
to be 14.1. Since this was primarily a pharmacist-conducted program, I did not 
review the detail of the progress of clinical course such as the control of disease 
process but hard clinical endpoints. Taken together, the proven efficacy of the drugs 
explained why that the improved outcomes are related to increase drug compliance 
as shown in the Cox regression model. 
Most patients with chronic disease have a life long prescription in order to 
prevent disease exacerbation. As shown in this study, non-compliance could 
compromise the efficacy of medication regimen leading to increased morbidity and 
mortality. Numerous studies 53,311,329-333 including mine had demonstrated that 
pharmacist by providing patient counseling in ambulatory settings improved 
medication compliance. Patient counseling was one of the many educational 
pathways that could minimize non-compliance problems, particularly those that 
might result from a patient's lack of understanding of the proper use of the drug. The 
availability of pharmacist to offer face-to-face counseling to patients was a step 
forward in the patient education process. With proper space allocation to provide a 
private patient counseling area, pharmacist might have greater opportunity to educate 
and inquire about compliance and the reasons for non-compliance. Maintenance of 
most behavior was known to decrease over time and as shown in some studies, 
compliance varied greatly even in individuals. 3,57,173,179 This study also reveals 
that low compliance cannot be 'cured' and improved compliance at one single time 
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point would not be sustained without pharmacist's periodic telephone reinforcement. 
Thus efforts to improve compliance must be maintained for as long as the treatment 
was needed. 
Compliant patients identified at baseline were somewhat in the Maintenance 
phase (changes have been in effect) according to the Trans-theoretical model but 
some of them were still prone to the Relapse phase (a regression to former behavior 
that could occur at any stage). It was reflected by 7-12% of these patients with 
medication compliance deteriorated upon second and final reassessments. 
Maintenance was the target stage when self-control of the problematic behavior was 
more or less established. This stage might still be characterized by a feeling of 
temptation to return to former stages, especially if the environment was filled with 
cues that used to trigger the problematic behavior. Pharmacist should help reduce any 
temptation across all problem situations and ensure maximum confidence in the 
individual's ability to resist relapse. 
After pharmacist's initial counseling, non-compliant patients turned 
compliant as shown at the second visit (CT- and CT+) had took a step further that 
demonstrated they were willingly to change and went to the Preparation (small steps 
of changing) or Action (active steps of changing) stage. Patients at the action stage 
were engaged in modifying their problematic behaviors. They endeavored to 
interrupt habitual patterns and to exert control over their behaviors by using different 
techniques (e.g. contingency management or stimulus control). They must also 
discover strategies aimed at preventing a lapse becoming a relapse which represents 
a complete return to the problematic behavior. 
On the other hand, those patients who remained non-compliant after the 
initial counseling (NCT- and NCT+) were still at the Pre-contemplation (no intention 
of changing) or Contemplation (start to think about changing but not yet committed 
to a plan of action) stage. They were unaware, unwilling or discouraged to change 
particular problematic behaviors. They were not convinced that the negative aspects 
of the problems outweighed the positive. They usually held the opinion that their 
behaviors were well controlled and under self-regulation. Others evaluated the 
possibility and consequences of change. They gave thought to the losses and rewards 
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that a successful change would bring. However, they still lacked the necessary 
commitment for change in the near future. Definitely, these groups of patients 
needed further reinforcement to step forward. 
About 58% of NCT- became compliant at the end of the 2-year after 
pharmacist's further counseling during the second visit. This was compared to 81% 
of NCT+ who became fully compliant upon receiving pharmacist's periodic 
telephone intervention. Also, significantly more CT+ patients remained compliant 
after the second visit compared to CT- patients who lacked pharmacist 's continuous 
support and intervention. These strongly suggested that efforts to improve 
compliance must be maintained for as long as the treatment was needed. In this 
respect, patient counseling on medication use and compliance reinforcement should 
be considered an integral part of each clinic visit. 
My findings indicate that pharmacist's telephone intervention reduces 
mortality in patients with a variety of medical conditions and who were treated with 
5 or more chronic medications. Over the 2-year study period, significantly fewer 
patients in the pooled intervention group (n=25, 11.4%) than the control group 
(n=38, 17.0%) died (unadjusted RR 1.63, P=0.028). After adjusting for other 
covariates, the hazard of 2-year mortality for those without pharmacist's telephone 
intervention was increased by 40% (95% CI, 1.002 to 2.757; P=0.049). The risk 
reduction was related to the sustained improvement in drug compliance and blood 
pressure. The telephone call has provided patients with the knowledge on the general 
principles of medicine use. The importance of discussing their medications or health-
related problems with their physicians was also emphasized. Patients were given the 
opportunity to ask the pharmacist questions regarding their drug therapy. Patients 
were told to repeat the key messages they received which provided an opportunity 
for clarifying misunderstandings, mental rehearsing, and reinforcing commitment. 
Reinforcement of dietary restriction and the importance of medication compliance 
also took place during follow-up. Each of these elements likely contributed to the 
significant reduction in death observed in this study. 
The West of Scotland Coronary Prevention Study (WOSCOPS) assessed the 
reduction of cardiovascular morbidity and mortality with the use of pravastatin in 
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patients who had no history of cardiovascular disease but who had elevated baseline 
total cholesterol (TC) and low-density lipoprotein (LDL) concentrations (mean 土 SD, 
272 士 23 and 192 士 17mg/dL，respectively). 359 this randomized, double blind, 
placebo-controlled study, 6595 men between 45-64 years of age were randomly 
assigned to receive 40mg pravastatin or placebo. After approximately five years of 
treatment, the risk of nonfatal myocardial infarction or death from coronary heart 
disease (CHD) was 31% lower with pravastatin (P<0.001). The number of patients 
who would need to be treated (NNT) for five years with pravastatin to prevent one 
nonfatal myocardial infarction or one death from CHD was 42. 
The Air Force/Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS) assessed the ability of lovastatin to reduce cardiovascular 
events in patients without a history of CHD whose TC and LDL levels were 
considered average (mean 士 SD, 221 ± 21 and 150 士 17mg/dL, respectively), but 
whose high-density lipoprotein (HDL) concentration was below average (36 土 
5mg/dL for men and 40 士 5mg/dL for women). 360 in this randomized, double blind, 
placebo-controlled study, 5608 men and 997 women were randomly assigned to 
receive lovastatin (20-40mg/day) or placebo. After a mean follow up period of 5.2 
years, subjects taking lovastatin was associated with a 37% reduction in acute major 
cardiovascular events (fatal or nonfatal myocardial infarction, unstable angina, or 
sudden cardiac death) compared with patients receiving placebo (P<0.001) (NNT, 
49). 
The Scandinavian Simvastatin Survival Study (4S) was a randomized, 
placebo-controlled trial that assessed the effect of simvastatin on mortality and CHD 
events in patients with pre-existing CHD. Subjects (n=4444) with a mean 土 SD 
baseline TC and LDL concentrations of 260 土 25 and 188 士 25mg/dL respectively 
were randomly assigned to simvastatin 20-40mg/day or placebo. 361 After an 
average follow up period of 5.4 years, simvastatin was proved to reduce the relative 
risk of total mortality by 30% (NNT, 30) and coronary death by 42% (NNT, 29)， 
compared to placebo (P<0.05 for each comparison). 
/ 
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The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) 
trial randomized 9014 subjects with CHD to pravastatin 40mg/day placebo for 
approximately six years. 362 At baseline, the subjects had a mean TC and LDL 
concentration of 218 and 150mg/dL respectively. After a mean follow up period of 
6.1 years, pravastatin was associated with a 24% reduction in the relative risk of 
cardiac death (NNT, 53) and a 22% reduction in the risk of death from all causes 
(NNT, 32). 
The Cholesterol and Recurrent Events (CARE) trial studied the effects of 
pravastatin on mortality from CHD in patients with a history of myocardial infarction 
whose cholesterol levels were considered average or only mildly elevated. 363 This 
was a randomized, placebo-controlled study that involved 4159 patients. At baseline, 
patients had a mean 土 SD TC and LDL concentration of 209 土 17 and 139 土 
15mg/dL, respectively. After five years, pravastatin reduced the risk of death from 
CHD or nonfatal myocardial infarction by 24% (NNT, 33) (P=0.003). 
When compared to the above large randomized clinical trials, the benefit 
from the pharmacist's telephone reinforcement for our polypharmacy patients (NNT, 
14.1) should be considered very worthwhile. 
A few randomized controlled trials had shown that cardiovascular mortality 
could be reduced by 20% for a 5 to 6mmHg reduction in diastolic blood pressure. 
364,365 Although I did not perform comprehensive review of the medical records, I 
did measure the effect of the progress on blood pressure (BP). More than 97% of 
these patients were receiving cardiovascular drugs, BP measurement which is a 
proven surrogate marker for mortality and cardiovascular mortality were available in 
all patients. The mean reduction of diastolic blood pressure was significantly greater 
for the CT+ (-4.3mmHg, P=0.039) compared to CT- and also there was a trend for 
intervention groups to have more pronounced reduction in diastolic blood pressure 
reduction than their control counterparts. The trend that the intervention groups had 
greater improvement in blood pressure control corroborates the recognized effects of 
drug compliance in improving blood pressure control which may contribute to 
improved clinical outcome. 
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It was disappointing to find that pharmacist's intervention was not effective in 
improving ER and hospital admissions in this group of relatively old, taking at least 5 
chronic medications with poor co-morbidities patients. However, it did make a 
difference in shortening the length of hospital stays for CT+ when compared to CT-
and NCT-. Also, a trend was observed that CT+ patients got the fewest number of 
ER and hospital admissions together with the shortest length of hospital slays 
amongst the 4 groups. This revealed that those with improved medication 
compliance and under pharmacist's intervention benefited the most in terms of the 
secondary outcomes. 
5.8 The role of pharmacist in chronic care 
Pharmaceutical care has been deemed pharmacy's mission for the 1990's. 366 Hepler 
and Strand defined pharmaceutical care as 'the process through which a pharmacist 
cooperates with a patient and other professionals in designing, implementing, and 
monitoring a therapeutic plan that will produce specific therapeutic outcomes for the 
patient.' 367 One of the functions of a pharmacist is to provide competently 
monitoring of compliance and proper drug use, especially in chronic diseases.、幻 
Applying theory to the real world is often difficult, regardless of the 
professional discipline. In the pharmacy, patients on chronic medications usually fall 
into one of two categories: (1) new patients starting chronic medications for the first 
time, or (2) return patients already taking chronic medication. The pharmacist's 
opportunity to affect a patient's long-term drug therapy outcomes was perhaps 
highest at the initiation of therapy because the first visit set the stage for future 
interactions. The pharmacist should take the time to begin a 'therapeutic alliance' 
based on mutual respect, liking, trust and commitment to the work of treatment with 
the patient. This therapeutic alliance was possible only when the patient believed the 
pharmacist was competent, was trustworthy, and truly cared about the patient. 
Pharmacists were in a unique position because they could actually show the 
medicine to the patient, 'allowing information exchange relating to the use at the time 
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of counseling. They could also demonstrate certain skills such as inhaler use 
technique and help to individualize drug regimen. Hence, pharmacists could provide 
patient education and reinforcement as required to optimize pharmaceutical care. 
In the management of chronic disease where pharmaceutical care played a 
major role, pharmacist got a special relationship with both physicians and patients. 
Hence, the pharmacist might 'bridge the gap' between the therapeutic objectives of 
the physician and the special problems and/or concerns of the patient. Physicians 
tended to fear that patient-centered conversations would lengthen the average 
consultation visit time, though often they were seen to ascertain whether the patient 
had indeed complied with the regimen before an upward dosage adjustment. On the 
other hand, patients might not tell doctors about their non-compliance for fear of 
being reprimanded or refuted. Pharmacist might help to narrow the chasm between 
ideality and reality in medicine: between the results of clinical trials and those 
achieved in clinical practice, between intention and action, and finally between 
information and behavior. 
Pharmacists like other health care professionals encountered patients with 
unhealthy behaviors on a daily basis. Such behaviors were puzzling to us, especially 
when we provided information that clearly stated the benefits of health behavior and 
the dangers of unhealthy behavior. We did not understand why people continued to 
smoke even when their respiratory systems were compromised. We did not 
understand why individuals would engage in sub-optimal eating behaviors when they 
had been warned of the consequences. Our frustration could easily spill over into 
anger and ultimately led to removing ourselves psychologically from a position of 
positively influencing the person's health. The frustration described above needed not 
be reasoned to isolate us from the patient. The predicament was best understood and 
resolved by recognizing that health behavior was the behavior extension of health 
beliefs and values. Unhealthy behavior was unavoidably irrational and inconsistent. 
A person would continue to smoke in spite of respiratory tract infection because 
smoking was habitual. It was triggered by cues of situation and circumstance. A 
person might be well aware of the dangers of smoking and yet continued to smoke, 
as he or she was not motivated by health considerations at the time of smoking. 
Likewise, people might be anorexic and refused to consume sufficient calories to 
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sustain themselves because of their unrealistic image of the ideal body shape and 
weight. Furthermore, friends who had preceded them in this behavior might not have 
suffered any consequences. 
Of course the decision to comply with the treatment regimen ultimately rest 
with the patient. It must be recognized that sometimes no strategy would work, and 
the patient would not comply with treatment despite the best efforts of the health care 
professionals involved. 
Whether or not a patient took his medication correctly resulted from a 
complex interaction between the patient, his illness, the physician and the medication 
he prescribed. In a problem without clear-cut causes, it remained difficult to identify 
'risk factors' which could contribute to low compliance. Some of the factors 
suggested in the literature and confirmed in my study were socio-demographic 
variables which could not be changed easily e.g. an isolated person who lived alone 
and could not read labels. Others were more amenable to modification e.g. drug 
regimen and drug knowledge, while some were more difficult to change e.g. patient 
attitudes and health beliefs. 
For individuals motivated to comply but who had insufficient knowledge on 
the correct procedures or health concept, the provision of information should be 
beneficial. It was because these patients were already in the Contemplation (start to 
think about changing, not yet committed to a plan of action), Preparation (small steps 
of changing) or Action (active steps in changing) stage according to the Trans-
theoretical model. If the patients were in the Contemplation stage, the task of 
pharmacist was to build intention, commitment and skills for preparation behavior. 
Earlier success and role models can be used if necessary and helped them to practice 
skills through small steps. If the patients were in the Preparation stage, the task of 
pharmacist was to develop and negotiate a realistic and individualized 
implementation plan e.g. to anticipate problems, develop individual solutions and 
enlist support with these patients. When the patient was ready for action, the task was 
to reaffirm commitment and follow-up. Pharmacist should help patients integrated 
new behavior into daily activities and assured continuity of care or collaboration. 
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For those who thought they were ’knowledgeable' and insufficiently 
motivated，additional information about the regimen was unlikely to enhance 
compliance at this moment. Patients believed that they knew themselves, their bodies 
and their illness better than their doctors did, and such it was 'safe' to veer from 
medical guidance. Extra care and attention were needed to correct their attitude and 
of course this was the most challenging and was a resource intensive work as these 
patients were still at the Pre-contemplation stage (unawareness of the need to 
change). The task of pharmacist was to define and agree on the problem with the 
patients through assessing patients' prior knowledge, expectations and concepts, 
clarifying understanding as well as transferring up-to-date information to them. The 
keys were to start from patient's view, ask for expectations and use patient's 
language. Patients should be provided with different options to change behavior and 
helped to select and individualize the action to increase the probability of success. 
This would increase the patient's realistic perception of the drug efficacy and the 
benefits of taking action, both of which were essential if compliance levels were to 
be enhanced. 
For strategies to improve compliance to be effective, health-care 
professionals must not only believe that non-compliance was an important problem 
but were also willing to take steps to help patients comply with treatment regimen. I 
proposed enquiry about medication regimen and compliance with individualized 
counseling should be an integral part of each visit. Many patients with chronic 
diseases had been taking the same medication for many years, giving them a data 
sheet every time they renewed their prescriptions would probably be a waste of time 
and money. Interventions to treat the ’disease’ of non-compliance, like those used to 
treat any other illnesses, must be tailored to the needs and circumstances of the 
individual patient and based on the underlying causes. Intervention strategies that 
have been proven to be effective should be selected and individualized with 
reinforcement periodically or whenever required to reduce the relapse rate. In this 
respect, my study has strongly supported that a pharmacist's interview followed by 
regular telephone intervention in polypharmacy patients was effective in improving 
compliance with benefits on clinical outcomes and utilization of health care 
resources as well as reducing premature mortality. Telephone calls were free within 
Hong Kong, which was an advantage and valuable asset in carrying out this type of 
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intervention here and also this was eminently adaptable to the typical busy clinical 
setting, and I have found it to be very acceptable to patients. 
Stepwise and tailor-made approaches could be employed to counsel patients 
depending on their readiness to learn. Negotiating with the patient involved 
developing a partnership, establishing the patient's preferences for information and 
decision-making, responding to the patient's ideas, concerns and expectations, 
identifying choices, negotiating decisions and managing conflict. This process, 
which took time, might need several consultations for completion. If possible, 
recommendations should be divided into small incremental steps. This way each 
little step accomplished could be used to build self-esteem, promote self-efficacy and 
to help patient solve problem in face of failure or a barrier in their attempt to modify 
behavior. 
Take an example of a pharmacist's involvement in diabetes education: 
Basic 
• How to take oral anti-diabetic drugs (e.g. dose, frequency) 
• Adverse effects of the medication 
• Importance of wearing a medical alert bracelet 
• Proper insulin storage 
• Proper disposal of syringes and lancets 
Intermediate 
• Signs and symptoms, causes, and treatment of hypoglycemia 
• Use of a blood glucose monitor 
• Caring for the feet 
• Drawing up and self administration of insulin 
• When to monitor urine ketones 
• General information about dietary intake/nutrition 
• General information about exercise 




• Defining treatment goals e.g. blood glucose, blood pressure and blood cholesterol 
levels 
• Importance of contacting the primary healthcare provider in adjusting diabetes 
therapy when blood glucose concentration is outside target range 
• Importance of obtaining yearly dilated eye examinations 
• Importance of obtaining regular laboratory testing to monitor glycosylated 
hemoglobin, lipid profile, serum creatinine, microalbuminuria 
• Sick day management 
This intervention consisted of extensive information on medication^, constant 
support and reinforcement for compliant behavior, as well a self-monitoring system. 
Wherever possible, patients should be provided with explicit directions, with purpose 
or importance of therapy explained, important points being repeated and with 
consistent advice between visits and between pharmacists and doctors being 
provided. Open-ended questions should be employed beforehand as these helped 
determine the patients' knowledge of his or her disease and medications. These also 
ensured that the patient understood how to use and what to expect from the 
medications by the end of the counseling session. 
^Extensive information on medication: 
(1) Name and description of medication 
(2) Reason why the medication was prescribed 
(3) Medication storage under any special conditions 
(4) How often during a 24-h period should the medication be taken 
(5) For how many days should the medication be taken 
(6) Should the medication be taken with food or on an empty stomach 
(7) Any special directions or precautions for preparation, administration and use of 
the medication 
(8) Any over-the-counter (OTC) products or other medications which could affect 
the one prescribed 
(9) What happens to the body if a dose is missed 
(10) How the medication affects the body 
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(11) Does the medication have side effects 
(12) What are these side effects 
(13) How to avoid the side effects 
(14) Action to be taken if a dose is missed 
(15) Way to monitor the medication's effects 
(16) Techniques for self monitoring therapy 
4 
In this study, the amount of medical information needed by patients varied 
considerably and it reflected wide variations of their baseline knowledge. This 
reinforced a point that patients were not a homogeneous group and should be treated 
as individuals. Moreover, the results suggested that review of the case notes alone 
would fail to predict which patients would need additional help. Although some 
physicians hold the view that they could intuitively detect drug defaulters, the 
evidence indicated otherwise. Literature made it clear that there was no stereotypical 
’drug defaulter' and that there was no easy predictor to identify at risk patient and 
hence no simple or single solution to solve the problem. In addition, compliance 
varied greatly even in individuals and might change over time, necessitating the 
regular use of detection methods to measure compliance level as part of the 
assessment of treatment efficacy. 
There were many strategies and devices designed to enhance medication 
compliance, but the ultimate success of any intervention would likely depend on its 
effectiveness in targeting and addressing issues specific to the individual patient. 
Telling someone to take a three-times-a-day medication with breakfast, lunch and 
dinner was inappropriate for the patient who ate only two meals a day. Instructing a 
patient to take prednisolone at 8:00 am was inappropriate if the person worked a 
night shift and slept during the day. Tailoring the medication to fit the patient's 
lifestyle with minimal interruption (or minimal change in 'work') might be the best 
compliance aid of all. Simplifying instructions for patients by showing them all the 
medications that could be taken at the same time would often avoid overwhelming 
the patient with the number of medications they were to take. 
Persistently asking patients about their cue and how well it reminded them to 
/ 
take their medication not only helped patients developed personalized cueing 
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systems but also reminded them that health care professionals had a consistent 
interest in making sure they took their medication. This interaction showed patients 
that they were cared, thereby encouraging compliance. 
For low literacy patient, they might need color-coding or symbols such as the 
sun, the moon, or a clock face on their bottles to help reinforce proper compliance. 
Medication calendars for drug therapy such as prednisolone tapers or for unusual 
warfarin regimens could also be very helpful, allowing the patient to see the exact 
quantity to be taken on any given day. 
Good communication motivated patients to use their medications 
appropriately. Patients who like and trust their pharmacist trust the treatments they 
are prescribed. Pharmacists who are warm, friendly and approachable promote such 
trust. They provide information and encourage communication, allow their patients 
to develop a sense of control with the relationship and treatment plan. The 
pharmacist's willingness to spend time with a patient, listen to his or her concerns, 
and attempt to understand their perceptions and belief about the illness and its 
treatment are positive indicators which will promote patients' commitment to 
changing health beliefs and behavior. Besides, patients were more likely to give 
spontaneous account of their complaints, health beliefs and additional information 
which would enable practitioners to make better decisions about diagnosis, 
prescribing, administration, and drug therapy monitoring. 
Helping patients developed a question list prior to their visit, encouraged 
them to ask questions during the consultation, coached them on asking questions of 
and negotiated decisions with their physician were also of paramount importance. 
It was essential to provide the patient with realistic expectations while 
emphasizing the benefits of compliance. The pharmacist should encourage the 
patient to participate in setting goals with the physician as well as with the 
pharmacist. While discussing the purpose of the medication, the patient and the 
pharmacist should agree on a time frame during which they expected results to occur, 
as well as on what those results should be. Without this knowledge, patients might 
discontinue medications on their own, disappointed with the minimal results. This 
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information also gave the patient an idea when to approach the physician or 
pharmacist if there had been no results. For example, the pharmacist and a patient 
starting on atenolol might agree on a target blood pressure for the next visit, giving 
the patient a tangible goal. 
5.9 The role of physician in chronic care 
The traditional model of the partnership between doctor and patient assumed 'doctors 
know best' and that the patient ’followed doctors' orders'. Such a 'compliance' model, 
which relied on an imbalance of power，could lead to conflict and the patient failing 
to tell the truth or to comply with advice. A better model for the doctor-patient 
relationship was one based on concordance. This model was concerned with 
promoting a frank exchange of views between patient and doctor, with the full 
participation of the patient in the resultant therapeutic alliance. The task of the 
patient was to convey his or her health beliefs to the doctor. The task of the doctor 
was to enable this to happen, to convey his or her professionally informed health 
beliefs to the patient, and to help the patient make informed choices about the 
diagnosis and treatment. The concordance model allowed the patient and doctor to 
agree to differ. Failure in the context of concordance was the failure of patient and 
doctor to reach an agreed course of action. In short, compliance signified the 
theoretical intention of prescription; concordance signified the practical and ethical 
goal of treatment. 
Medicine relied on partnerships, and the one between patient and doctor was 
particularly important. A successful partnership required mutual trust and 
understanding, and much of the responsibility for forging this relationship rest with 
the doctor. Not only must doctors know what they were treating and why, they also 
needed to understand the benefits and risks of any approach they advocated. 
Wherever possible, all this should be shared with the patient before making a joint 
decision on treatment strategy. In sharing, both partners must face the reality that 
despite the most advanced therapy, treatments might fail. 
Physicians must share the responsibility in improving patient compliance. 
They should maintain a high index of suspicion that every patient was a possible 
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non-complier and that the explanation for therapeutic failure could be non-
compliance. Physicians who worried that a patient-centered communication would 
greatly prolong the consultation time should leam to understand that it was less 
expensive to promote compliance than to hospitalize people due to non-compliance. 
Post-prescribing follow up of patients should be undertaken to individualize therapy 
to meet therapeutic targets and to improve compliance. Patients must be empowered 
and given guidance and assistance to comply with medication regimens. While the 
patient was ultimately responsible for the final compliance decision, they should be 
encouraged to discuss with health care professionals e.g. physicians and pharmacists 
regarding their wishes, problems or concerns so as to reach 'concordance'. 
5.10 Possible sources of bias and limitations 
In this study, I had the problem usually encountered in compliance studies, which 
resulted in an incomplete picture of compliance; because interviews were only 
conducted on patients who came back for follow up. The patients with the poorest 
compliance did not even attend clinics and they would not be included in this study. I 
therefore studied a self-selected population and might not be fully representative of 
the study population. 
Patients' anxiety about the hospital setting might affect their ability to recall 
their drug-taking behavior accurately or they might not wish to reveal the whole truth 
for fear of embarrassment. Moreover, some patients might see the drugs dispensed as 
their personal belongings and were unwilling to return unused medications. 
5.11 Further studies 
The goal of therapy is to help patients maintain or improve their health, not to 
arbitrarily enforce their compliance to schedules of medication usage. Over-
emphasizing perfect compliance to prescribed regimens would give a false 
implication that rigorous medication taking improves outcome and those in which the 
prescription rather than the patient's behavior should be changed. Therefore, 
interventions should be designed not only to improve compliance but also to address 
/ 
the broader spectrum of patient outcomes that were so valued by health services 
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researchers. These included patient satisfaction, patient empowerment, 
comprehension and understanding, as well as markers of clinical significance 
including quality of life, functional status, and enhancement of emotional health and 
well-being. The phenomenon of 'white-coat compliance' suggested in the literature 
that most patients could and did, at least briefly, improve their compliance prior to 
scheduled medical examinations. This finding demonstrated a sense of accountability 
for good compliance might be a strong stimulus to improvement. Psychosocial and 
emotional determinants were important parameters but that they needed to be 
scientifically evaluated and incorporated in patient management tool. Here, I must 
admit that I am not a psycho-social worker and have not involved these domains 
which need more objective tools or measures for proper assessment on future studies. 
Patient compliance was a major health issue, with outcomes related to levels 
of morbidity, mortality and drug wastage. Apart from these direct health care costs, 
there were also the indirect costs that included loss of productivity, a quality of life 
and psychosocial burden of both patients and his family and carer. Given the 
magnitude of non-compliance rates as high as 50%, the potential for cost savings 
through improvement of compliance could be substantial. My data show that 
sustained compliant behaviors were associated with lower emergency room visits, 
less frequent hospitalization and shorter hospital stays compared to those who were 
non-compliant. Although formal health economics analysis was not performed, it 
was obvious that improved drug compliance could potentially reduce the total 
treatment costs and lost workdays. Moreover, the greater decrease in blood pressure 
in compliant patients might also enable doctors to reduce the complexity of a 
regimen and thus saved drug costs. 
More importantly, interventions to improve compliance must be subjected to 
cost-benefit analysis including opportunity costs where resource spent on these 
subjects may lead to reduced service provision to other patient groups. Logic 
suggests that the most efficient approach to tackle compliance problem is to predict 
accurately those 'modifiable' patients at highest risk and then to use the most specific 
and effective means to improve their behavior. Such a strategy may be efficient than 
to focus our compliance-enhancing efforts on the minority of patients who are most 
/ 
at risk but are unlikely to change their behavior. Future research can no longer afford 
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to ignore the costs of providing such programs but this should be measured against 
the potential cost savings of early identification of older people at risk of medication 
related problems. 
This study confirms that pharmacist's telephone intervention is associated 
with a 40% reduction in risk of early mortality and further studies can experiment 
with new ways of achieving more effective strategies. ‘ 
Further study like this should be done using electronic monitoring devices 
which was proven to be a more reliable measurement tool. The relative hazard to all 
cause mortality may actually be higher than that reported in this study as I tended to 
under-estimate the non-compliance prevalence. 
Although clinic attendance does not guarantee patient compliance with 
medications, non-attendees were frequently poor compliers. 102,122 my study, the 
defaulters had a significantly lower compliance score. This was associated with a 
markedly more frequent ER visits and hospitalization and also a longer length of 
hospital stay. In addition, these patients were more likely to die prematurely. 
Interestingly, patients taking anti-platelets or anti-coagulants, beta-blockers, calcium 
channel blockers and lipid-lowering drugs were more likely to keep appointments. 
The reasons for the defaults in these patients had to be explored but given the high 
morbidity and mortality rates and usage of health care resources, the defaulters are 
clearly a target population for intervention. 
Failure rates to keep medical appointments between 19% and 28% were not 
uncommon. 104,105 Patients defaulted follow-up were unlikely to be receiving any 
medication. As for patients who were cared for, the average compliance was about 
50%, keeping patients in care or under surveillance might be one of the most 
important compliant interventions. Alternatively, to reduce further deterioration in 
clinical condition and hence decreased use of health care resources, it would be 
important to recall patients who missed appointments, making every effort to keep 
them either in care or surveillance. 
/ 
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Finally, it is also of utmost importance to implement a strategy for raising 
public awareness of medication compliance and its related morbidity and mortality. 
5.12 Concluding remarks 
This study reports the evaluation of a pharmacist-led medication education program 
for polypharmacy patients in Hong Kong. The main outcome factor of interest was 
severe non-compliance with essential medications. This meant taking 80% or less or 
conversely 120% or more of those medications prescribed for the control of the 
patient's chronic medical condition. This study establishes that telephone counseling 
by pharmacist, apart from improving patient compliance, reduces risk of early 
mortality by 40%. 
During these 2 years through my close encounter with these patients having 
multiple co-morbidities, I could fully appreciate that patients needed help and 
understanding. Patients were generally found to welcome this informative and tailor-
made educational session. An important and effective strategy was to praise patients 
who follow their treatment plans, and to be supportive of patients who have difficulty 
meeting their goals. 
Besides knowledge-based improvement, psychological and emotional support 
should be considered of paramount importance. Empathic listening skill of the care 
providers encouraged patients to explore their feelings, vent emotions, and feel 
understood without being judged. A relationship characterized by empathy, 
understanding, support and respect was the foundation for positive changes. 
Pharmacists could help patients cope with their diseases by increasing their feelings 
of competence when they learned how to manage their disorders. Building on the 
foundation of a therapeutic alliance, pharmacists could enhance patient performance 
and compliance. The bonds of shared humanity - of trust, mutual respect, and 
concern - were the rewards of interaction between care provider and care recipient. It 
should be noted that treatment of the patient with disease(s) was far more 
instrumental and complex than treatment of disease(s) in the patient though this 
/ 
profound distinction was often unappreciated by caregivers. These philosophical 
160 
principles played probably key roles in our attempt to improve chronic care. 
Enhancing compliance is more art than science, and more trial and error than smooth 
precision. Success may be frustratingly difficult to achieve, but enhanced and 
suitable patient compliance should be the ultimate goal of the prescribing and 
dispensing process. 
A patient owned his body and destiny and, provided that he was properly 
informed, was the best judge of his own interests. He also remained the final master 
of the treatment decision and implementation. Compliance was a long and difficult 
path leading from efficacy to effectiveness; and as health care providers, we got the 




1. Chan JCN, Chan KT, Chan WK, et al. A drug utilisation survey of the use of lipid 
lowering drugs at the Hong Kong Hospital Authority hospitals. 1998 Hospital 
Authority Convention 1998, Hong Kong. 
2. Becker MH, Maiman LA. Strategies for enhancing patient compliance. Journal of 
Community Health 1980;6:113-35. 
3. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is 
medication taken as prescribed? A novel assessment technique. Journal of 
American Medical Association 1989;261:3273-7. 
4. Cameron C. Patient compliance: recognition of factors involved and suggestions 
for promoting compliance with therapeutic regimens. Journal of Advanced 
Nursing 1996;24:244-50. 
5. Bond WS, Hussar DA. Detection methods and strategies for improving medication 
compliance. American Journal of Hospital Pharmacy 1991 ;48:1978-87. 
6. Urquhart J. Ascertaining how much compliance is enough with outpatient 
antibiotic regimens. Postgraduate Medical Journal 1992;68:S49-59. 
7. Wright EC. Non-compliance--or how many aunts has Matilda? Lancet 
1993;342:909-13. 
8. The HOPE Study Investigators. The HOPE (Heart Outcome Prevention 
Evaluation) Study: the design of a large, simple randomized trial of an 
angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients 
at high risk of cardiovascular events. Canandian Journal of Cardiology 
1996;12:127-37. 
9. Scandinavian Simvastatin Survival Study Group. Reducing the Risk of Coronary 
Events: Evidence from the Scandinavian Simvastatin Survival Study (4S) 
Baseline serum cholesterol and treatment effect in the Scandinavian 
Simvastatin Survival Study (4S). American Journal of Cardiology 
1995;76:64C-68C. 
10. The Scandinavian Simvastatin Survival Study Group. Randomised trial of 
cholesterol lowering in 4444 patients with coronary heart disease: The 
Scandinavian Simvastatin Survival Study Group. Lancet 1994;344:1383-9. 
/ 
162 
11. The SOLVD Investigator. Effect of enalapril on mortality and the development 
of heart failure in asymptomatic patients with reduced left ventricular ejection 
fractions. New England Journal of Medicine 1992;327:685-91. 
12. The SOLVD Investigators. Effect of enalapril on survival in patients with 
reduced left ventricular ejection fractions and congestive heart failure. New 
England Journal of Medicine 1991;325:293-302. 
13. Hansson L，Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure 
lowering and low-dose aspirin in patients with hypertension: principal results 
of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study 
Group. Lancet 1998;351:1755-1762. 
14. Katon W. Improvement of outcomes in chronic illness. Archives of Internal 
Medicine 2000;9:709-11. 
15. Miller NH, Hill M, Kottke T，Ockene IS. The multilevel compliance challenge: 
recommendations for a call to action. A statement for healthcare 
professionals. Circulation 1997;95:1085-90. 
16. The Coronary Drug Project Group. Influence of adherence to treatment and 
response of cholesterol on mortality in the coronary drug project. New 
England Journal of Medicine 1980;303:1038-41. 
17. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of 
propranolol in patients with acute myocardial infarction, I: mortality results. 
Journal of American Medical Association 1982;247:1707-14. 
18. Horwitz R, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ. 
Treatment adherence and risk of death after a myocardial infarction. Lancet 
1990;336:542-5. 
19. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Archives 
of Internal Medicine 1993;153:1863-8. 
20. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence 
to the risk of death after myocardial infarction in women. Journal of 
American Medical Association 1993;270:742-4. 
21. Epstein LH. The direct effects of compliance on health outcome. Health 
Psychology 1984;3:385-93. 
22. Epstein LH, Cluss PA. A behavioral medicine perspective on adherence to long-
term medical regimens. Journal of Consultation on Clinical Psychology 
1982;50:950-7i. 
163 
23. Haynes RB, Taylor DW, Sackett DL. Compliance in Health Care. Baltimore: 
Johns Hopkins University Press, 1979. 
24. Vander SR. Measurement of patient compliance and the interpretation of 
randomized clinical trials. European Journal of Clinical Pharmacology 
1991;41:27-35. 
25. Langer N. Culturally competent professionals in therapeutic alliances enhance 
patient compliance. Journal of Health Care for the Poor & Underserved 
1999;10:19-26. 
26. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of 
recent research. Clinical Pharmacokinetics 1994;27:202-15. 
27. Eisen SA, Miller DK, Woodward RS. The effect of prescribed daily dose 
frequency on patient medication compliance. Archives of Internal Medicine 
1990;150:1881-4. 
28. Levy M, Mermelstein L, Hemo D. Medical admissions due to noncompliance 
with drug therapy. International Journal of Clinical Pharmacology and 
Therapeutics and Toxicology 1982;20:600-4. 
29. Hentinen M, Kyngas H. Compliance of young diabetics with health regimens. 
Journal of Advanced Nursing 1992;17:530-6. 
30. Madden B. The hybrid model for concept development: its value for the study of 
therapeutic alliance. Advances in Nusing Science 1990;12:75-87. 
31. Lerner BH. From careless consumptives to recalcitrant patients: the historical 
construction of noncompliance. Social Science and Medicine 1997;45:1423-
31. 
32. Simons MR. Interventions related to compliance. Nursing Clinics of North 
America 1992;27:477-94. 
33. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision 
making? Social Science and Medicine 1992;34:507-13. 
34. Kolton KA, Piccolo P. Patient compliance: a challenge in practice. Nurse 
Practitioner 1988;12:37-50. 
35. Barofsky I. Compliance adherence and the therapeutic alliance: Steps in the 
development of self care. Social Science and Medicine 1978;12:369-76. 
36. Stimson G. Obeying doctors orders - a view from the other side. Social Science 
and Medicine 1974;8:97-105. 
/ 
164 
37. Lutfey KE, Wishner WJ. Beyond "compliance" is "adherence". Improving the 
prospect of diabetes care. Diabetes Care 1999;22:635-9. 
38. Fawcett J. Compliance: definitions and key issues. Journal of Clinical Psychiatry 
1995;56:S4-10. 
39. Boyer BA, Lerman C, Shipley TE, McBrearty J, Quint A, Goren E. Discordance 
between physician and patient perceptions in the treatment of diabetes 
mellitus: a pilot study of the relationship to adherence and glycemic control. 
Diabetes Educator 1996;22:493-9. 
40. McNabb WL. Adherence in diabetes: can we define it and can we measure it? 
Diabetes Care 1997;20:215-8. 
41. Moore KN. Compliance or collaboration? The meaning for the patient. Nursing 
Ethics 1995;2:71-7. 
42. Marinker M. From compliance to concordance: achieving shared goals in 
medicine taking: London: Royal Pharmaceutical Society; Merck, Sharp and 
Dohme, 1997. 
43. Chen J. "Medication concordance" is best helped by improving consultation 
skills. British Medical Journal 1999;318:670-1. 
44. Milburn HJ, Cochrane GM. Compliance and concordance with treatment. British 
Medical Journal 1997;314:1905-6. 
45. Cochrane GM. Compliance and outcomes in patients with asthma. Drugs 
1996;52:S12-9. 
46. Dirks JF, Kinsman RA. Nondichotomous patterns of medication usage: the yes-
no fallacy. Clinical Pharmacology and Therapeutics 1982;31:413-7. 
47. Corden ZM, Bosley CM, Rees PJ, Cochrane GM. Home nebulized therapy for 
patients with COPD: patient compliance with treatment and its relation to 
quality of life. Chest 1997;112:1278-82. 
48. Luscher TF, Vetter H, Siegenthaler W, Vetter W. Compliance in hypertension: 
facts and concepts. Journal of Hypertension 1985;3:S3-10. 
49. Dracup KA, Meleis AL Compliance: an interactionist approach. Nursing 
Research 1982;31:31-5. 
50. Markowitz M. Eradication of rheumatic fever: an unfulfilled hope. Circulation 
1970;41:1077-84. 
51. Cochrane GM. Therapeutic compliance in asthma: its magnitude and 
/ 
implications. European Respiratory Journal 1992;5:122-4. 
165 
52. Hamilton RA, Briceland LL. Use of prescription refill records to assess patient 
compliance. American Journal of Hospital Pharmacy 1992;49:1691-6. 
53. Mullen PD, Green LW, Persinger G. Clinical trials of patient education for 
chronic conditions: A comparative meta-analysis of intervention types. 
Preventive Medicine 1985;14:753-81. 
54. Edwards M, Pathy MSJ. Drug counseling in the elderly and predicting 
compliance. Practitioner 1984;228:291. 
55. Eraker SA, Kirscht JP，Becker MH. Understanding and improving patient 
compliance. Annals of Internal Medicine. 1984;100:258-68. 
56. Sweeney SJ, Dixon JS，Sutcliffe I. The impact of the clinical pharmacist on 
compliance in a geriatric population. Pharmaceutical Journal 1989;18:R4-6. 
57. Rudd P, Byyny RL, Zachary V, et al. The natural history of medication 
compliance in a drug trial: limitations of pill counts. Clinical Pharmacology 
and Therapeutics 1989;46:169-76. 
58. Ling M, Ho J, Lee A, et al. An inter-disciplinary approach to improve prescribing 
and compliance of patients treated with multiple medications - a preliminary 
analysis of a pilot study for continuous quality improvement. Hospital 
Authority 1998 Convention 1998，Hong Kong. 
59. Hawe P, Higgins G. Can medication education improve the drug compliance of 
the elderly? Evaluation of an inhospital program. Patient Education & 
Counseling \99Q)\U:\5\. 
60. Rudd P. Compliance with antihypertensive therapy: A shifting paradigm. 
Cardiology Review 1994;2:230-40. 
61. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary 
Prevention Trial Results. II. The relationship of reduction in incidence of 
coronary heart disease to cholesterol lowering. Journal of American Medical 
Association 1984;251:365-74. 
62. Morris LS, Schulz RM. Patient compliance: an overview. Journal of Clinical 
Pharmacy and Therapeutics 1992;17:183-195. 
63. Urquhart J. Pharmacoeconomic consequences of variable patient compliance 
with prescribed drug regimens. Pharmacoeconomics 1999;15:4. 
64. Le HX, Castle SC, Percy LA. Development and implementation of a geriatric 
polypharmacy clinic. ASHP-Midyear-Clinical-Meeting 1996;31:P-490D. 
/ 
166 
65. Berg JS，Dischler J，Wagner DJ，Raia JJ, Palmer-Shevlin N. Medication 
compliance: a healthcare problem. Annals of Pharmacotherapy 1993;27:S1-
24. 
66. Sullivan SD, Kreling DH, Hazlet TK. Non-compliance with medication regimens 
and subsequent hospitalizations: a literature analysis of hospitalization 
estimates. Journal of Research on Pharmacoeconomics 1990;2:19-33. 
67. Grymonpre RE, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR. Drug-
associated hospital admissions in older medical patients. Journal of American 
Geriatric Society 1988;36:1092-8. 
68. Stradberg LR. Drugs as a reason for nursing home admissions. Americal Health 
Care Association Journal 1984;10:20-3. 
69. Cowen M，Jim LK, Boyd EL, et al. Some possible effects of patient 
noncompliance. Journal of American Medical Association 1981 ；245:1121. 
70. Maronde RF, Chan LS，Larsen FJ, Strandberg LR, Laventurier MF, Sullivan SR. 
Underutilization of antihypertensive drugs and associated hospitalization. 
Medical Care 1989;27:1159-66. 
71. Rozenfeld V, Pflomm JM, Singh KK, Bazil MK, Cheng JWM. Assessing the 
impact of medication consultations with a medication event monitoring 
system. Hospital Pharmacy 1999;34:539-549,559. 
72. Burgess MM. Ethical and economic aspects of noncompliance and overtreatment. 
Canadian Medical Association Journal 1989;141:777-780. 
73. Becker MH. Patient adherence to prescribed therapies. Medical Care 
1985;23:539-55. 
74. Rand CS’ Wise RA, Murphy S. Measuring adherence to asthma medication 
regimens. American Journal of Respiratory and Critical Care Medicine 
1994;149:S69-S78. 
75. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and 
adverse drug reactions in hospitalization of the elderly. Archives of Internal 
Medicine 1990;150:841-5. 
76. Todd WE. New mindsets in asthma: interventions and disease management. J 
Care Manage 1995;1:2-8. 
77. Psaty BM, Koepsell TD，Wagner EH. The relative risk of incident coronary heart 
disease associated with recently stopping the use of beta-blockers. Journal of 
American Medical Association 1990;263:1653-7. 
167 
78. Rudd P. Clinicians and patients with hypertension: unsettled issues about 
compliance. American Heart Journal 1995;130:572-9. 
79. Urquhart J. Patient Compliance in Medical Practice and Clinical Trials. New 
York: Raven Press, 1991. 
80. Didlake RH, Dreyfus K, Kermman RH. Patient noncompliance: a major cause of 
late graft failure in cyclosporine-treated renal transplants. Transplantation 
Proceedings 1988;20:63-9. 
81. Priddy JT, Kass MA, Gordon MO. Factors related to compliance with topical 
pilocarpine treatment. Investigation on Ophthalmology & Visual Science 
1987;28:37. 
82. Rovelli M，Palmeri D，Vossler E, Bartus S, Hull D, Scweizer R. Non-compliance 
in renal transplant recipients. Transplantation proceedings 1989;21:833-4. 
83. Rovelli M, Palmeri D, Vossler E, Bartus S, Hull D，Scweizer R. Non-compliance 
in renal transplant recipients: evaluation by socioeconomic groups. 
Transplantation Proceedings 1989;21:3979-81. 
84. Royal Pharmaceutical Society of Great Britain. Partnership in medicine taking: a 
consultative document. Royal Society of Great Britain, London 1996. 
85. Wright JM，Htun Y, Leong MG, Forman P, Ballard RC. Evaluation of the use of 
calendar blister packaging on patient compliance with STD syndromic 
treatment regimen. Sexually Transmitted Diseases 1999;26:556-63. 
86. Williams AB. Adherence to HIV regimens: 10 vital lessons. American Journal of 
A^wr^mg 2001;101:37-43. 
87. Insull W. The problem of compliance to cholesterol altering therapy. Journal of 
Internal Medicine 1997;241:317-25. 
88. Horn CR，Clark TJH，Cochrane GM. Compliance with inhaled therapy and 
morbidity from asthma. Respiratory Medicine 1990;84:67-70. 
89. Miller NH. Compliance with treatment regimens in chronic asymptomatic 
diseases. America! Journal of Medicine 1997;102:43-9. 
90. Salzman C. Medication compliance in the elderly. Journal of Clinical Psychiatry 
1995;56:S18-23. 
91. Hussey LC, Gilliland K. Compliance, low literacy and locus of control. Nursing 
Clinics of North America 1989;24:605-11. 
92. Paes AH, Bakker A，Soe-Agnie CJ. Impact of dosage frequency on patient 
/ 
compliance. Diabetes Care 1997;20:1512-7. 
168 
93. Monane M，Monane S, Semla T. Optimal medication use in elders. Key to 
successful aging. Western Journal of Medicine 1997;167:233-7. 
94. Urquhart J, De Klerk E. Contending paradigms for the interpretation of data on 
patient compliance with therapeutic drug regimens. Statistics in Medicine 
1998;17:251-67, 387-9. 
95. McDermott MM, Schmitt B，Wallner E. Impact of medication non-adherence on 
coronary heart disease outcomes: A critical review. Archives of Internal 
Medicine 1997;157:1921-1929. 
96. Cramer JA，Scheyer R, Mattson R. Compliance declines between clinic visits. 
Archives of Internal Medicine 1990;150:1509-10. 
97. Feinstein AR. On white coat effects and the electronic monitoring of compliance. 
Archives of Internal Medicine 1990;150:1377-8. 
98. Aronson JK, Hardman M. Patient compliance. British Medical Journal 
1992;305:1009-1011. 
99. Raynor DK. Patient compliance: the pharmacist's role. International Journal of 
Pharmacy Practice 1992;1:126-35. 
100. Griffith S. A review of the factors associated with patient compliance and the 
taking of prescribed medicines. British Journal of General Practice 
1990;40:114-6. 
101. Muscari ME. Rebels with a cause. American Journal of Nursing 1998;98:26-30. 
102. Richardson JL, Shetton DR, Krailo M. The effect of compliance with treatment 
on survival among patients with hematologic malignancies. Journal of 
Clinical Oncology 1990;8:356-64. 
103. Beardon PHG, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald 
TM. Primary non-compliance with prescribed medication in primary care. 
British Medical Journal 1993;307:846-848. 
104. Oppenheim GL, Bergman JJ, English EC. Failed appointments: a review. 
Journal of Family Practice 1979;8:789-96. 
105. Smith CM, Yawn BP. Factors associated with appointment keeping in a family 
practice residency clinic. Journal of Family Practice 1994;38:25-9. 
106. Sackett D, Snow J. The magnitude of compliance and noncompliance. 
Baltimore: John Hopkins University Press, 1979. 
107. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid lowering 
medications. Journal of American Medical Association 1998;279:1458-62. 
169 
108. Rogers PG, Bullman WR. Prescription medicine compliance: A review of the 
baseline of knowledge. A report of the National Council on Patient 
Information and Education. Journal of Pharmacoepidemiology 1995;2:3. 
109. Nagasawa M, Smith MC, Barnes JH, Fincham JE. Meta-analysis of correlates of 
diabetes patients' compliance with prescribed medications. Diabetes 
Education 1990;16:192-200. 
110. Clark LT. Improving compliance and increasing control of hypertension: needs 
of special hypertensive populations. American Heart Journal 1991;121:664-
9. 
111. Greenberg RN. Overview of patient compliance with medication dosing: a 
literature review. Clinical Therapeutics 1984;6:592-9. 
112. Dekker FW, Dieleman FE, Kaptein AA, Mulder JD. Compliance with 
pulmonary medication in general practice. European Respiratory Journal 
1993;6:886-90. 
113. Chong CKL, Yuen YH, Chan JCN, Chang S, Lee SC, Critchley JAJH. A patient 
compliance survey in a general medical clinic. Journal of Clinical Pharmacy 
and Therapeutics 1997;22:323-6. 
114. Evans L, Spelman M. The problem of non-compliance with drug therapy. Drugs 
1983;25:63-76. 
115. Conrad P. The meaning of medication: another look at compliance. Social 
Science and Medicine 1985;20:29-37. 
116. Cramer JA. Practical issues in medication compliance. Transplantation 
Proceedings 1999;31:7S-9S. 
117. McElnay JC, McCallion CR, al-Deagi F, Scott M. Self-reported medication 
non-compliance in the elderly. European Journal of Clinical Pharmacology 
1997;53:171-8. 
118. Cooper JK, Love DW, Raffoul PR. Intentional prescription nonadherence 
(noncompliance) by the elderly. Journal of American Geriatric Society 
1982;30:329-33. 
119. Fedder DO. Managing medication and compliance: physician-pharmacist-
patient interaction. Journal of American Geriatric Society 1982;30:S113-7. 
120. Sclar DA. Improving medication compliance: a review of selected issues. 
Clinical Therapeutics 1991;13:436-40. 
/ 
170 
121. Pullar T, Feely M. Problems of compliance with drug treatment: new solutions? 
Pharmaceutical Journal 1990;245:213-5. 
122. Coons SJ, Sheahan SL, Martin SS, Hendricks J, Robbins CA, Johnson J A. 
Predictors of medication noncompliance in a sample of older adults. Clinical 
Therapeutics 1994;16:110-7. 
123. Hasford J. Compliance and the benefit/risk relationship of antihypertensive 
treatment. Journal of Cardiovascular Pharmacology 1992;20:S30-4. 
124. Rudd P. In search of the gold standard for compliance assessment (editorial). 
Archives of Internal Medicine 1979;139:627-8. 
125. Craig HM. Accuracy of indirect measures of medication compliance in 
hypertension. Research in Nursing Health 1985;8:61-6. 
126. Pearson RM. Who is taking their tablets. British Medical Journal 
1982;285:757-8. 
127. Stockwell ML, Shulz RM. Patient compliance - an overview. Journal of 
Clinical Pharmacy and Therapeutics 1992;17:283-95. 
128. Oseasohn C, Graveley EA, Hudepohl NC. Issues in medication compliance 
research. The Canadian Journal of Nursing Research 1989;21:35-43. 
129. Dunbar J. Adherence measures and their utility. Controlled Clinical Trials 
1984;5:515-21. 
130. Cramer JA, Spiker B. Patient compliance in medical practice and clinical trials. 
New York: Raven Press, 1991. 
131. Spilker B. Methods of Assessing and Improving Patient Compliance in Clinical 
Trials. New York: Raven Press Ltd, 1991. 
132. Rogers WK, Wilson KM, Becker CE. Methods for detecting disulfiram in 
biologic fluids: application in studies of compliance and effect of divalent 
cations on bioavailability. Alcoholism, Clinical and Experimental Research 
1978;2:375-80. 
133. Thompson WL. Adherence measures and their utility. Proceedings of the 
workshop on the development of markers or use as adherence measures in 
clinical studies. Controlled Clinical Trials 1984;5:S522-5. 
134. Nakahara Y. Hair analysis for abused and therapeutic drugs. National Institute 
of Health Sciences 2000;1:1. 
135. Wolen RL, Crabtree RE, Caimichael RH. Tracer microspheres as compliance 
markers in clinical research. Proceedings of the workshop on the 
171 
development of markers or use as adherence measures in clinical studies. 
Controlled Clinical Trials 1984;5:S540-3. 
136. Fales HM. Alternative adherence markers scheme. Proceedings of the workshop 
on the development of markers or use as adherence measures in clinical 
studies. Controlled Clinical Trial 1984;5:S476-8. 
137. Caron HS, Roth HP. Patient's cooperation with a medical regimen: difficulties 
in identifying the non-cooperator. Journal of American Medical Association 
1968;203:120-4. 
138. Rodewald LE, Maiman LA, Faye HR, Borch RF, Forbes GB. Deuterium oxide 
as a tracer for measurement of compliance in pediatric clinical drug trials. 
Journal of Paediatrics 1989;114:885-91. 
139. Dubbert PM. Riboflavine as a tracer of medication compliance. Journal of 
Behavioral Medicine 1985;8:287-99. 
140. Young LM, Haakenson CM, Lee KK. Riboflavine use as a drug marker in 
Veterans Administration Cooperative Studies, Proceedings of the workshop 
on the development of markers of use as adherence measures in clinical 
studies. Controlled Clinical Trials 1984;5:S497-504. 
141. Maenpaa H, Javala K, Pirkrarainen J, Malleonen M, Heinonen OP, Manninen 
V. Minimal dose of digoxin: a new marker for compliance to medication. 
European Heart Journal 1987;8:S31-7. 
142. Feely M, Cooke J, Price D, et al. Low dose phenobarbitone as an indicator of 
compliance with drug therapy. British Journal of Clinical Pharmacology 
1987;24:77-83. 
143. Porter AMW. Drug defaulting in general practice. British Medical Journal 
1969;1:218-22. 
144. Pullar T, Birtwell AJ, Wiles PG, Hay A, Seely MP. Use of pharmacologic 
indicator to compare compliance with tablets prescribed to be taken once, 
twice, or three times daily. Clinical Pharmacology and Therapy 
1988;44:540-5. 
145. Pullar T, Kumar S，Tindall H, Feely M. Time to stop counting tablets? Clinical 
Pharmacology and Therapeutics 1989;46:163-8. 
146. Maenpaa H, Manninen V, Heinonen OP. Compliance with medication in the 
Helsinki Heart Study. European Journal of Clinical Pharmacology 
1992;42 :15-9. ' 
172 
147. Finney JW, Friman PC, Rapof fMA, Christophersen ER. Improving compliance 
with antibiotic regimens for otitis media. Randomized clinical trial in a 
pediatric clinic. American Journal of Diseases of Children 1985;139:89-95. 
148. Wing RR, Epstein LH, Nowalk MP, Scott N，Koeske R. Compliance to self-
monitoring of blood glucose: a marked-item technique compared with self-
report. Diabetes Care 1985;8:456-60. 
149. Inui TS, Carter WB, Pecoraro RE. Screening for noncompliance among patients 
with hypertension: is self-report the best available measure? Medical Care 
1981;19:1061-4. 
150. Park LC, Lipman RS. A comparison of patient dosage deviation reports with 
pill counts. Psychopharmacologia 1964;6:299-302. 
151. Oxman AD, Guyatt GH. Guidelines for reading literature reviews. Canadian 
Medical Association Journal 1988;138:697-703. 
152. Weintraub M, Au WYW, Lasagna L. Compliance as a determinant of serum 
digoxin concentration. Journal of American Medical Association 
1973;224:481-5. 
153. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bemholz MJ. Can simple 
clinical measurements detect patient compliance? Hypertension 1980;2:757-
64. 
154. Haynes RE, McKibbon KA, Kanani R. Systematic review of randomised trials 
of interventions to assist patients to follow prescriptions for medications. 
Lancet 1996;348:383-6. 
155. Black DM, Brand RJ, Greenlick M, et al. Compliance to treatment for 
hypertension in elderly patients: the SHEP pilot study. Journal of 
Gerontololgy 1987;42:552-7. 
156. Norell SE. Accuracy of patient interviews and estimates by clinical staff in 
determining medication compliance. Social Science and Medicine 
1981;15E:57-61. 
157. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a 
comparison of patient self-report, pill counts, and microelectronic monitoring. 
Journal of Clinical Oncology 1993;11:1189-97. 
158. Fletcher SW, Pappius EM, Harper SJ. Measurement of medication compliance 
in a clinical setting: comparison of three methods in patients prescribed 
digoxin. Archives of Internal Medicine 1979;139:635-8. 
173 
159. Wagner GJ, Rabkin JG. Measuring medication adherence: are missed dose 
reported more accurately than perfect compliance? AID Care 2000;12:405-8. 
160. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient 
taking the treatment as prescribed? Journal of American Medical Association 
1993;269:2779-81. 
161. DiMatteo MR, Sherbourne CD, Hays RD, et al. Physicians' characteristics 
influence patients' adherence to medical treatment: results from the Medical 
Outcomes Study. Health Psychology 1993;12:93-102. 
162. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a 
self-reported measure of medication adherence. Medical Care 1986;24:67-74. 
163. Guerrero D, Rudd P, Bryant-Kosling C, Middleton B, Middleton BF. 
Antihypertensive medication-taking. Investigation of a simple regimen. 
American Journal of Hypertension 1993;6:586-92. 
164. Kruse W, Nicholaus T, Rampmaier J, Weber E, Schlierf G. Actual versus 
prescribed timing of lovastatin doses assessed by electronic compliance 
monitoring. European Journal of Clinical Pharmacology 1993;45:211-5. 
165. Myers ED, Calvert EJ. Information, compliance and side effects: A study of 
patients on antidepressant medication. British Journal of Clinical 
Pharmacology 1984;17:21-5. 
166. Chmelik F, Doughty A. Objective measurements of compliance in asthma 
treatment. Annals of Allergy 1994;73:527-32. 
167. Norman GR, McFarlane AH, Streiner DL, Neale K. Health diaries: strategies 
for compliance and relation to other measures. Medical Care 1982;20:623-9. 
168. Straka RJ, Fish JT, Benson SR, Suh JT. Patient self-reporting of compliance 
does not correspond with electronic monitoring: an evaluation using 
isosorbide dinitrate as a model drug. Pharmacotherapy 1997;17:126-32. 
169. van Berge Henegouwen MT, van Driel HF, Kasteleijn-Nolst Trenite DG. A 
patient diary as a tool to improve medicine compliance. Pharmacy World & 
Science 1999;21:21-4. 
170. Allen RM, Jones MP, Oldenburg B. Randomised trial of an asthma self-
management programme for adults. Thorax 1995;50:731-8. 
171. Tashkin DP, Rand C, Nides M，et al. A nebulizer chronolog to monitor 
compliance with inhaler use. American Journal of Medicine 1991;91:33S-
36S. ‘ 
174 
172. Cramer JA. Microelectronic systems for monitoring and enhancing patient 
compliance with medication regimens. Drugs 1995;49:321-7. 
173. Kruse W, Weber E. Dynamics of drug regimen compliance: its assessment by 
microprocessor-based monitoring. European Journal of Clinical 
Pharmacology 1990;38:561-5. 
174. Potter LS. Oral contraceptive compliance and its role in the effectiveness of the 
method. In: Cramer JA, Spilker B, eds. Compliance in medical practice and 
clinical trials. New York: Raven Press, 1991: 195-207. 
175. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 
5-isosorbide mononitrate: a comparative study. Journal of International 
Medical Research 1994;22:266-72. 
176. Urquhart J. Correlates of variable patient compliance in drug trials: relevance in 
the new health care environment. Advance in Drug Research 1995;26:237-
57. 
177. Matsuyama JR, Mason BJ, Jue SG. Pharmacists' interventions using an 
electronic medication-event monitoring device's adherence data versus pill 
counts. Annals of Pharmacotherapy 1993;27:851-5. 
178. Urquhart J. Variable patient compliance in ambulatory trials: nuisance, treat, 
opportunity. Journal of Antimicrobial Chemotherapy 1995;32:643-9. 
179. Rudd P, Ahmed S，Zachary V，Barton C, Bonduelle D. Improved compliance 
measures: applications in an ambulatory hypertensive drug trial. Clinical 
Pharmacology and Therapeutics 1990;48:676-85. 
180. Waeber B, Erne P, Saxenhofer H, Heynen G. Use of drugs with more than a 
twenty-four-hour duration of action. Journal of Hypertension 1994;12:S67-
71. 
181. Detry JM, Block P, De Backer G, Degaute JP, Six R. Patient compliance and 
therapeutic coverage: amlodipine versus nifedipine (slow-release) in the 
treatment of angina pectoris: Belgian Collaborative Group. Journal of 
International Medical Research 1994;22:278-86. 
182. Kruse W, Kruse WE, Rampmaier J, Runnebaum B，Weber E. Dosage frequency 
and drug compliance behaviour - a comparative study on compliance with a 
medication to be taken twice or four times daily. European Journal of 
Clinical Pharmacology 1991 ;41:589-92. 
175 
183. Kruse W, Rampmaier J, Ullrich G，Weber E. Patterns of drug compliance with 
medications to be taken once and twice daily assessed by continuous 
electronic monitoring in primary care. International Journal of Clinical 
Pharmacology & Therapeutics 1994;32:452-7. 
184. Rudd P, Ramesh J, Bryant-Kosling C, Guerrero D. Gaps in cardiovascular 
medication taking: the tip of the iceberg. Journal of General Internal 
Medicine 1993;8:659-66. 
185. Inui TS, Yourtee EL, Williamson JW. Improved outcomes in hypertension after 
physician tutorials. Annals of Internal Medicine 1976;84:646-51. 
186. Rittenhouse BE. A novel compliance assessment technique. The randomized 
response interview. International Journal of Technology Assessment in 
Health Care 1996;12:498-510. 
187. Paterson DL. Adherence to protease inhibitor therapy and outcomes in patients 
with HIV infection. Annals of Internal Medicine 2000;133:21-30. 
188. Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a 
regimen of digoxin therapy in family practice. Canadian Medical Association 
Jowr^a/ 1980;123:119-22. 
189. Roth HP, Caron HS. Accuracy of doctors' estimates and patients' statements on 
adherence to a drug regimen. Clinical Pharmacology and Therapeutics 
1978;23:361-70. 
190. Du Pasquier-Fediaevsky L, Tubiana-Rufi N. Discordance between physician 
and adolescent assessments of adherence to treatment: influence of H b A l c 
level. Diabetes Care 1999;22:1445-9. 
191. Mushlin Al, Appel FA. Diagnosing potential non-compliance: physician's 
ability in a behavioral dimension of medical care. Archives of Internal 
Medicine 1977;137:318-21. 
192. O'Hanrahan M, O'Malley K. Compliance with drug treatment. British Medical 
Jowrwa/1981;283:298-300. 
193. Cordis L, Markowitz M, Lilienfeld AM. The inaccuracy in using interviews to 
estimate patient reliability in taking medications at home. Medical Care 
1969;7:49-54. 
194. England ML, Hershman JM. Serum TSH concentration as an aid to monitoring 
compliance with thyroid hormone in hypothyroidism. American Journal of 
Medicine 1986;292:264-6. 
176 
195. Kelly J. Making sense of drug compliance by patients. Nursing Times 
1995;91:40-1. 
196. Enlund H, Tuomilehto J，Turakka H. Patient report validated against 
prescription record for measuring use of and compliance with 
antihypertensive drugs. Acta Medical Scandinavia 1981;209:271-5. 
197. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy 
records: methods, validity, and applications. Journal of Clinical 
Epidemiology 1997;50:105-16. 
198. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance 
assessment using centralized pharmacy records. Medical Care 1988;26:814-
23. 
199. Sclar DA, Skaer TL, Robinson LM. Antihypertensive pharmacotherapy: 
Economic outcomes in a health maintenance organization. Current 
Therapeutics Research 1994;55:1056-66. 
200. Morisky DE, Malotte CK, Choi P, Davidson P, Rigler S, Sugland B. A patient 
education program to improve adherence rates with antituberculosis drug 
regimens. Health Education Quarterly 1990;17:253-67. 
201. Pilote L, Tulsky JP, Zolopa AR, Hahn JA, Schecter GF, Moss AR. Tuberculosis 
prophylaxis in the homeless. A trial to improve adherence to referral. 
Archives of Internal Medicine 1996;156:161-5. 
202. Macharia WM, Leon G, Rowe BH，Stephenson BJ, Haynes RB. An overview of 
interventions to improve compliance with appointment keeping for medical 
services. Journal of American Medical Association 1992;267:1813-7. 
203. Weis SE, Slocum PC, Blais FC, King B，Nunn M, Matney GB. The effect of 
directly observed therapy on the rates of drug resistance and relapse of 
tuberculosis. New England Journal of Medicine 1994;330:1179-84. 
204. Wilkinson D. High compliance tuberculosis treatment programme in a rural 
community. Lancet 1994;343:647-8. 
205. China Tuberculosis Control Collaboration. Results of directly observed short-
course chemotherapy in 112842 Chinese patients with smear-positive 
tuberculosis. Lancet 1996;347:358-62. 




207. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of 
tuberculosis: we can't afford not to try it. New England Journal of Medicine 
1993;328:576-8. 
208. Conway B, Prasad J, Reynolds R, al. e. Nevirapine (NVP) and protease inhibitor 
(Pl)-based regimens in a directly observed therapy (DOT) program for 
intravenous drug users (IDUs). 9th Conference on Retroviruses and 
Opportunistic Infections 2002, Seattle, Washington.: Abstract 545. 
209. Blackwell B. Drug therapy: patient compliance. New England Journal of 
Medicine 1973;289:249-52. 
210. Hanchak NA, Patel MB, Berlin JA, Strom BL. Patient misunderstanding of 
dosing instructions. Journal of General Internal Medicine 1996;11:325-8. 
211. Ostrom JR, Hammarlund ER, Christensen DB, Plein JB, Kethley AJ. 
Medication usage in an elderly population. Medical Care 1985;23:157-64. 
212. Zuccollo G, Liddell H. The elderly and the medication label: doing it better. Age 
^gemg 1985;14:371-6. 
213. Fletcher SW, Fletcher RH, Thomas DC. Patients' understanding of prescribed 
drugs. Journal of Community Health 1979;4:183-9. 
214. Hill MJ. Patient Compliance: An Issue for Nursing. Dermatology Nursing 
1999;11:328,348. 
215. Caldwell JR, Cobb S, Dowling MD, De Jongh D. The dropout problem in 
antihypertensive treatment. Journal of Chronic Disease 1970;22:579-92. 
216. Al-Nakhi A，Kadiri A, Elghazali S, et al. Treatment of type 1 diabetes with 
insulin lispro during Ramadan. 2000，Henry B. Gonzalez Convention Centre, 
Marriott Riverwalk and Marriott Rivercenter; San Antonio, Texas: A352-3. 
217. Roky R, Chapotot F, Hakkou F, Benchekroun MT, Buquet A. Sleep during 
Ramadan intermittent fasting. Journal of Sleep Research 2001;10 :319-27. 
218. Astrow AB，Puehalski CM, Sulmasy DP. Religion, spirituality and health care: 
social, ethical and practical considerations. The Americal Journal of Medicine 
2001;110:283-7. 
219. Finnerty JW, Friman PC, Rapoff MA. Improving compliance with antibiotic 
regimens for otitis media: randomized clinical trial in a pediatric clinic. 
American Journal of the Diseases of Childhood 1985;139:89-95. 
/ 
178 
220. Home R, Weinman J. The beliefs about medicines questionaire (BMQ): a new 
method for assessing lay beliefs about medicines. Paper presented at the 
British Psychological Association Annual Conference 1995, London. 
221. Fallsberg M. Reflections on medicines & medication: a qualitative analysis 
among people on long term drug regimens: Lingkoping University, 1991. 
222. Britten DM. Patients' ideas about medicines: a qualitative study in a general 
practice. British Journal of General Practice 1994;44:465-8. 
223. Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common 
sense to understand treatment adherence and affect cognition interactions. 
Cognitive Therapy and Research 1992;16:143-63. 
224. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: 
application to addictive behaviors. American Psychology 1992;47:1102-14. 
225. DiMatteo MR. Enhancing patient adherence to medical recommendations. 
Journal of American Medical Association 1994;271:79-80. 
226. Stockwell DH, Madhavan S, Cohen H, Gibson G, Alderman M. The 
determinant of hypertension awareness, treatment and control in a insured 
population. American Journal of Public Health 1994;82:1607-12. 
227. Kasl SV. Issues in patient adherence to health care regimens. Journal of Human 
Stress 1975;1:5-17，48. 
228. Lindquist TL, Lawerence JB, Knuiman MW. Influence of lifestyle coping, and 
job stress on blood pressure in men and women. Amercian Heart Association 
1997;29:1-7. 
229. Roberson MHB. The meaning of compliance: patient perspectives. Quality 
Health Review 1992;2:7-26. 
230. Marinker M. Personal paper: Writing prescriptions is easy. British Medical 
Journal 1997;314:747-8. 
231. Pendleton D. Knowledge and compliance: not linked after all? The 
Pharmaceutical Journal 1992;February: 196. 
232. Colley CA, Lucas LM. Polypharmacy: the cure becomes the disease. Journal of 
General Internal Medicine 1993;8:278-83. 
233. Latiolais CJ, Berry CC. Misuse of prescription medications by outpatients. Drug 
Intellectual Clinical Pharmacy 1969;3:270-7. 
/ 
179 
234. Murray MD, Darnell J, Weinberger M, Martz BL. Factors contributing to 
medication noncompliance in elderly public housing tenants. Drug 
Intellectual Clinical Pharmacy 1986;20:146-52. 
235. Graveley EA, Oseashon CS. Multiple drug regimens: medication compliance 
among veterans 65 years and older. Research in Nursing and Health 
1991;14:51-8. 
236. Hulka BS, Cassel JC, Kupper LL, Burdette JA. Communication, compliance, 
and concordance between physicians and patients with prescribed 
medications. American Journal of Public Health 1987;66:847-53. 
237. Stewart RB. Polypharmacy in the elderly: a fait accompli? Annals of 
Pharmacotherapy 1990;24:321-3. 
238. Stewart RB, Caranaso GJ. Medication compliance in the elderly. Medical 
Clinics of North America 1989;73:1551-63. 
239. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the 
elderly. New England Journal of Medicine 1989;321:303-10. 
240. Fedder DO. Drug use in the elderly: issues of noncompliance. Drug Intellectual 
Clinical Pharmacy 1984;18:158-62. 
241. Morrow D, Leirer V, Sheikh J. Adherence and medication instructions. Reviews 
and recommendations. Journal of American Geriatric Society 1988;36:1147-
60. 
242. Noyes MA, Lucas DS，Stratton MA. Principles of geriatric pharmacotherapy. 
Journal of Geriatric Drug Therapy 1996;10:5-35. 
243. Klein LE, German PS, Levine DM, et al. Medication problems among 
outpatients. Archives of Internal Medicine 1984;144:1185-8. 
244. Nolan L, O'Malley K. Prescribing for the elderly. Part 1: Sensitivity of the 
elderly to adverse drug reactions. Journal of American Geriatric Society 
1988;36:142-9. 
245. Hughes SG. Prescribing for the elderly patient: why do we need to exercise 
caution? British Journal of Clinical Pharmacology 1998;46:531-3. 
246. Montamat SC, Cusack B. Overcoming problems with polypharmacy and drug 
misuse in the elderly. Clinical Geriatric Medicine 1992;8:143-58. 
247. Beers MH, Ouslander JG. Risk factors in geriatric drug prescribing: a practical 
guide to avoiding problems. Drugs 1989;37:105-112. 
/ 
180 
248. Kruse W, Rampmaier J, Frauenrath-Volkers C, et al. Drug prescribing patterns 
in old age. A study of the impact of hospitalization on drug prescriptions and 
follow-up survey in patients in 75 years and older. European Journal of 
Clinical Pharmacology 1991;41:441-7. 
249. Rockwood K. Medical management of frailty: confession of a gnostic. 
Canadian Medical Association Journal 1997;157:1081 -4. 
250. Cadieux RJ. Drug interactions in the elderly. How multiple drug use increases 
risk potentially. Postgraduate Medicine 1989;86:179-86. 
251. Corlett AJ. Caring for older people: aids to compliance with medication. British 
MedicalJournal 1996;313:926-9. 
252. Stewart RB, Moore MT, May FE. Changing patterns of therapeutic agents in the 
elderly. A ten-year overview. Age Ageing 1991;20:182-8. 
253. Lindley CM, Tully MP, Paramsoth V, Tallis RC. Inappropriate medication is a 
major cause of adverse drug reactions in elderly patients. Age Ageing 
1992;21:294-300. 
254. Shea S, Misra D, Ehrlich M, Field L, Francis CK. Correlates of nonadherence to 
hypertension treatment in a inner-city minority population. American Journal 
of Public Health 1992;82:1607-12. 
255. Faller NA. Noncompliance. Ostomy Wound Management 1993;39:35-8. 
256. Slack MK, Brooks AJ. Adolescents' compliance with therapeutic regimens. 
American Journal of Health System Pharmacy 1995 ；52:1417-21. 
257. Lowes R. Patient-centered care for better patient adherence. Family Practice 
Management 1998;5:46-52. 
258. Svarstad BL，Chewning BA, Sleath BL, Claesson C. The brief medication 
questionnaire: a tool for screening patient adherence and barriers to 
adherence. Patient Education and Counseling 1999;37:113-24. 
259. Cameron K, Gregor F. Chronic illness and compliance. Journal of Advanced 
Nursing\9%1\11:61\-6. 
260. Wilkinson CR, Williams MR. Strengthening patient-provider relationships. 
Lippincott's case management 2002;7:86-99. 
261. Wilkinson J. Understanding motivation to enhance patient compliance. British 
Journal of Nursing 1997;6:879-84. 
262. Hussey LC. Minimizing effects of low literacy on medication knowledge and 
compliance among the elderly. Clinical Nursing Research 1994;3:132-45, 
181 
263. Cargill JM. Medication compliance in elderly people: influencing variables and 
interventions. Journal of Advanced Nursing 1992;17:422-6. 
264. McMahon T, Clark CM, Bailie GR. Who provides patients with drug 
information? British Medical Journal 1987;294:355-6. 
265. Friedman RH, Kazis LE, Jette A, et al. A telecommunications system for 
monitoring and counseling patients with hypertension. Impact on medication 
adherence and blood pressure control. American Journal of Hypertension 
1996;9:285-92. 
266. Kemp R, Hayward P，Applewhaite G，Everitt B, David A. Compliance therapy 
in psychotic patients: randomised controlled trial. British Medical Journal 
1996;312:345-9. 
267. Kemp R, Kirov G, Everitt B，Hayward P, David A. Randomised controlled trial 
of compliance therapy. 18-month follow-up. British Journal of Psychiatry 
1998;172:413-9. 
268. Raynor DK, Booth TG, Blenkinsopp A. Effects of computer generated reminder 
charts on patients' compliance with drug regimen. British Medical Journal 
1993;306:1158-61. 
269. Simpson J, May LG. Self administration in hospital towards better compliance. 
Hospital Pharmacy Practice 1992;2:30-3. 
270. Whyte LA. Medication cards for elderly people: a study. Nursing Standard 
1994;8:25-8. 
271. Becker LA, Glanz K, Sobel E，Mossey J, Zinn SL, Knott KA. A randomized 
trial of special packaging of antihypertensive medications. Journal of Family 
Practice 1986;22:357-61. 
272. Binstock ML, Franklin KL. A comparison of compliance techniques on the 
control of high blood pressure. American Journal of Hypertension 
1988;1:192S-4S. 
273. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of 
health education in promoting prescription refill compliance among patients 
with hypertension. Clinical Therapeutics 1991;13:489-95. 
274. Hill MN, Miller NH. Compliance enhancement. A call for multidisciplinary 
team approaches. Circulation 1996;93:4-6. 
182 
275. Dunbar J, Dwyer K, Dunning EJ. Compliance with antihypertensive regimen: a 
review of the research in the 1980's. Social Behavioral Medicine 1991;13:31-
9. 
276. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids 
and monitoring. Drugs & Aging 1998;12:7-15. 
277. Kjellgren KI, Ahlner J, Saljo R. Taking antihypertensive medication-
controlling or co-operating with patients? International Journal of 
Cardiology 1995;47:257-68. 
278. Murray MD, Birt J A, Manatunga AK, Darnell JC. Medication compliance in 
elderly outpatients using twice-daily dosing and unit-of-use packaging. 
Annals of Pharmacotherapy 1993;27:616-21. 
279. Mackowiak ED, O'Connor TW, Thomason M, et al. Compliance devices 
preferred by elderly patients. American Pharmacy 1994;NS34:47-52. 
280. Proos M, Reiley P, Eagon J, Stengrevices S, Castile J, Aarion D. A study of the 
effects of self medication on patients' knowledge of and compliance with 
their medication regime. Journal of Nursing Care Quality, special report 
1992:18-26. 
281. Furlong S. Do programmes of medicine self-administration enhance patient 
knowledge, compliance and satisfaction? Journal of Advanced Nursing 
1996;23:1254-62. 
282. Haynes RB, Sackett DL, Gibson ES, Taylor DW, Hackett BC, Roberts RS. 
Improvement of medication compliance in uncontrolled hypertension. Lancet 
1976;i: 1265-8. 
283. Vivian BG, Wilcox JR. Compliance communication in home health care: a 
mutually reciprocal process. Qualitative Health Research 2000;10:103-116. 
284. Garrity TF, Garrrity AR. The nature and efficacy of intervention studies in the 
National High Blood Pressure Education Research Program. Journal of 
Hypertension Supplementary 1985;3:S91-5. 
285. Glanz K, Kirscht JP, Rosenstock IM. Linking research and practice in patient 
education for hypertension, patient responses to four educational 
interventions. Medical Care 1981;19:141-52. 
286. King JL, Schommer JC, Wirsching RG. Patients' knowledge of medication care 
plans after hospital discharge. American Journal of Health-System Pharmacy 
1998;55:1389-93. 
183 
287. Moser M. Noncompliance in the management of hypertension: a different 
perspective. Primary Cardiology 1995;21:3-4. 
288. Gatley MS. To be taken as directed. Journal of Royal College of General 
Practice 1968;16:39-44. 
289. Francis V, Korsch BM, Morris MJ. Gaps in doctor-patient communication. New 
England Journal of Medicine 1969;280:535-40. 
290. Rudd P. Maximizing compliance with antihypertensive therapy. Drug and 
Therapeutics 1992;December:25-32. 
291. Thomas DR. "The brown bag" and other approaches to decreasing 
polypharmacy in the elderly. North Clinics Medical Journal 1991;52:5656. 
292. Colt H, Shapiro A. Drug-induced illness as a cause for admission to a 
community hospital. Journal of the American Geriatrics Society 
1989;37:323-6. 
293. Sweetman L, Howard D, O'Neill D. Once-daily medications for older patients in 
the general hospital. Journal of the American Geriatrics Society 1999;47:629. 
294. Farmer KC, Jacobs EW, Phillips CR. Long-term patient compliance with 
prescribed regimens of calcium channel blockers. Clinical Therapeutics 
1994;16:271-2, 316-26. 
295. Stewart RB. Noncompliance in the elderly: is there a cure? Drugs and Aging 
1991;1:163-7. 
296. Carr A. Compliance with medical advice. British Journal of General Practice 
1990;40:358-60. 
297. Mullen PD. Compliance becomes concordance. British Medical Journal 
1997;314:691-2. 
298. Pratt JH, Jones JJ. Noncompliance with therapy: an ongoing problem in treating 
hypertension. Primary Cardiology 1995;21:34-8. 
299. Henbest RJ, Stewart M. Patient-centredness in the consultation. 2: Does it really 
make a difference? Family Practice 1990;7:28-33. 
300. Sharkness CM, Snow DA. The patient's view of hypertension and compliance. 
American Journal of Preventive Medicine 1992;8:141-6. 
301. Piatt FW, Tippy PK. Helping patients adhere to the regimen. Patient Care 
1994;28:43-52. 
184 
302. Nathan A, Goodyer L, Lovejoy A, Rashid A. 'Brown bag' medication reviews as 
a means of optimizing patients' use of medication and of identifying potential 
clinical problems. Family Practice 1999;16:278-82. 
303. Kirscht JP, Kirscht JL, Rosenstock IM. A test of interventions to increase 
adherence to hypertensive medical regimens. Health Education Quarterly 
Journal 1981;8:261-72. 
304. Sackett DL. Introduction and the magnitude of compliance and non-complinace. 
Baltimore: The Johns Hopkins University Press, 1976. 
305. Stockwell ML, Schulz RM. Medication compliance: the patient's perspective. 
Clinical Therapeutics 1993;15:593-607. 
306. Nichol MB, Venturini F, Sung JC. A critical evaluation of the methodology of 
the literature on medication compliance. Annals of Pharmacotherapy 
1999;33:531-40. 
307. The Diabetes Control and Complications Trial Research Group. The effect of 
intensive treatment of diabetes on the development and progression of long-
term complications in insulin-dependent diabetes mellitus. New England 
Journal of Medicine 1993;329:977-86. 
308. Haynes RB, Montague P，Oliver T, McKibbon KA, Brouwers MC, Kanani R. 
Interventions for helping patients follow prescriptions for medications. The 
Cochrane Library 1999;4. 
309. Kok G, van der Borne B，Mullen PD. Effectiveness of health education and 
health promotion: Meta-analyses of effect studies and determinants of 
effectiveness. Patient Education and Counseling 1997;30:19. 
310. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D，Svarstad B. 
Effectiveness of interventions to improve patient compliance: a meta-
analysis. Medical Care 1998;36:1138-61. 
311. Mazucca SA. Does patient education in chronic disease have any therapeutic 
value? Journal of Chronic Diseases 1982;35:521-9. 
312. Posavac EJ. Evaluations of patient education programs: A meta-analysis. 
Evaluation and the Health Professions 1980;3:47. 
313. Posavac EJ, Sinacore JM, Botherton SE, Helford MC, Turpin RS. Increasing 
compliance to medical treatment regimens: A meta-analysis of program 
evaluation. Evaluation and the Health Professions 1985;8:7. 
185 
314. Brown S. Studies of educational interventions and outcomes in diabetic adults: 
A meta-analysis revisited. Patient Educaton and Counseling 1990;16:189. 
315. Giuffrida A, Torgerson DJ. Should we pay the patient? Review of financial 
incentives to enhance patient compliance. British Medical Journal 
1997;315:703-7. 
316. Hess JD. The ethics of compliance: a dialectic. Advances in Nursing Science 
1996;19:18-27. 
317. Dolan M, Green LW, Persinger GS. Clinical trials of patient education for 
chronic conditions: a comparative meta-analysis of intervention types. 
Preventive Medicine 1985;14:753-81. 
318. Britten N, Weinman J. A review of the literature on drug adherence. Royal 
Society of Great Britain, London 1996. 
319. McGavock H. A review of the literature on drug adherence. Royal 
Pharmaceutical Society of Great Britain, London 1996. 
320. National Heart Lung and Blood Institute Working Group on Patient 
Compliance. Management of patient compliance in the treatment of 
hypertension. Hypertension 1982;4:415-23. 
321. Kruse M. Patient compliance with drug treatment - new perspectives on an old 
problem. Clinical Investigation 1992;70:163-6. 
322. Trostle JA. Medical compliance as an ideology. Social Science and Medicine 
1988;27:1299-308. 
323. Kroenke K, Pinholt EM. Reducing polypharmacy in the elderly: a controlled 
trial of physician feedback. Journal of the American Geriatrics Society 
1990;38:31-6. 
324. Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a 
clinical pharmacist intervention to improve inappropriate prescribing in 
elderly outpatients with polypharmacy. American Journal of Medicine 
1996;100:428-37. 
325. Lobas NH, Lepinski PW, Abramowitz PW. Effects of pharmaceutical care on 
medication cost and quality of patient care in an ambulatory-care clinic. 
American Journal of Hospital Pharmacy. 1992;49:1681-8. 
326. Hatoum HT, Akhras K. 1993 Bibliography: a 32-year literature review on the 
value and acceptance of ambulatory care provided by pharmacists. Annals of 
Pharmacotherapy. 1993;27:1106-19. 
186 
327. Lipton HL, Byrns PJ，Soumerai SB, Chrischilles EA. Pharmacists as agents of 
change for rational drug therapy. International Journal of Technology 
Assessment in Health Care 1995;11:485-508. 
328. Jaber LA, Halapy H, Fernet M, Fienmalapalli S, Diwakaran H. Evaluation of a 
pharmaceutical care model on diabetes management. Annals of 
pharmacotherapy 1996;30:238-43. 
329. Bond CA, Monson R. Sustained improvement in drug documentation, 
compliance, and disease control. A four year analysis of an ambulatory care 
model. Archives of Internal Medicine 1984;144:1159. 
330. Chriquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic 
with usual medical care. Archives of Internal Medicine 1998;158:1641-7. 
331. Shibley MC, Pugh CB. Implementation of pharmaceutical care services for 
patients with hyperlipidemia by independent community pharmacy 
practitioners. Annals of Pharmacotherapy 1997;31:713-9. 
332. Wilt VM，Gums JG, Ahmed 01, Moore LM. Outcome analysis of a pharmacist-
managed anticoagulation service. Pharmacotherapy 1995;15:732-9. 
333. Morris LA. Effects of written drug information on patient knowlegde and 
compliance: A literature review. American Journal of Public Health 
1979;69:47-52. 
334. Halpern SD, Karlawish JHT, Berlin JA. The continuing unethical conduct of 
underpowered clinical trials. Journal of the American Medical Association 
2002;288:358-62. 
335. Chan JCN, Cheung CK, Cheung MYF，Swaminathan R, Critchley JAJH, 
Cockram CS. Abnormal albuminuria as a predictor of mortality and renal 
impairment in Chinese patients with NIDDM. Diabetes Care 1995;18:1013-
6. 
336. Joint Formulary Committee. British National Formulary: British Medical 
Association, Royal Pharmaceutical Society of Great Britain, 2002. 
337. Melnikow J, Kiefe C. Patient compliance and medical research: issues in 
methodology. Journal of General Internal Medicine 1994;9:96-105. 
338. Stewart MS. The validity of an interview to assess a patient's drug taking. 
American Journal of Preventive Medicine 1987;3:95-100. 
339. McGann E. Medication compliance in adults with asthma. American Journal of 
Nursing 1999;99:45-6. 
187 
340. Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J. Effects of a medicine 
review and education programme for older people in general practice. British 
Journal of Clinical Pharmacology 2000;50:172-5. 
341. Cramer JA. Compliance with contraceptives and other treatments. Obstetrics 
and Gynecology 1996;88:S4-12. 
342. Rudd P. Partial compliance: implications for clinical practice. Journal of 
Cardiovascular Pharmacology 1993;22:Sl-5. 
343. Campbell TM, Stamm PL, Johnson JR. Improving drug use in a capitated 
program for the poor. American Journal of Health-System Pharmacy 
1997;54:2449-50. 
344. Bockowski JA, Zeichner A. Medication compliance and the elderly. Clinical 
Gerontology 1985;4:3-15. 
345. Kendrick R, Bayne JRD. Compliance with prescribed medication by elderly 
patients. Candian Medical Association Journal 1982;127:961-2. 
346. Buckalew LW, Coffield KE. An investigation of drug expectancy as a function 
of capsule colour and size and preparation form. Journal of 
Psychopharmacology 1982;2:245-8. 
347. Simmons D，Upjohn M, Gamble G. Can medication packaging improve 
glycemic control and blood pressure in type 2 diabetes?: results from a 
randomized controlled trial. Diabetes Care 2000;23:153-6. 
348. Norell SE. Methods in assessing drug compliance. Acta Medical Scandinavia 
1983;683:S35-40. 
349. Fincke BG, Miller DR, Spiro A. The interaction of patient perception of 
overmedication with drug compliance and side effects. Journal of General 
Internal Medicine 1998;13:182-5. 
350. Carlson JE. Perils of polypharmacy: 10 steps to prudent prescribing. Geriatrics 
1996;51:26-35. 
351. Schwartz RK, Soumerai SB, Avom J. Physician motivating for non scientific 
drug prescribing. Social Science and Medicine 1989;28:577-82. 
352. Arnold GJ. Avoiding inappropriate drug prescribing: fundamental priniciples 
for rational medication management. Clinical Nurse Specialist 1999;13:289-
95. 
188 
353. Taggart AJ, Johnson GD, McDevitt DG. Does the frequency of daily dosage 
influence compliance with digoxin therapy? British Journal of Clinical 
Pharmacology 1981;1:31-4. 
354. Kruse W，Koch-Gwinner P, Nikolaus T, Oster P, Schlierf G, Weber E. 
Measurement of drug compliance by continuous electronic monitoring: a 
pilot study in elderly patients discharged from hospital. Journal of Americam 
Geriatric Society 1992;40:1151-5. 
355. Levy G. A pharmacokinetic perspective on medicament noncompliance. 
Clinical Pharmacology and Therapeutics 1993;54:242-4. 
356. Haynes RB, Sackett DL, Talyor DW, Toberts RS, Johnson AL. Manipulation of 
the therapeutic regimen to improve compliance: conceptions and 
misconceptions. Clinical Pharmacology and Therapeutics 1977;22:125-30. 
357. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical 
correlates, economic impact. European Heart Journal 1996;17:S8-15. 
358. Urquhart J. Partial compliance in cardiovascular disease: risk implications. 
British Journal of Clinical Practice 1994;73:S2-12. 
359. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with 
pravastatin in men with hypercholesterolemia. New England Journal of 
Medicine 1995;333:1301-7. 
360. Downs J, Clearfield M, Weis S, et al. Primary prevention of acute coronary 
events with lovastatin in men and women with average cholesterol levels: 
results of AFCAPS/TexCAPS. Journal of American Medical Association 
1998;279:1615-22. 
361. Scandinavian Simvastatin Survival Study Group. Randomized trial of 
cholesterol lowering in 4444 patients with coronary heart disease: the 
Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9. 
362. Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. 
Prevention of cardiovascular events and death with pravastatin in patients 
with coronary heart disease and a broad range of initial cholesterol levels. 
New England Journal of Medicine 1998;339:1349-57. 
363. Sacks F，Pfeffer M, Moye L, et al. The effect of pravastatin on coronary events 
after myocardial infarction in patients with average cholesterol levels. New 
England Journal of Medicine 1996;335:1001 -9. 
4 
189 
364. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary 
heart disease. Part 2. Short-term reductions in blood pressure: Overview of 
randomized drug trials in their epidemiological context. Lancet 
1990;225:827-38. 
365. Burnier M, Brunner HR. Angiotensin II receptor antagonists in hypertension. 
Kidney International 1998;54:S107-11. 
366. Penna R. Pharmaceutical care: pharmacy's mission for the 1990s. American 
Journal of Hospital Pharmacy 1990;47:543-9. 
367. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































j ” :�::::::.:. r， 
较 , 义 . 空 . . . . • .. . , . . � . ' “ . . � : . : - : : H :： ‘ : . � - : 
. • •‘ - .,.:. ...:‘： 
卢 . • ： • ..’•’- . :... ..、 、：. - . ‘ •‘ ... 
• ‘ • ； :.. -... . . ： ‘ . - ‘ . - . , , .• ‘ 
• r � - - � - . • . ... .-—--.:-.-.� •  v-^  •厂 . 1 . . ‘ 
... ‘ . -；；' ‘ • • ：：^  . . . - ” - 广 . . . . . . . ， • ； ; 
: > : • ‘ . . . - • . • “ / t 二：.,‘:-..-， '《LV“- ： . ‘•-•、、. ‘ ： , . 
•、'. ‘ • ;’...-々....:,.；•-:-•..々-V :广？,r； ： ；^ 
• “ . . •• - a,".-/-- -；^ ‘ V •; • •：； -r". ••这. . . . . ‘ . , . -
• . . . •广 y - . . 二/.,.‘.•‘,••，、"、•/‘.. • •‘ 
• ： , - < ’ . I' V.'^：：'.,^-^- ‘；. « …•， • •^•• .、..•‘‘ .、 
.. . . • ‘ 
• .V • .•• • . . : ‘ . ； -
, • . \ , , \ • '•‘ ••-•^ '•r ；‘ ‘ ‘ •’ - ... 
. . , ‘ - . , � . . : / . : : . . : ‘ 
• . , 越 赫 ※ 输 f c . . : 。 : . 
• • ' ' . 、二？- ：： 、《 . . . -’ 
. . . . . . 1 . •>*• - ；• • ‘ - 、- I,- . , . , , 
. f i .,'/::..':�•/•I：-' r-Jj. •• 。： • . - ^ 
• ‘： � — > K 厂 ： � •“ •.、. 
, . , , . . . . . " . i � , . " , . - . V ^ ‘ • .：‘ 
. • . .. 矛恭广：；、. - .、 : . 
, . ’ , ,-�:•. - • • 
•• .• .，."，，•..‘ t,' ‘ “ • 
. • •• • • . 心 . . . 
. . . . . • � . . 
. .. • . •<—‘._ 
- ！ . • ^ • .. , • ‘ 
. . . - ...,.、..；„• ^ 
.• • • ： • . 
. � ‘ » 'V 
• - . ,1 . ^.,.... . . • 
‘ • r . . 
-










C U H K L i b r a r i e s 
mmmm 
DDM07Tfl3M 
